abdominal B-PHE
mass I-PHE
; O
accumulation O

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
infectious B-PHE
and O
parasitic B-PHE
disease I-PHE
( O
unspecified O
) O
and O
pediatric O
indications O
. O

-DOCSTART- O


Treatment O
of O
protracted O
diarrhea B-PHE
due O
to O
hypofunction B-PHE
of I-PHE
the I-PHE
spleen I-PHE
, O
seminal B-PHE
emission I-PHE
, O
leukorrhagia B-PHE
, O
palpitation B-PHE
, O
insomnia B-PHE
. O

-DOCSTART- O


it O
contains O
polysaccharide O
and O
polypeptide O
mainly O
. O

1 O
Inhibiting O
synthesis B-PHE
of I-PHE
DNA I-PHE
and I-PHE
RNA I-PHE
in O
cancer O
cells O
. O

2 O
Inhibiting O
sarcoma180 B-PHE
and O
Ehrlich-Ascites B-PHE
tumor I-PHE
in O
vitro O
. O

-DOCSTART- O


injury B-PHE
due O
to O
trauma B-PHE

-DOCSTART- O


Rikkunshito O
, O
an O
herbal O
medicine O
, O
suppresses O
cisplatin-induced B-PHE
anorexia I-PHE
in O
rats O
via O
5-HT2 O
receptor O
antagonism O
. O

-DOCSTART- O


Heat B-PHE
sensation I-PHE
in O
the O
chest O
, O
palms O
and O
soles O

-DOCSTART- O


To O
nourish O
blood B-PHE
and O
consolidate O
the O
yin O
; O

To O
pacify O
the O
liver B-PHE
and O
stop O
pain B-PHE
; O

To O
soothe O
liver O
yang O

-DOCSTART- O


Penbutolol O
is O
indicated O
in O
the O
treatment O
of O
mild O
to O
moderate B-PHE
arterial I-PHE
hypertension I-PHE
. O

It O
may O
be O
used O
alone O
or O
in O
combination O
with O
other O
antihypertensive O
agents O
, O
especially O
thiazide-type O
diuretics O
. O

Penbutolol O
is O
contraindicated O
in O
patients O
with O
cardiogenic B-PHE
shock I-PHE
, O
sinus B-PHE
bradycardia I-PHE
, O
second B-PHE
and I-PHE
third I-PHE
degree I-PHE
atrioventricular I-PHE
conduction I-PHE
block I-PHE
, O
bronchial B-PHE
asthma I-PHE
, O
and O
those O
with O
known O
hypersensitivity B-PHE
. O

-DOCSTART- O


To O
quicken O
blood B-PHE
and O
nourish O
heart B-PHE
, O
constrain O
lung B-PHE
and O
astringe B-PHE
intestines O
. O

-DOCSTART- O


Similar O
to O
zidovudine O
, O
efavirenz O
inhibits O
the O
activity B-PHE
of I-PHE
viral I-PHE
RNA-directed I-PHE
DNA I-PHE
polymerase I-PHE
( O
i.e O
. O
, O
reverse B-PHE
transcriptase I-PHE
) O
. O

Antiviral O
activity O
of O
efavirenz O
is O
dependent O
on O
intracellular O
conversion O
to O
the O
active O
triphosphorylated O
form O
. O

The O
rate O
of O
efavirenz O
phosphorylation O
varies O
, O
depending O
on O
cell O
type O
. O

It O
is O
believed O
that O
inhibition O
of O
reverse B-PHE
transcriptase I-PHE
interferes O
with O
the O
generation B-PHE
of I-PHE
DNA I-PHE
copies I-PHE
of I-PHE
viral I-PHE
RNA I-PHE
, O
which O
, O
in O
turn O
, O
are O
necessary O
for O
synthesis O
of O
new O
virions O
. O

Intracellular O
enzymes O
subsequently O
eliminate O
the O
HIV B-PHE
particle I-PHE
that O
previously O
had O
been O
uncoated O
, O
and O
left O
unprotected O
, O
during O
entry O
into O
the O
host O
cell O
. O

Thus O
, O
reverse O
transcriptase O
inhibitors O
are O
virustatic O
and O
do O
not O
eliminate O
HIV B-PHE
from O
the O
body O
. O

Even O
though O
human O
DNA B-PHE
polymerase I-PHE
is O
less O
susceptible O
to O
the O
pharmacologic O
effects O
of O
triphosphorylated O
efavirenz O
, O
this O
action O
may O
nevertheless O
account O
for O
some O
of O
the O
drug's O
toxicity O
. O

-DOCSTART- O


Dexamethasone O
is O
a O
glucocorticoid B-PHE
agonist I-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness O
, O
absorption B-PHE
, O
Strength O
and O
power O
, O
Liver B-PHE
health I-PHE
, O
Inflammation B-PHE
, O
Liver B-PHE
, O
Others O
, O
motility B-PHE

-DOCSTART- O


However O
, O
like O
other O
antihypertensives O
, O
they O
all O
have O
to O
be O
self-administered O
daily O
and O
don't O
provide O
a O
good O
solution O
for O
improving O
patient O
compliance O
. O

-DOCSTART- O


( O
1 O
) O
/ O
morbid B-PHE
leukorrhea I-PHE
; O
( O
2 O
) O
gynecological B-PHE
diseases I-PHE
( O
in O
a O
broad O
sense O
) O

-DOCSTART- O


To O
cause O
catharsis O
and O
purge O
away O
heat B-PHE
, O
to O
reduce O
heat B-PHE
in O
blood B-PHE
and O
counteract O
toxicity B-PHE
, O
and O
to O
eliminate O
blood B-PHE
stasis I-PHE
and O
stimulate O
menstrual B-PHE
discharge I-PHE
. O

-DOCSTART- O


blood B-PHE
vomiting I-PHE
due O
to O
weakness B-PHE
and O
fatigue B-PHE

-DOCSTART- O


To O
clear O
away O
heat B-PHE
and O
toxic B-PHE
materials I-PHE
, O
remove O
dampness B-PHE
and O
destroy O
trichomonad B-PHE
and O
fungus B-PHE
, O
remove O
the O
necrotic B-PHE
tissue I-PHE
and O
promote O
granulation B-PHE
, O
and O
arrest O
pain B-PHE
by O
removing O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


To O
reduce O
masses B-PHE
by O
dissipating O
blood B-PHE
stasis I-PHE
, O
and O
to O
relieve O
pain B-PHE
by O
removing O
stagnancy B-PHE
of O
food O
. O

-DOCSTART- O


Pneumonia B-PHE
, I-PHE
Pneumocystis I-PHE
Carinii I-PHE

-DOCSTART- O


Treatment O
of O
attack O
of O
damp-heat B-PHE
manifested O
by O
stuffiness B-PHE
and O
fullness O
sensation O
in O
the O
abdomen B-PHE
, O
or O
causing O
acute B-PHE
dysentery I-PHE
of O
jaundice B-PHE
, O
high O
fever B-PHE
accompained O
by O
impairment B-PHE
of O
conciousness B-PHE
, O
fidgetness O
and O
insomnia B-PHE
due O
to O
exuberant O
fire O
, O
spitting B-PHE
of I-PHE
blood I-PHE
and O
epistaxis B-PHE
caused O
by O
heat B-PHE
in O
the O
blood O
, O
inflammation B-PHE
of O
the O
eye O
, O
acid B-PHE
regurgitation I-PHE
, O
toothache B-PHE
, O
diabetes B-PHE
, O
carbuncles B-PHE
and O
sores B-PHE
, O
external O
use O
for O
eczema B-PHE
and O
other O
skin B-PHE
diseases I-PHE
with O
exudation O
, O
purulent B-PHE
discharge I-PHE
from O
the O
ear O
. O

Rhizoma O
Coptidis O
( O
processed O
with O
wine O
) O
Inflammation B-PHE
of O
the O
eye O
, O
ulcers B-PHE
in O
the O
mouth O
. O

Rhizoma O
Coptidis O
( O
processed O
with O
ginger O
) O
Stuffiness O
and O
fullness O
sensation O
in O
the O
abdomen B-PHE
with O
nausea B-PHE
and O
vomiting B-PHE
caused O
by O
damp-heat B-PHE
in O
combination O
with O
cold B-PHE
. O

-DOCSTART- O


vigilance O
, O
Physical B-PHE
performance I-PHE
and O
fitness O
, O
Endurance O
, O
activation O
, O
attention O
, O
energy B-PHE
supply I-PHE
and O
recovery O
, O
Metabolism B-PHE
, O
sleep B-PHE
, O
Memory B-PHE
, O
Arousal B-PHE
, O
Others O
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


To O
strengthen O
spleen B-PHE
and O
benefit O
dampness B-PHE
; O

To O
kill O
worms B-PHE
and O
stop O
diarrhea B-PHE

-DOCSTART- O


five O
kinds O
of O
fluid-retention B-PHE
syndromes I-PHE

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
toothache B-PHE
, O
knee B-PHE
joint I-PHE
pain I-PHE
, O
scab B-PHE
and O
lichen B-PHE
, O
eczema B-PHE
, O
trichomoniasis B-PHE
, O
scalds B-PHE
, O
wound B-PHE
, O
enduring B-PHE
sores I-PHE
, O
bilharziosis B-PHE
, O
cough B-PHE
and O
asthma B-PHE
. O

-DOCSTART- O


settle O
fright O

-DOCSTART- O


[Case O
of O
pneumonitis B-PHE
caused O
by O
Yokukansan] O
. O

-DOCSTART- O


Reducing O
signs O
and O
symptoms O
of O
Crohn's B-PHE
disease I-PHE
and O
treatment O
of O
moderately O
to O
severely O
active O
rheumatoid B-PHE
arthritis I-PHE
( O
RA B-PHE
) O
. O

-DOCSTART- O


Treament O
of O
unprocessed O
Fructus O
Hordei O
Germinatus O
: O

Anorexia B-PHE
due O
to O
diminished B-PHE
function I-PHE
of I-PHE
the I-PHE
spleen I-PHE
, O
galactostasis B-PHE
. O

Fructus O
Hordei O
Germinatus O
( O
stir-fried O
) O
: O

Indigestion B-PHE
, O
weaning O
a O
baby O
. O

Fructus O
Hordei O
Germinatus O
( O
charred O
) O
: O

Retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
with O
epigastric B-PHE
distension I-PHE
and O
pain B-PHE
. O

-DOCSTART- O


soften O
hard B-PHE
mass I-PHE

-DOCSTART- O


strengthen O
the O
teeth B-PHE

-DOCSTART- O


Like O
other O
macrolides O
, O
it O
then O
penetrates O
bacteria O
cell O
wall O
and O
reversibly O
binds O
to O
domain O
V O
of O
the O
23S O
ribosomal O
RNA O
of O
the O
50S O
subunit O
of O
the O
bacterial O
ribosome O
, O
blocking O
translocation B-PHE
of I-PHE
aminoacyl I-PHE
transfer-RNA I-PHE
and I-PHE
polypeptide I-PHE
synthesis I-PHE
. O

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
Minimal O
Differentiation O

-DOCSTART- O


To O
promote O
blood B-PHE
circulation I-PHE
, O
remove O
blood B-PHE
stasis I-PHE
and O
improve O
microcirculation B-PHE
. O

-DOCSTART- O


To O
invigo O
rate O
the O
function B-PHE
of I-PHE
the I-PHE
spleen I-PHE
, O
to O
regulate O
the O
function B-PHE
of I-PHE
the I-PHE
stomach I-PHE
, O
and O
to O
promote O
the O
flow B-PHE
of I-PHE
milk I-PHE
. O

-DOCSTART- O


nourish O
bone B-PHE
marrow I-PHE

-DOCSTART- O


Swelling B-PHE
pain I-PHE
in O
joints O
, O
numbness B-PHE
in O
limbs O
, O
knocks B-PHE
and O
falls B-PHE
, O
cough B-PHE
and O
asthma B-PHE
, O
heat B-PHE
strangury I-PHE
, O
poisonous B-PHE
snake I-PHE
bite I-PHE
. O

-DOCSTART- O


To O
clear O
damp B-PHE
heat I-PHE
, O
resolve O
sore O
toxin B-PHE
, O
disperse O
swelling B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Dermatological B-PHE
systems I-PHE
health I-PHE
, O
General O
skin B-PHE
health I-PHE
, O
Others O

-DOCSTART- O


Sabarubicin O
blocking O
of O
DNA B-PHE
replication I-PHE
reduced O
the O
counteractive B-PHE
activity I-PHE
of I-PHE
mutagenic I-PHE
translesional I-PHE
bypass I-PHE
replication I-PHE
across O
cisplatin-DNA O
adducts O
. O

-DOCSTART- O


dryness B-PHE
of O
mouth O

-DOCSTART- O


Endurance O
, O
energy B-PHE
supply I-PHE
and O
recovery B-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE

-DOCSTART- O


Treatment O
of O
aching B-PHE
and O
weakness B-PHE
of O
the O
loins O
and O
knees O
, O
asthma B-PHE
and O
cough B-PHE
of O
deficiency-cold B-PHE
type O
, O
seminal O
emission O
, O
impotence B-PHE
. O

-DOCSTART- O


It O
causes O
blood B-PHE
vessels I-PHE
to I-PHE
narrow I-PHE
, O
resulting O
in O
an O
increase O
in O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


To O
kill O
worms B-PHE
. O

-DOCSTART- O


sores B-PHE
due O
to O
swelling B-PHE
of I-PHE
carbuncle I-PHE
. O

-DOCSTART- O


Palonosetron O
is O
a O
selective O
serotonin O
5-HT O
3 O
receptor O
antagonist O
. O

The O
antiemetic O
activity O
of O
the O
drug O
is O
brought O
about O
through O
the O
inhibition O
of O
5-HT O
3 O
receptors O
present O
both O
centrally O
( O
medullary O
chemoreceptor O
zone O
) O
and O
peripherally O
( O
GI O
tract O
) O
. O

This O
inhibition O
of O
5-HT O
3 O
receptors O
in O
turn O
inhibits O
the O
visceral B-PHE
afferent I-PHE
stimulation I-PHE
of O
the O
vomiting O
center O
, O
likely O
indirectly O
at O
the O
level O
of O
the O
area B-PHE
postrema I-PHE
, O
as O
well O
as O
through O
direct O
inhibition O
of O
serotonin B-PHE
activity I-PHE
within O
the O
area B-PHE
postrema I-PHE
and O
the O
chemoreceptor B-PHE
trigger I-PHE
zone I-PHE
. O

Alternative O
mechanisms O
appear O
to O
be O
primarily O
responsible O
for O
delayed O
nausea B-PHE
and O
vomiting B-PHE
induced O
by O
emetogenic O
chemotherapy O
, O
since O
similar O
temporal O
relationships O
between O
between O
serotonin B-PHE
and O
emesis B-PHE
beyond O
the O
first O
day O
after O
a O
dose O
have O
not O
been O
established O
, O
and O
5-HT O
3 O
receptor O
antagonists O
generally O
have O
not O
appeared O
to O
be O
effective O
alone O
in O
preventing O
or O
ameliorating O
delayed O
effects O
. O

It O
has O
been O
hypothesized O
that O
palonosetron's O
potency O
and O
long O
plasma O
half-life O
may O
contribute O
to O
its O
observed O
efficacy O
in O
preventing O
delayed O
nausea B-PHE
and O
vomiting B-PHE
caused O
by O
moderately O
emetogenic O
cancer O
chemotherapy O
. O

-DOCSTART- O


HIV-1 B-PHE
Infections I-PHE

-DOCSTART- O


dyspepsia B-PHE
; O
indigestion B-PHE

-DOCSTART- O


blood B-PHE
vomiting I-PHE

-DOCSTART- O


refers O
to O
the O
pain B-PHE
and O
damage B-PHE
due O
to O
the O
physical O
injury B-PHE

-DOCSTART- O


Applicable O
to O
cases O
of O
watery B-PHE
diarrhea I-PHE
with O
increased O
gurgling O
sounds O
, O
abdominal B-PHE
pain I-PHE
, O
nausea B-PHE
, O
vomiting B-PHE
, O
vexation B-PHE
, O
thirst B-PHE
, O
yellow B-PHE
and I-PHE
greasy I-PHE
fur I-PHE
, O
soft O
and O
floating O
, O
smooth B-PHE
pulse I-PHE
, O
which O
are O
attributive O
to O
dampness-heat B-PHE
of I-PHE
intestines I-PHE
and I-PHE
stomach I-PHE
( O
predominantly O
da O

-DOCSTART- O


Emtricitabine O
is O
an O
analogue O
of O
cytidine O
. O

The O
drug O
works O
by O
inhibiting O
reverse B-PHE
transcriptase I-PHE
, O
the O
enzyme O
that O
copies O
HIV B-PHE
RNA I-PHE
into O
new O
viral O
DNA O
. O

By O
interfering O
with O
this O
process O
, O
which O
is O
central O
to O
the O
replication O
of O
HIV B-PHE
, O
emtricitabine O
can O
help O
to O
lower O
the O
amount O
of O
HIV B-PHE
, O
or O
viral B-PHE
load I-PHE
. O

Efavirenz O
falls O
in O
the O
NNRTI O
class O
of O
antiretrovirals O
. O

Both O
nucleoside O
and O
non-nucleoside O
RTIs O
inhibit O
the O
same O
target O
, O
the O
reverse B-PHE
transcriptase I-PHE
enzyme I-PHE
, O
an O
essential O
viral B-PHE
enzyme I-PHE
which O
transcribes O
viral O
RNA O
into O
DNA O
. O

-DOCSTART- O


To O
revitalize O
blood B-PHE
and O
desolve O
stagnation B-PHE

-DOCSTART- O


Festering O
sore B-PHE
or O
abscess B-PHE
with O
inadequate O
drainage O
or O
initial O
granulation O
. O

-DOCSTART- O


This O
is O
a O
symptom O
with O
powerlessness B-PHE
in O
a O
waist O
and O
knee O
. O

-DOCSTART- O


This O
is O
pectoral B-PHE
pain I-PHE
with O
stuffiness B-PHE
and O
pain B-PHE
in O
the O
heart O
. O

-DOCSTART- O


Glaucoma B-PHE
, O
Open-angle O

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE
B I-PHE

-DOCSTART- O


Urinary B-PHE
Bladder I-PHE
Diseases I-PHE

-DOCSTART- O


Once O
bound O
, O
the O
receptor O
/ O
ligand O
complex O
localizes O
to O
the O
nucleus O
and O
acts O
as O
a O
DNA B-PHE
binding I-PHE
transcription I-PHE
factor I-PHE
, O
regulating O
gene B-PHE
expression I-PHE
. O

-DOCSTART- O


unblock O
the O
network B-PHE
vessels I-PHE

-DOCSTART- O


a O
diseade O
of O
chronic B-PHE
dysentery I-PHE
. O

Caused O
by O
the O
central O
Gi O
falling O
down O
due O
to O
deficiency B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE
from O
chronic B-PHE
dysentery I-PHE
. O

A O
symptom O
of O
feces B-PHE
with I-PHE
pus I-PHE
and I-PHE
blood I-PHE
and O
slight O
stomach B-PHE
pain I-PHE

-DOCSTART- O


redness B-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
a O
cold B-PHE
, O
weak B-PHE
waist I-PHE
and I-PHE
knee I-PHE
. O

-DOCSTART- O


Circulating O
Tumor B-PHE
Cells I-PHE
in O
Pancreatic O
Cancer O
Surgery O

-DOCSTART- O


Exerting O
prolong O
hypotensive B-PHE
effect I-PHE
in O
anesthetized O
animals. O
. O

-DOCSTART- O


1 O
Eliminating O
heat B-PHE
and O
toxic B-PHE
materials I-PHE
( O
carbuncle B-PHE
, O
erysipelas B-PHE
, O
burn B-PHE
, O
ulcer B-PHE
, O
sorethroat B-PHE
) O
, O
used O
as O
decoction O
, O
oral O
or O
external O
use O
, O
or O
gargle O
, O
also O
for O
the O
prevention O
and O
treatment O
of O
epidemic B-PHE
febrile I-PHE
diseases I-PHE
, O
such O
as O
influenza B-PHE
, O
epidemic B-PHE
meningitis I-PHE
, O
encephalitis B-PHE
, O
etc O
. O

2 O
. O
Clearing O
dampness-heat B-PHE
( O
diarrhea B-PHE
, O
dysentery B-PHE
and O
leukorrhagia B-PHE
of O
dampness-heat B-PHE
type O
) O
. O

Recently O
being O
used O
for O
acute O
and O
chronic B-PHE
pyelitis I-PHE
. O

3 O
To O
kill O
parasite B-PHE
( O
ancylostomoasos B-PHE
and O
filariasis B-PHE
) O
. O

-DOCSTART- O


To O
eliminate O
mass B-PHE
, O
reduce O
fullness B-PHE
, O
strengthen O
spleen B-PHE
and O
regulate O
stomach B-PHE
. O

-DOCSTART- O


Labetuzumab O
is O
a O
humanized O
monoclonal O
antibody O
used O
to O
treat O
cancer B-PHE
. O

Retrieved O
from O
http://en.wikipedia.org/wiki/Labetuzumab O

-DOCSTART- O


Tourette B-PHE
Syndrome I-PHE

-DOCSTART- O


prolonged O
chronic B-PHE
headache I-PHE

dead B-PHE
coldness I-PHE
of O
the O
extremities O

morbid B-PHE
condition I-PHE
of O
intense B-PHE
pain I-PHE
in O
the O
chest O
and O
abdomen O
, O
sudden O
coldness B-PHE
of O
the O
two O
feet O
, O
restlessness B-PHE
with O
disinclination B-PHE
ti O
eat O
and O
unsmooth O
pulse B-PHE

-DOCSTART- O


developmemt O
of O
manic B-PHE
syndrome I-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
relieve O
pain B-PHE
, O
quicken O
blood B-PHE
and O
disperse O
swelling B-PHE
. O

-DOCSTART- O


constrain O
sweat B-PHE
and O
the O
intestine B-PHE

-DOCSTART- O


( O
1 O
) O
pea-like O
skin B-PHE
sores I-PHE
; O
pox B-PHE
pea-shaped O
eruption B-PHE
filled O
with O
setrotic O
fluid O
such O
as O
smallpox B-PHE
and O
chickenpox B-PHE
. O

( O
2 O
) O
blister B-PHE

-DOCSTART- O


Cyclophosphamide's O
active O
metabolites O
aldophosphamide O
and O
phosphoramide O
mustard O
bind O
to O
DNA B-PHE
, O
thereby O
inhibiting O
DNA B-PHE
replication I-PHE
and O
initiating O
cell B-PHE
death I-PHE
. O

-DOCSTART- O


distribution O
) O
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Strength B-PHE
and O
power B-PHE
, O
Body B-PHE
weight I-PHE

-DOCSTART- O


a O
disease O
with O
pain B-PHE
in I-PHE
the I-PHE
joints I-PHE

-DOCSTART- O


BACKGROUND O
: O
Crohn's B-PHE
disease I-PHE
( O
CD B-PHE
) O
is O
a O
chronic B-PHE
inflammatory I-PHE
disease I-PHE
with O
increasing O
incidence O
in O
children O
. O

Current O
medications O
have O
potentially O
serious O
side O
effects O
, O
hence O
increasing O
interest O
in O
alternative O
therapies O
. O

We O
previously O
developed O
an O
herbal O
formula O
, O
FAHF-2 O
, O
based O
on O
a O
classical O
traditional O
Chinese O
herbal O
formula O
Wu O
Mei O
Wan O
that O
has O
long O
been O
used O
in O
China O
to O
treat O
colitis B-PHE
. O

We O
investigated O
FAHF-2's O
potential O
anti-inflammatory B-PHE
effects O
. O

METHODS O
: O
FAHF-2 O
efficacy O
was O
tested O
in O
vivo O
in O
the O
CD45RbRAG1 O
transfer O
colitis O
model O
. O

Weight B-PHE
loss I-PHE
, O
colonic O
histology O
, O
and O
cytokine B-PHE
production I-PHE
from O
mesenteric B-PHE
lymph I-PHE
nodes I-PHE
were O
assessed O
. O

Human O
peripheral B-PHE
blood I-PHE
mononuclear I-PHE
cells I-PHE
( O
PBMCs B-PHE
) O
and O
colonic O
biopsies O
were O
obtained O
from O
children O
newly O
diagnosed O
with O
CD O
and O
controls O
and O
cultured O
with O
or O
without O
FAHF-2 O
. O

Cytokine B-PHE
levels I-PHE
were O
measured O
by O
multiplex O
immunoassay O
. O

The O
effect O
of O
FAHF-2 O
on O
TNF-慣 B-PHE
- O
producing O
cells B-PHE
was O
determined O
by O
flow O
cytometry O
. O

NF-kB B-PHE
signaling I-PHE
was O
investigated O
in O
human O
lamina B-PHE
propria I-PHE
mononuclear I-PHE
cells I-PHE
upon O
FAHF-2 O
treatment O
by O
In O
- O
Cell O
Western O
. O

RESULTS O
: O
FAHF-2 O
- O
treated O
mice O
had O
decreased B-PHE
weight I-PHE
loss I-PHE
, O
improved O
histology O
, O
and O
reduced O
TNF-慣 B-PHE
, O
IL-17 B-PHE
, O
IL-6 B-PHE
, O
and O
IFN-y B-PHE
production O
. O

In O
vitro O
treated O
PBMCs B-PHE
produced O
less O
TNF-慣 B-PHE
, O
IFN-y B-PHE
, O
and O
IL-12 B-PHE
. O

FAHF-2 O
reduced O
the O
TNF-a B-PHE
- O
producing O
monocytes B-PHE
and O
T B-PHE
cells I-PHE
. O

-DOCSTART- O


relieve O
toxicity B-PHE
and O
alleviate O
edema B-PHE

-DOCSTART- O


Recurrent O
Childhood B-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


relieve O
heat B-PHE
and O
dissipate O
stasis B-PHE

-DOCSTART- O


Nonalcoholic B-PHE
Steatohepatitis I-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
Without O
Maturation O

-DOCSTART- O


1 O
Applicable O
to O
cases O
of O
hypovolumic B-PHE
and I-PHE
cardiogenic I-PHE
shock I-PHE
which O
are O
attributed O
to O
exhaustion B-PHE
of O
primordial O
energy O
and O
yang-energy O
. O

2 O
Also O
applicable O
to O
cases O
of O
hemorrhagic B-PHE
shock I-PHE
attributed O
to O
yang O
depletion O
. O

-DOCSTART- O


Simvastatin O
competitively O
inhibits O
HMG-CoA B-PHE
reductase I-PHE
, O
lowers O
plasma O
cholesterol O
and O
lipoprotein B-PHE
levels O
, O
and O
modulates O
immune B-PHE
responses I-PHE
by O
suppressing O
MHC O
II O
on O
interferon O
gamma-stimulated O
, O
antigen-presenting O
cells O
such O
as O
human O
vascular O
endothelial O
cells O
. O

Ezetimibe O
localizes O
and O
appears O
to O
act O
at O
the O
brush O
border O
of O
the O
small O
intestine O
and O
inhibits O
the O
absorption O
of O
cholesterol O
. O

Atorvastatin O
competitively O
inhibits O
hepatic B-PHE
hydroxymethyl-glutaryl I-PHE
coenzyme I-PHE
A I-PHE
( O
HMG-CoA B-PHE
) O
reductase O
, O
the O
enzyme O
which O
catalyzes O
the O
conversion O
of O
HMG-CoA O
to O
mevalonate O
, O
a O
key O
step O
in O
cholesterol B-PHE
synthesis I-PHE
. O

-DOCSTART- O


To O
dispel O
cold B-PHE
, O
eliminate O
damp B-PHE
and O
phlegm B-PHE
, O
and O
arrest O
emesis B-PHE
or O
nausea B-PHE
. O

-DOCSTART- O


Stagnation O
of O
qi O
in O
the O
liver O
and O
the O
stomach O
marked O
by O
distending O
pain I-PHE
in O
the O
epigastrium O
, O
feeling O
of O
stuffiness B-PHE
and O
fullness B-PHE
in O
the O
chest O
, O
anorexia B-PHE
, O
belching B-PHE
and O
acid B-PHE
regurgitation I-PHE
. O

-DOCSTART- O


dysentery B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myelomonocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


Kampo O
medicines O
are O
currently O
manufactured O
under O
strict O
quality O
controls O
. O

The O
Ministry O
of O
Health O
, O
Labour O
and O
Welfare O
of O
Japan O
has O
approved O
148 O
Kampo O
formulas O
. O

There O
is O
increasing O
evidence O
for O
the O
efficacy O
of O
Kampo O
medicines O
, O
and O
some O
are O
used O
clinically O
for O
palliative O
care O
in O
Japan O
. O

The O
specific O
aim O
of O
this O
review O
is O
to O
evaluate O
the O
clinical O
use O
of O
Kampo O
medicines O
in O
palliative O
care O
in O
the O
treatment O
of O
cancer O
. O

The O
conclusions O
are O
as O
follows O
: O
Juzentaihoto O
inhibits O
the O
progression O
of O
liver B-PHE
tumors I-PHE
in O
a O
dose-dependent O
manner O
and O
contributes O
to O
long-term O
survival O
. O

Hochuekkito O
has O
clinical O
effects O
on O
cachexia B-PHE
for O
genitourinary B-PHE
cancer I-PHE
and O
improves O
the O
QOL O
and O
immunological B-PHE
status I-PHE
of O
weak O
patients O
, O
such O
as O
postoperative O
patients O
. O

Daikenchuto O
increases O
intestinal B-PHE
motility I-PHE
and O
decreases O
the O
postoperative B-PHE
symptoms I-PHE
of O
patients O
with O
total O
gastrectomy O
with O
jejunal O
pouch O
interposition O
, O
suppresses O
postoperative O
inflammation B-PHE
following O
surgery O
for O
colorectal B-PHE
cancer I-PHE
, O
and O
controls O
radiation-induced O
enteritis B-PHE
. O

Rikkunshito O
contributes O
to O
the O
amelioration O
of O
anorectic B-PHE
conditions I-PHE
in O
cancer B-PHE
cachexia-anorexia I-PHE
syndrome I-PHE
. O

Goshajinkigan O
and O
Shakuyakukanzoto O
reduce O
the O
neurotoxicity B-PHE
of O
patients O
with O
colorectal B-PHE
cancer I-PHE
who O
undergo O
oxaliplatin O
and O
FOLFOX O
( O
5-fluorouracil/folinic O
acid O
plus O
oxaliplatin O
) O
therapy O
. O

Hangeshashinto O
has O
the O
effect O
of O
preventing O
and O
alleviating O
diarrhea B-PHE
induced O
by O
CPT-11(irinotecan O
) O
and O
combination O
therapy O
with O
S-1/CPT-11 O
. O

O'rengedokuto O
significantly O
improves O
mucositis B-PHE
caused O
by O
anticancer B-PHE
agents O
. O

-DOCSTART- O


infertility B-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
vomiting B-PHE
because O
of O
Cold-Damp B-PHE
. O

-DOCSTART- O


Symptoms O
of O
menopause B-PHE
. O

-DOCSTART- O


Excessive O
Repair O

-DOCSTART- O


dizziness B-PHE
; O
vertigo B-PHE

-DOCSTART- O


To O
replenish O
yin O
of O
the O
lung B-PHE
and O
stomach B-PHE
, O
remove O
heat B-PHE
from O
the O
lung O
, O
and O
promote O
fluid B-PHE
secretion I-PHE
. O

-DOCSTART- O


Its O
chief O
component O
is O
berberine O
. O

-DOCSTART- O


Not O
discarded O
retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE

-DOCSTART- O


hemoptysis B-PHE

-DOCSTART- O


Temporomandibular B-PHE
Joint I-PHE
Dysfunction I-PHE

-DOCSTART- O


dribbling B-PHE
urination I-PHE
; O
dribbling B-PHE
of I-PHE
urine I-PHE

-DOCSTART- O


Diagnostic O
yield O
and O
adverse O
effects O
of O
MRI-guided O
free-hand O
brain O
biopsies O
through O
a O
mini-burr O
hole O
in O
dogs O
with O
encephalitis O
. O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
adverse O
effects O
( O
chemotherapy O
) O
and O
bone B-PHE
marrow I-PHE
transplant O
. O

-DOCSTART- O


Treatment O
of O
: O
1 O
Deficient O
yin O
of O
the O
lungs B-PHE
with O
heat B-PHE
manifested O
as O
dry B-PHE
cough I-PHE
or O
cough B-PHE
with O
scanty O
sputum B-PHE
, O
hoarse B-PHE
voice I-PHE
from O
a O
chronic B-PHE
cough I-PHE
, O
dry B-PHE
throat I-PHE
and O
thirst B-PHE
. O

Glehnia O
root O
( O
Shashen O
) O
is O
used O
with O
Ophiopogon O
root O
( O
Maidong O
) O
and O
Tendrilled O
fritillary O
bulb O
( O
Chuanbeimu O
) O
. O

2 O
Body O
fluids O
consumed O
by O
febrile B-PHE
diseases I-PHE
manifested O
as O
dry B-PHE
tongue I-PHE
and O
poor B-PHE
appetite I-PHE
. O

Glehnia O
root O
( O
Shashen O
) O
is O
used O
with O
Ophiopogon O
root O
( O
Maidong O
) O
, O
Fresh O
rehmannia O
root O
( O
Shengdihuang O
) O
and O
Fragrant O
solomonseal O
rhizome O
( O
Yuzhu O
) O
in O
the O
formula O
Yiwei O
Tang O
. O

-DOCSTART- O


Lenalidomide O
inhibits O
TNF-alpha B-PHE
production I-PHE
, O
stimulates O
T B-PHE
cells I-PHE
, O
reduces O
serum B-PHE
levels I-PHE
of I-PHE
the I-PHE
cytokines I-PHE
vascular I-PHE
endothelial I-PHE
growth I-PHE
factor I-PHE
( O
VEGF B-PHE
) O
and O
basic B-PHE
fibroblast I-PHE
growth I-PHE
factor I-PHE
( O
bFGF B-PHE
) O
, O
and O
inhibits O
angiogenesis B-PHE
. O

-DOCSTART- O


stop O
bleeding B-PHE
and O
stabilize O
pain B-PHE

-DOCSTART- O


Detection O
of O
primary O
and O
metastatic B-PHE
pheochromocytoma I-PHE
or O
neuroblastoma B-PHE

-DOCSTART- O


insubstantial O
wind B-PHE

-DOCSTART- O


Liver B-PHE
Disease I-PHE

-DOCSTART- O


Acute B-PHE
Exacerbations I-PHE
of I-PHE
Chronic I-PHE
Bronchitis I-PHE

-DOCSTART- O


pulmonary B-PHE
asthenia I-PHE
; O
lung B-PHE
atropy I-PHE
; O
pulmonary B-PHE
flaccidity I-PHE
syndrome I-PHE

-DOCSTART- O


Wind-cold B-PHE
common I-PHE
cold I-PHE
, O
headache B-PHE
, O
cough B-PHE
and O
asthma B-PHE
, O
deep-source B-PHE
nasal I-PHE
congestion I-PHE
, O
cold B-PHE
pain I-PHE
in O
stomach O
duct O
and O
abdomen O
, O
wind-cold-damp B-PHE
impediment I-PHE
, O
cold-damp B-PHE
vaginal I-PHE
discharge I-PHE
, O
dysmenorrhea B-PHE
, O
toxin B-PHE
swelling I-PHE
of I-PHE
sores I-PHE
, O
wind O
papule B-PHE
itching O
. O

-DOCSTART- O


dizziness B-PHE
and O
vertigo B-PHE

-DOCSTART- O


This O
is O
a O
syndrome B-PHE
with I-PHE
numbness I-PHE
and O
a O
pain B-PHE
due O
to O
Wind-Dampness B-PHE
. O

-DOCSTART- O


To O
replenish O
the O
liver B-PHE
and O
kidney B-PHE
, O
improve O
eyesight B-PHE
and O
promote O
the O
growth B-PHE
of I-PHE
black I-PHE
hair I-PHE
. O

-DOCSTART- O


Childhood B-PHE
B I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


burns B-PHE
; O
fire B-PHE
burns I-PHE

-DOCSTART- O


sparrow B-PHE
vision I-PHE
; O
night B-PHE
blindness I-PHE

-DOCSTART- O


Pheochromocytoma B-PHE

-DOCSTART- O


alleviate O
edema B-PHE

-DOCSTART- O


spinal B-PHE
cord I-PHE
problems I-PHE
, O
pain B-PHE
etc O
. O

-DOCSTART- O


Bofutsushosan O
, O
a O
traditional O
Chinese O
formulation O
, O
prevents O
intimal B-PHE
thickening I-PHE
and O
vascular B-PHE
smooth I-PHE
muscle I-PHE
cell I-PHE
proliferation I-PHE
induced O
by O
balloon O
endothelial B-PHE
denudation I-PHE
in O
rats O
. O

-DOCSTART- O


To O
strengthen O
the O
body B-PHE
resistance I-PHE
to O
consolidate O
the O
constitution O
, O
replenish O
qi O
, O
invigorate O
the O
spleen B-PHE
and O
tonify O
the O
spleen B-PHE
and O
tonify O
the O
kidney B-PHE
to O
relieve O
mental B-PHE
strain I-PHE
. O

-DOCSTART- O


To O
dissipate O
binds O
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Mucosal B-PHE
Melanoma I-PHE

-DOCSTART- O


latent O
summer B-PHE
heat I-PHE
syndrome I-PHE

-DOCSTART- O


dry B-PHE
mouth I-PHE
; O

xerostomia B-PHE
; O

dryness B-PHE
of I-PHE
mouth I-PHE

-DOCSTART- O


Unresectable O
Metastasis O
Originating O
in O
Colonic B-PHE
Cancer I-PHE
. O

-DOCSTART- O


Croton O
seed O
( O
Badou O
) O
is O
used O
with O
Medicated O
leaven O
( O
Shenqu O
) O
, O
Arisaema O
tuber O
with O
bile O
( O
Dannanxing O
) O
and O
Cinnabar O
( O
Zhusha O
) O
in O
the O
formula O
Baochi O
San O
. O

-DOCSTART- O


warm O
large B-PHE
intestine I-PHE

-DOCSTART- O


absorption B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
motility B-PHE
, O
Others O

-DOCSTART- O


Nausea B-PHE

-DOCSTART- O


Treatment O
of O
loss B-PHE
of I-PHE
consciousness I-PHE
in O
stroke B-PHE
and O
epilepsy B-PHE
, O
sore B-PHE
throat I-PHE
, O
dyspnea B-PHE
and O
cough B-PHE
with O
phlegm B-PHE
difficult O
to O
spit O
out O
, O
constipation B-PHE
, O
external O
use O
for O
subcutaneous B-PHE
pyogenic I-PHE
infections I-PHE
. O

-DOCSTART- O


To O
kill O
roundworms B-PHE
; O

To O
kill O
worms B-PHE
; O

To O
move O
qi O
; O

To O
stop O
pain B-PHE

-DOCSTART- O


There O
are O
two O
isoforms O
of O
ACE O
: O
the O
somatic O
isoform O
, O
which O
exists O
as O
a O
glycoprotein O
comprised O
of O
a O
single O
polypeptide O
chain O
of O
1277 O
; O
and O
the O
testicular B-PHE
isoform I-PHE
, O
which O
has O
a O
lower O
molecular O
mass O
and O
is O
thought O
to O
play O
a O
role O
in O
sperm B-PHE
maturation I-PHE
and O
binding O
of O
sperm B-PHE
to O
the O
oviduct B-PHE
epithelium I-PHE
. O

Somatic O
ACE O
has O
two O
functionally O
active O
domains O
, O
N O
and O
C, O
which O
arise O
from O
tandem O
gene B-PHE
duplication I-PHE
. O

Although O
the O
two O
domains O
have O
high O
sequence O
similarity O
, O
they O
play O
distinct O
physiological O
roles O
. O

The O
C-domain O
is O
predominantly O
involved O
in O
blood B-PHE
pressure I-PHE
regulation I-PHE
while O
the O
N-domain O
plays O
a O
role O
in O
hematopoietic B-PHE
stem I-PHE
cell I-PHE
differentiation I-PHE
and I-PHE
proliferation I-PHE
. O

ACE O
inhibitors O
bind O
to O
and O
inhibit O
the O
activity O
of O
both O
domains O
, O
but O
have O
much O
greater O
affinity O
for O
and O
inhibitory O
activity O
against O
the O
C-domain O
. O

Enalaprilat O
, O
the O
principle O
active B-PHE
metabolite I-PHE
of O
enalapril O
, O
competes O
with O
ATI O
for O
binding O
to O
ACE O
and O
inhibits O
and O
enzymatic B-PHE
proteolysis I-PHE
of O
ATI O
to O
ATII O
. O

Decreasing O
ATII B-PHE
levels I-PHE
in O
the O
body O
decreases O
blood B-PHE
pressure I-PHE
by O
inhibiting O
the O
pressor B-PHE
effects I-PHE
of I-PHE
ATII I-PHE
as O
described O
in O
the O
Pharmacology O
section O
above O
. O

Enalapril O
also O
causes O
an O
increase O
in O
plasma B-PHE
renin I-PHE
activity I-PHE
likely O
due O
to O
a O
loss O
of O
feedback O
inhibition O
mediated O
by O
ATII O
on O
the O
release O
of O
renin B-PHE
and/or O
stimulation O
of O
reflex O
mechanisms O
via O
baroreceptors O
. O

Enalaprilat's O
affinity O
for O
ACE O
is O
approximately O
200000 O
times O
greater O
than O
that O
of O
ATI O
and O
300-1000 O
times O
greater O
than O
that O
enalapril O
. O

-DOCSTART- O


Blockade O
of O
dopaminergic O
D2 O
receptors O
in O
the O
limbic B-PHE
system I-PHE
alleviates O
positive O
symptoms O
of O
schizophrenia B-PHE
such O
as O
hallucinations B-PHE
, O
delusions B-PHE
, O
and O
erratic B-PHE
behavior I-PHE
and O
speech O
. O

Blockade O
of O
serotonergic O
5-HT O
2 O
receptors O
in O
the O
mesocortical B-PHE
tract I-PHE
, O
causes O
an O
excess O
of O
dopamine O
and O
an O
increase O
in O
dopamine O
transmission O
, O
resulting O
in O
an O
increase O
in O
dopamine O
transmission O
and O
an O
elimination O
of O
core O
negative O
symptoms O
. O

Dopamine O
receptors O
in O
the O
nigrostriatal O
pathway O
are O
not O
affected O
by O
risperidone O
and O
extrapyramidal O
effects O
are O
avoided O
. O

Like O
other O
5-HT O
2 O
antagonists O
, O
risperidone O
also O
binds O
at O
alpha(1)-adrenergic O
receptors O
and O
, O
to O
a O
lesser O
extent O
, O
at O
histamine O
H1 O
and O
alpha(2)-adrenergic O
receptors O
. O

-DOCSTART- O


one O
of O
cough B-PHE
that O
gets O
worst O
at O
night O
. O

That O
occurs O
by O
insubstantial O
Fire O
in O
the O
lung O
due O
to O
insufficiency O
of O
the O
kidney O
Eum O

-DOCSTART- O


insufficiency O
of O
heart B-PHE
Gi O

-DOCSTART- O


Stage O
II O
Contiguous O
Adult B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


Heparin O
binds O
to O
antithrombin B-PHE
III I-PHE
to O
form O
a O
heparin-antithrombin O
III O
complex O
. O

-DOCSTART- O


a O
disease O
like O
a O
cholera B-PHE
. O

That O
Has O
a O
abdominal B-PHE
pain I-PHE
, O
vomiting B-PHE
and O
diarrhea B-PHE
caused O
by O
dirty O
and O
acute O
filthy O
Gi O

-DOCSTART- O


lack O
of O
essence O
and O
blood B-PHE

-DOCSTART- O


asthma B-PHE
; O

dyspnea B-PHE
; O

abnormal O
rising O
of O
Gi O
; O

upward O
Gi O
dyspnea O
due O
to O
upward O
adverse O
flow O
of O
the O
lung-Gi O

-DOCSTART- O


Intercritical O
Gout B-PHE

-DOCSTART- O


promote O
sweating B-PHE

-DOCSTART- O


Docetaxel O
binds O
to O
microtubules O
reversibly O
with O
high O
affinity O
, O
which O
stabilises O
microtubules O
and O
prevents O
depolymerisation O
from O
calcium O
ions O
, O
decreased B-PHE
temperature I-PHE
and O
dilution B-PHE
, O
preferentially O
at O
the O
plus O
end O
of O
the O
microtubule O
. O

Irinotecan O
, O
a O
prodrug O
, O
is O
converted O
to O
a O
biologically O
active O
metabolite O
7-ethyl-10-hydroxy-camptothecin O
( O
SN-38 O
) O
by O
a O
carboxylesterase-converting O
enzyme O
. O

SN-38 O
inhibits O
topoisomerase B-PHE
I I-PHE
activity I-PHE
by O
stabilizing O
the O
cleavable O
complex O
between O
topoisomerase B-PHE
I I-PHE
and O
DNA B-PHE
, O
resulting O
in O
DNA B-PHE
breaks I-PHE
that O
inhibit O
DNA B-PHE
replication I-PHE
and O
trigger O
apoptotic B-PHE
cell I-PHE
death I-PHE
. O

-DOCSTART- O


Liver B-PHE
cancer I-PHE

-DOCSTART- O


1 O
Morellic B-PHE
acid I-PHE
, O
one O
of O
its O
components O
, O
inhibits O
Ehrljch-Ascites B-PHE
tumour I-PHE
and O
sarcoma180 B-PHE
. O

2 O
Inhibiting O
BEL-7402 B-PHE
species I-PHE
of O
hepatic B-PHE
cancer I-PHE
cells I-PHE
and O
HeLa B-PHE
cells I-PHE
in O
vitro O
. O

3 O
Increasing O
white B-PHE
blood I-PHE
cells I-PHE
and O
promoting O
its O
phagocytosis B-PHE
during O
the O
treatment O
of O
cancer B-PHE
in O
experimental O
animals O

-DOCSTART- O


heavy B-PHE
eyes I-PHE

-DOCSTART- O


moderate O
sinews B-PHE
and O
bones B-PHE

-DOCSTART- O


deficiency B-PHE
of O
the O
kidney O
; O

deficiency B-PHE
syndrome I-PHE
of O
the O
kidney O
the O
pathological B-PHE
changes I-PHE
due O
to O
deficiency B-PHE
of O
the O
kidney O
essence O
, O
usually O
characterized O
by O
dizziness B-PHE
, O
tinnitus B-PHE
, O
lumbago B-PHE
, O
nocturnal B-PHE
emission I-PHE
, O
impotence B-PHE
, O
lassitude B-PHE
, O
forgetfulness B-PHE
. O

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
t(16;16)(p13.1;q22 O
) O
; O
CBFB-MYH11 O

-DOCSTART- O


Mouth B-PHE
sore I-PHE
, O
clove B-PHE
sore I-PHE
, O
hemorrhoids B-PHE
, O
scrotal B-PHE
eczema I-PHE
, O
bleeding B-PHE
due O
to O
external B-PHE
injury I-PHE
. O

-DOCSTART- O


This O
disease B-PHE
has O
a O
characteristics O
of O
gradual O
onset O
, O
plat O
form O
of O
ulceration B-PHE
, O
mild O
or O
no O
pain B-PHE
, O
no O
change O
of O
skin B-PHE
color I-PHE
or O
dark O
reddish O
or O
blackened O
color O
change O
, O
mild O
or O
no O
fever B-PHE
, O
not O
well O
subsided O
or O
healed O
, O
occasional O
lump B-PHE
formation I-PHE
, O
no O
pus B-PHE
, O
long O
duration O
of O
treatment O
, O
thin O
colourful O
discharge O
, O
Chimse O
and O
weak O
Mac O
. O

-DOCSTART- O


To O
drain O
accumulated O
cold B-PHE
downward O

-DOCSTART- O


As O
first O
clinical O
data O
indicate O
, O
the O
achieved O
blood B-PHE
pressure I-PHE
reduction I-PHE
was O
particularly O
pronounced O
in O
the O
early O
morning O
when O
the O
vaccine O
effect O
suppressed O
the O
naturally O
occurring O
morning O
rise O
in O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


Kallmann B-PHE
Syndrome I-PHE

-DOCSTART- O


Hydroflumethiazide O
is O
a O
thiazide O
diuretic O
that O
inhibits O
water B-PHE
reabsorption I-PHE
in O
the O
nephron O
by O
inhibiting O
the O
sodium-chloride B-PHE
symporter I-PHE
( O
SLC12A3 B-PHE
) O
in O
the O
distal O
convoluted O
tubule O
, O
which O
is O
responsible O
for O
0.05 O
of O
total O
sodium B-PHE
reabsorption I-PHE
. O

Normally O
, O
the O
sodium-chloride O
symporter O
transports O
sodium O
and O
chloride O
from O
the O
lumen O
into O
the O
epithelial O
cell O
lining O
the O
distal O
convoluted O
tubule O
. O

The O
energy O
for O
this O
is O
provided O
by O
a O
sodium O
gradient O
established O
by O
sodium-potassium B-PHE
ATPases I-PHE
on O
the O
basolateral B-PHE
membrane I-PHE
. O

Once O
sodium O
has O
entered O
the O
cell O
, O
it O
is O
transported O
out O
into O
the O
basolateral O
interstitium O
via O
the O
sodium-potassium O
ATPase O
, O
causing O
an O
increase O
in O
the O
osmolarity B-PHE
of I-PHE
the I-PHE
interstitium I-PHE
, O
thereby O
establishing O
an O
osmotic B-PHE
gradient I-PHE
for O
water B-PHE
reabsorption I-PHE
. O

By O
blocking O
the O
sodium-chloride B-PHE
symporter I-PHE
, O
Hydroflumethiazide O
effectively O
reduces O
the O
osmotic B-PHE
gradient I-PHE
and O
water B-PHE
reabsorption I-PHE
throughout O
the O
nephron O
. O

-DOCSTART- O


For O
calming O
liver B-PHE
and O
containing O
wind B-PHE

-DOCSTART- O


The O
powder O
of O
Croton O
seed O
( O
Badou O
) O
is O
blown O
into O
the O
throat B-PHE
to O
cause O
vomiting B-PHE
. O

-DOCSTART- O


To O
tonify O
the O
liver B-PHE
and O
the O
kidney B-PHE
, O
to O
strengthen O
the O
tendons B-PHE
and O
bones B-PHE
, O
and O
to O
prevent O
miscarrige B-PHE
. O

-DOCSTART- O


uncomfortable O
of O
the O
heart B-PHE
and O
gallbladder B-PHE

-DOCSTART- O


It O
contains O
about O
0.5 O
of O
fatty O
oil O
, O
exerting O
antitussive O
effect O
. O

-DOCSTART- O


To O
arrest O
seminal B-PHE
emission I-PHE
, O
to O
restrain O
urination B-PHE
, O
and O
to O
check O
diarrhea B-PHE
. O

cturnal B-PHE
emission I-PHE
, O
spermatorrhea B-PHE
, O
enuresis B-PHE
, O
frequent B-PHE
urination I-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
excessive O
leukorrhea B-PHE
, O
protracted O
diarrhea B-PHE
, O
chronic B-PHE
dysentery I-PHE
. O

-DOCSTART- O


For O
dispelling O
wind-dampness B-PHE
and O
dispersing O
coldness B-PHE
. O

-DOCSTART- O


Indicated O
in O
the O
treatment O
of O
moderate O
to O
severe O
pain B-PHE
. O

Consider O
for O
those O
prone O
to O
constipation B-PHE
or O
respiratory B-PHE
depression I-PHE
. O

Tramadol O
is O
used O
to O
treat O
postoperative O
, O
dental O
, O
cancer B-PHE
, O
and O
acute B-PHE
musculosketetal I-PHE
pain I-PHE
and O
as O
an O
adjuvant O
to O
NSAID O
therapy O
in O
patients O
with O
osteoarthritis B-PHE
. O

-DOCSTART- O


Nevirapine O
binds O
directly O
to O
reverse B-PHE
transcriptase I-PHE
and O
blocks O
the O
RNA-dependent B-PHE
and I-PHE
DNA-dependent I-PHE
DNA I-PHE
polymerase I-PHE
activities O
by O
causing O
a O
disruption B-PHE
of I-PHE
the I-PHE
enzyme's I-PHE
catalytic I-PHE
site I-PHE
. O

-DOCSTART- O


Strengthen O
the O
heart B-PHE
and O
replenish O
qi O
, O
activating O
yang O
and O
blood B-PHE
circulation I-PHE
, O
promoting O
the O
restoration B-PHE
of I-PHE
consciousness I-PHE
with O
drugs O
of O
fragnant O
flavour O
, O
relieving O
pain B-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Body B-PHE
weight I-PHE

-DOCSTART- O


aversion O
to O
cold B-PHE
; O

severe B-PHE
chillness I-PHE
; O

creeping B-PHE
chills I-PHE

-DOCSTART- O


Colorectal B-PHE
Cancer I-PHE

-DOCSTART- O


There O
are O
two O
isoforms O
of O
ACE O
: O
the O
somatic O
isoform O
, O
which O
exists O
as O
a O
glycoprotein O
comprised O
of O
a O
single O
polypeptide O
chain O
of O
1277 O
; O
and O
the O
testicular O
isoform O
, O
which O
has O
a O
lower O
molecular O
mass O
and O
is O
thought O
to O
play O
a O
role O
in O
sperm B-PHE
maturation I-PHE
and O
binding O
of O
sperm O
to O
the O
oviduct O
epithelium O
. O

Somatic O
ACE O
has O
two O
functionally O
active O
domains O
, O
N O
and O
C, O
which O
arise O
from O
tandem O
gene O
duplication O
. O

Although O
the O
two O
domains O
have O
high O
sequence O
similarity O
, O
they O
play O
distinct O
physiological O
roles O
. O

The O
C-domain O
is O
predominantly O
involved O
in O
blood B-PHE
pressure I-PHE
regulation I-PHE
while O
the O
N-domain O
plays O
a O
role O
in O
hematopoietic O
stem O
cell O
differentiation O
and O
proliferation O
. O

ACE O
inhibitors O
bind O
to O
and O
inhibit O
the O
activity O
of O
both O
domains O
, O
but O
have O
much O
greater O
affinity O
for O
and O
inhibitory O
activity O
against O
the O
C-domain O
. O

Quinaprilat O
, O
the O
principle O
active O
metabolite O
of O
quinapril O
, O
competes O
with O
ATI O
for O
binding O
to O
ACE O
and O
inhibits O
and O
enzymatic O
proteolysis O
of O
ATI O
to O
ATII O
. O

Decreasing O
ATII O
levels O
in O
the O
body O
decreases O
blood B-PHE
pressure I-PHE
by O
inhibiting O
the O
pressor O
effects O
of O
ATII O
as O
described O
in O
the O
Pharmacology O
section O
above O
. O

Quinaprilat O
also O
causes O
an O
increase O
in O
plasma O
renin O
activity O
likely O
due O
to O
a O
loss O
of O
feedback O
inhibition O
mediated O
by O
ATII O
on O
the O
release O
of O
renin O
and/or O
stimulation O
of O
reflex O
mechanisms O
via O
baroreceptors O
. O

-DOCSTART- O


The O
role O
of O
crude O
polysaccharide O
fractions O
on O
the O
mitogenic B-PHE
activity I-PHE
by O
Shosaikoto O
. O

-DOCSTART- O


dyspnea B-PHE
and O
tachypnea B-PHE
; O

shortness B-PHE
of I-PHE
breath I-PHE

-DOCSTART- O


A O
symptom O
that O
the O
lung O
is O
blocked O
up O
caused O
by O
symptoms O
due O
to O
retention B-PHE
of I-PHE
phlegm I-PHE
. O

-DOCSTART- O


Anesthesia B-PHE
With O
Use O
of O
LMA O
( O
Laryngeal O
Mask O
Airway O
) O

-DOCSTART- O


cough B-PHE
with I-PHE
blood I-PHE
due O
to O
a O
damaged B-PHE
lungs I-PHE
because O
of O
exhaustion B-PHE
syndrome I-PHE

-DOCSTART- O


To O
nourish O
yin O
and O
moisterize O
lung B-PHE
; O

To O
suppress O
fire O
and O
desolve O
phlegm B-PHE

-DOCSTART- O


carbuncle B-PHE
and O
cellulitis B-PHE

-DOCSTART- O


impetigo B-PHE
; O
pyoderma B-PHE

-DOCSTART- O


having O
painful B-PHE
and I-PHE
benumbed I-PHE
joint I-PHE

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Megakaryoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


desire O
for O
vomiting B-PHE
; O
feel O
nauseated B-PHE
; O
nausea B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
adult O
patients O
diagnosed O
with O
anaplastic B-PHE
astrocytoma I-PHE
whose O
disease O
has O
progressed O
after O
therapy O
with O
nitrosourea O
and O
procarbazine O
, O
as O
well O
as O
concomitantly O
with O
radiation O
therapy O
for O
treatment O
of O
newly O
diagnosed O
glioblastoma B-PHE
multiforme I-PHE
. O
Also O
used O
as O
maintenance O
therapy O
for O
glioblastoma B-PHE
multiforme I-PHE
. O

-DOCSTART- O


amenorrhea B-PHE

-DOCSTART- O


acute B-PHE
appendicitis I-PHE
; O
periappendicular B-PHE
abscess I-PHE
; O
intestinal B-PHE
carbuncle I-PHE
; O
intestinal B-PHE
abscess I-PHE

-DOCSTART- O


Treatment O
of O
jaundice B-PHE
caused O
by O
damp-heat B-PHE
, O
heat B-PHE
stroke I-PHE
with O
diarrhea B-PHE
, O
urolithiasis B-PHE
and O
hematuria B-PHE
, O
carbuncles B-PHE
and O
boils B-PHE
, O
traumatic B-PHE
injuries I-PHE
. O

-DOCSTART- O


epistaxis B-PHE

-DOCSTART- O


Indacaterol O
works O
by O
stimulating O
adrenergic O
beta-2 O
receptors O
in O
the O
smooth O
muscle O
of O
the O
airways O
. O

Tiotropium O
is O
a O
muscarinic O
receptor O
antagonist O
, O
often O
referred O
to O
as O
an O
antimuscarinic O
or O
anticholinergic O
agent O
. O

-DOCSTART- O


Quality O
of O
life O
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Others O
, O
Protective B-PHE
immunity I-PHE
, O
Inflammation B-PHE

-DOCSTART- O


Traumatic B-PHE
brain I-PHE
injury I-PHE

-DOCSTART- O


Follicular B-PHE
Lymphoma I-PHE

-DOCSTART- O


Rikkunshito O
( O
RKT O
) O
, O
a O
Japanese O
traditional O
medicine O
, O
has O
been O
shown O
to O
stimulate O
food O
intake O
in O
rats O
with O
cisplatin-induced B-PHE
anorexia I-PHE
; O
however O
, O
the O
underlying O
mechanisms O
remain O
unknown O
. O

In O
this O
study O
, O
we O
investigated O
whether O
RKT O
is O
involved O
in O
the O
degradation O
of O
peripheral B-PHE
ghrelin I-PHE
. O

RKT O
inhibited O
decreases O
in O
plasma B-PHE
ghrelin I-PHE
level I-PHE
and O
enhanced O
acyl- B-PHE
to I-PHE
desacyl-ghrelin I-PHE
( O
A/D B-PHE
) O
ratio O
in O
cisplatin-treated O
rats O
. O

Several O
components O
of O
RKT O
demonstrated O
inhibitory O
activity O
against O
ghrelin B-PHE
deacylating I-PHE
enzymes I-PHE
. O

In O
addition O
, O
10-gingerol O
, O
a O
component O
of O
RKT O
, O
inhibited O
exogenous O
ghrelin B-PHE
deacylation I-PHE
. O

Therefore O
, O
RKT O
may O
enhance O
plasma B-PHE
acyl I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
, O
at O
least O
in O
part O
, O
by O
inhibiting O
the O
circulating O
ghrelin B-PHE
degrading I-PHE
enzyme I-PHE
. O

-DOCSTART- O


disperse O
wind B-PHE
and O
eliminate O
dampness B-PHE

-DOCSTART- O


extinguish O
wind B-PHE
and O
stabilize O
fright B-PHE

-DOCSTART- O


invigorate O
blood B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


To O
disperse O
accumulation O
, O
disinhibit O
diaphragm B-PHE
, O
precipitate O
heat B-PHE
toxin I-PHE
. O

-DOCSTART- O


Kampo O
( O
traditional O
Japanese O
herbal O
) O
medicines O
are O
taken O
orally O
due O
to O
which O
the O
gastric B-PHE
mucosal I-PHE
immune I-PHE
system I-PHE
may O
act O
as O
one O
of O
the O
major O
targets O
for O
the O
expression O
of O
pharmacological O
activity O
. O

The O
inner O
surface O
of O
the O
intestinal O
tract O
possesses O
a O
large O
area O
of O
mucosal O
membranes O
, O
and O
the O
intestinal O
epithelial O
cells O
sit O
at O
the O
interface O
between O
a O
lumen O
and O
a O
lymphocyte O
- O
rich O
lamina O
propria O
. O

The O
cross O
talk O
that O
occurs O
between O
these O
compartments O
serves O
to O
maintain O
intestinal B-PHE
homeostasis I-PHE
, O
and O
the O
cytokine B-PHE
network I-PHE
plays O
an O
important O
role O
in O
the O
cross O
talk O
. O

In O
this O
study O
, O
the O
effect O
of O
Hochuekkito O
( O
HET O
) O
, O
one O
of O
Kampo O
medicines O
, O
on O
cytokine B-PHE
secretion I-PHE
of O
intestinal O
epithelial O
cells O
was O
investigated O
. O

When O
murine O
normal O
colonic O
epithelial O
cell O
- O
line O
MCE301 B-PHE
cells I-PHE
were O
stimulated O
with O
HET O
, O
the O
contents O
of O
granulocyte B-PHE
colony I-PHE
- I-PHE
stimulating I-PHE
factor I-PHE
( O
G B-PHE
- I-PHE
CSF I-PHE
) O
in O
the O
conditioned O
medium O
were O
significantly O
increased O
in O
dose O
- O
and O
time O
- O
dependent O
manners O
. O

The O
enhanced O
G B-PHE
- I-PHE
CSF I-PHE
gene I-PHE
transcription I-PHE
in O
MCE301 O
cells O
by O
the O
stimulation O
of O
HET O
was O
observed O
by O
RT O
- O
PCR O
. O

The O
enhanced O
G B-PHE
- I-PHE
G-CSF I-PHE
secretion I-PHE
by O
HET O
was O
also O
observed O
in O
C3H O
/ O
HeJ O
mice O
- O
derived O
primary O
cultured O
colonic O
epithelial O
cells O
. O

When O
the O
HET O
was O
fractionated O
, O
only O
the O
polysaccharide B-PHE
fraction I-PHE
( O
F B-PHE
- I-PHE
5 I-PHE
) O
enhanced O
the O
G B-PHE
- I-PHE
CSF I-PHE
secretion I-PHE
of O
MCE301 O
cells O
, O
and O
the O
activity O
of O
F B-PHE
- I-PHE
5 I-PHE
lost O
after O
the O
treatment O
of O
periodate O
that O
can O
degrade O
the O
carbohydrate O
moiety O
. O

These O
results O
suggest O
that O
HET O
enhances O
secretion B-PHE
of I-PHE
G I-PHE
- I-PHE
CSF I-PHE
from O
colonic O
epithelial O
cells O
and O
the O
polysaccharide O
is O
one O
of O
the O
active O
ingredients O
of O
HET O
. O

The O
enhanced O
G B-PHE
- I-PHE
CSF I-PHE
secretion I-PHE
by O
HET O
may O
partly O
contribute O
to O
the O
clinically O
observed O
various O
pharmacological O
activities O
of O
HET O
including O
immunomodulating B-PHE
activity I-PHE
. O

-DOCSTART- O


accumulation O
of O
pathogenic B-PHE
factors I-PHE
in O
the O
chest O
; O
accumulation O
of O
pathogens B-PHE
in O
the O
chest O
; O
knotted B-PHE
chest I-PHE
a O
syndrome O
due O
to O
accumulation O
of O
pathogenic O
heat B-PHE
or O
cold B-PHE
with O
stagnancy B-PHE
of I-PHE
fluid I-PHE
or O
phlegm B-PHE
or O
blood B-PHE
in O
the O
chest O
. O

-DOCSTART- O


Acute B-PHE
otitis I-PHE
media I-PHE
in O
children O
that O
is O
caused O
by O
susceptible O
strains O
of O
Haemophilus B-PHE
influenzae I-PHE
. O

-DOCSTART- O


To O
promote O
blood B-PHE
circulation I-PHE
, O
remove O
blood B-PHE
stasis I-PHE
, O
restore O
consciousness B-PHE
, O
remove O
obstruction B-PHE
in O
the O
channels O
, O
suppress O
the O
hyperfunction O
of O
liver-yang O
and O
stop O
endogenous B-PHE
wind I-PHE
to O
relieve O
convulsion B-PHE
. O

-DOCSTART- O


Renal B-PHE
Impairment I-PHE

-DOCSTART- O


Knocks B-PHE
and O
falls B-PHE
, O
stasis B-PHE
swelling I-PHE
pain I-PHE
, O
wind-damp B-PHE
impediment I-PHE
pain I-PHE
. O

-DOCSTART- O


Pectus B-PHE
Excavatum I-PHE

-DOCSTART- O


End B-PHE
Stage I-PHE
Renal I-PHE
Disease I-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Digestion B-PHE
, O
Energy O
/ O
food O
intake O
( O
apetite O
/ O
satiety O
) O
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Body B-PHE
fat I-PHE
deposition I-PHE
( O
total O
amount O

-DOCSTART- O


Chronic B-PHE
Kidney I-PHE
Disease I-PHE

-DOCSTART- O


To O
regulate O
qi O
, O
promote O
blood B-PHE
circulation I-PHE
and O
regulate O
menstruation B-PHE
. O

-DOCSTART- O


concurrent O
disease B-PHE
of O
the O
T'aeyang O
meridian O
and O
the O
Soyang O
meridian O

-DOCSTART- O


soothe O
diaphragm B-PHE

-DOCSTART- O


Stagnation O
of O
liver-qi O
, O
abnormal O
relation O
between O
spleen O
and O
stomach O
, O
sensation B-PHE
of I-PHE
fullness I-PHE
and O
obstruction B-PHE
over O
chest O
and O
diaphragm O
, O
distension B-PHE
at O
hypochondriac O
regions O
, O
stomach-ache B-PHE
, O
gastric B-PHE
upset I-PHE
, O
eructation B-PHE
, O
acid B-PHE
eructation I-PHE
, O
nausea B-PHE
and O
vomiting B-PHE
. O

-DOCSTART- O


Psychomotor B-PHE
Agitation I-PHE

-DOCSTART- O


Anemia B-PHE
in I-PHE
Chronic I-PHE
Renal I-PHE
Disease I-PHE

-DOCSTART- O


( O
1 O
) O
pestilent B-PHE
lesions I-PHE
; O
leprosy B-PHE
( O
2 O
) O
malignant B-PHE
furuncle I-PHE

-DOCSTART- O


To O
soothe O
liver B-PHE
and O
clear O
heat B-PHE
; O
To O
constrain O
qi O
and O
strengthen O
spleen B-PHE
; O
To O
calm O
spirit B-PHE

-DOCSTART- O


Stage O
IV O
Adult B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


Ascites B-PHE
. O

Croton O
seed O
( O
Badou O
) O
is O
used O
with O
Apricot O
seed O
( O
Xingren O
) O
. O

-DOCSTART- O


Indicated O
as O
symptomatic O
treatment O
of O
allergic B-PHE
reactions I-PHE
: O
urticaria B-PHE
, O
allergies B-PHE
of I-PHE
the I-PHE
upper I-PHE
respiratory I-PHE
tract I-PHE
such O
as O
hey B-PHE
fever I-PHE
and O
perennial B-PHE
rhinitis I-PHE
, O
food B-PHE
and I-PHE
drug I-PHE
allergies I-PHE
; O
pruritus B-PHE
of I-PHE
various I-PHE
origins I-PHE
, O
except O
pruritus B-PHE
due O
to O
cholestasis B-PHE
; O
insect B-PHE
bites I-PHE
. O

-DOCSTART- O


be O
torn O
of O
sore O
toxic O
pathogenic O
factor O

-DOCSTART- O


Aortic B-PHE
Valve I-PHE
Stenosis I-PHE

-DOCSTART- O


Pulmonary B-PHE
Arterial I-PHE
Hypertension I-PHE

-DOCSTART- O


Intraabdominal B-PHE
Infections I-PHE

-DOCSTART- O


relieve O
cough B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption O
, O
Lipid O
profile O
, O
DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
motility O
, O
Evacuation O

-DOCSTART- O


a O
continuum O
of O
pus B-PHE
and O
blood B-PHE
due O
to O
the O
parasite O
in O
the O
ear O

-DOCSTART- O


steaming B-PHE
bone I-PHE
disorder I-PHE

-DOCSTART- O


stranguria B-PHE
due O
to O
urinary B-PHE
stone I-PHE
; O
dysuria B-PHE
caused O
by O
urinary B-PHE
stone I-PHE
; O
stranguria B-PHE
due O
to O
urolithiasis B-PHE
; O
stony B-PHE
dysuria I-PHE
; O
dysuria B-PHE
caused O
by O
calculi B-PHE

-DOCSTART- O


ThioTEPA O
is O
used O
a O
as O
conditioning O
treatment O
prior O
to O
allogeneic O
or O
autologous O
haematopoietic O
progenitor O
cell O
transplantation O
( O
HPCT O
) O
in O
haematological B-PHE
diseases I-PHE
in O
adult O
and O
paediatric O
patients O
. O

Also O
, O
when O
high O
dose O
chemotherapy O
with O
HPCT O
support O
it O
is O
appropriate O
for O
the O
treatment O
of O
solid B-PHE
tumours I-PHE
in O
adult O
and O
paediatric O
patients O
. O

-DOCSTART- O


To O
benefit O
vital O
Qi O
, O
invigorate O
the O
spleen B-PHE
and O
nourish O
the O
stomach B-PHE
. O

For O
hypofunction B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE
, O
peptic B-PHE
ulcer I-PHE
and O
chronic B-PHE
gastritis I-PHE
. O

Recently O
, O
also O
used O
for O
the O
cancers B-PHE
of I-PHE
erophagus I-PHE
, I-PHE
stomach I-PHE
and I-PHE
intestines I-PHE
. O

-DOCSTART- O


heat B-PHE
in O
the O
stomach O
; O

stomach B-PHE
heat I-PHE
; O

stomach B-PHE
affected O
by O
heat B-PHE
impairment I-PHE
of O
the O
stomach O
by O
pathogenic B-PHE
heat I-PHE
or O
taking O
excessive O
heat-producing O
food O
, O
marked O
by O
thirst B-PHE
, O
halitosis B-PHE
, O
hyperorexia B-PHE
, O
oliguria B-PHE
with O
dark B-PHE
urine I-PHE
, O
constipation B-PHE
or O
even O
ulceration B-PHE
of O
the O
mouth O
, O
gingivitis B-PHE
. O

-DOCSTART- O


To O
stop O
pain B-PHE

-DOCSTART- O


promote O
the O
large B-PHE
intestine I-PHE

-DOCSTART- O


The O
large O
hydrophilic O
molecule O
is O
able O
to O
form O
hydrogen O
bond O
interactions O
with O
the O
terminal O
D-alanyl-D-alanine O
moieties O
of O
the O
NAM/NAG-peptides O
, O
which O
is O
normally O
a O
five-point O
interaction O
. O

-DOCSTART- O


Eyebrow B-PHE
Hypotrichosis I-PHE

-DOCSTART- O


clear O
heat B-PHE
and O
dry O
dampness B-PHE

-DOCSTART- O


cool O
the O
heart B-PHE

-DOCSTART- O


Valproic O
Acid O
acts O
by O
increasing O
gamma-aminobutyric B-PHE
acid I-PHE
levels I-PHE
in O
the O
brain O
or O
by O
altering O
the O
properties O
of O
voltage O
dependent O
sodium O
channels O
. O

Lamotrigine O
inhibits O
voltage-sensitive O
sodium O
channels O
and/or O
calcium O
channels O
, O
thereby O
stabilizing O
neuronal B-PHE
membranes I-PHE
and O
consequently O
modulating O
presynaptic O
transmitter O
release O
of O
excitatory O
amino O
acids O
. O

-DOCSTART- O


To O
resolve O
exterior O
, O
eliminate O
damp B-PHE
, O
relieve O
cough B-PHE
and O
calm O
asthma B-PHE
. O

-DOCSTART- O


Locally O
acting O
as O
an O
irritant O
for O
skin O
and O
mucosa O
; O
orally O
as O
a O
potent O
purgative O
. O

-DOCSTART- O


To O
relieve O
cough B-PHE
and O
dyspnea B-PHE
, O
and O
eliminate O
retained O
phlegm B-PHE
. O

-DOCSTART- O


Inhibitory O
effect O
of O
Chunghyuldan O
in O
prostaglandin O
E2 O
and O
nitric O
oxide O
biosynthesis O
of O
lipopolysaccharide-induced O
RAW O
264.7 O
cells O
. O

-DOCSTART- O


clear O
the O
lung B-PHE

-DOCSTART- O


Endocrine B-PHE
system I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Eldery O
, O
Woman O
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


pyogenic B-PHE
infections I-PHE
due O
to O
furuncle B-PHE

-DOCSTART- O


Norepinephrine O
functions O
as O
a O
peripheral O
vasoconstrictor O
by O
acting O
on O
alpha-adrenergic O
receptors O
. O

It O
is O
also O
an O
inotropic O
stimulator O
of O
the O
heart B-PHE
and O
dilator O
of O
coronary B-PHE
arteries I-PHE
as O
a O
result O
of O
it's O
activity O
at O
the O
beta-adrenergic O
receptors O
. O

-DOCSTART- O


Neurocognitive B-PHE
Function I-PHE
. O

-DOCSTART- O


stop O
diarrhea B-PHE

-DOCSTART- O


After O
binding O
to O
HER2 O
on O
the O
tumor B-PHE
cell I-PHE
surface O
, O
trastuzumab O
induces O
an O
antibody-dependent B-PHE
cell-mediated I-PHE
cytotoxicity I-PHE
against O
tumor B-PHE
cells I-PHE
that O
overexpress O
HER2 B-PHE
. O

Epirubicin O
intercalates O
into O
DNA O
and O
interacts O
with O
topoisomerase B-PHE
II I-PHE
, O
thereby O
inhibiting O
DNA B-PHE
replication I-PHE
and O
repair O
and O
RNA O
and O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


sudden O
turmoil B-PHE
; O

cholera B-PHE
disease I-PHE
; O

acute B-PHE
gastroenteritis I-PHE
; O

acute B-PHE
vomiting I-PHE
and O
diarrhea B-PHE
a O
group O
of O
diseases B-PHE
including O
cholera B-PHE
, O
characterized O
by O
sudden O
and O
drastic O
vomiting B-PHE
and O
diarrhea B-PHE
. O

-DOCSTART- O


This O
is O
running O
a O
fever B-PHE
due O
to O
epidemic B-PHE
. O

-DOCSTART- O


Mild O
Asthma B-PHE

-DOCSTART- O


Ramipril O
is O
an O
angiotensin-converting O
enzyme O
inhibitor O
, O
used O
to O
treat O
high B-PHE
blood I-PHE
pressure I-PHE
and O
congestive B-PHE
heart I-PHE
failure I-PHE
. O

Irbesartan O
, O
by O
blocking O
the O
binding O
of O
angiotensin O
II O
to O
the O
AT1 O
receptor O
, O
promotes O
vasodilation B-PHE
and O
decreases O
the O
effects B-PHE
of I-PHE
aldosterone I-PHE
. O

-DOCSTART- O


Treatment O
of O
wind-heat B-PHE
type O
common O
cold B-PHE
, O
headache B-PHE
and O
dizziness B-PHE
, O
inflammation B-PHE
of O
the O
eye O
, O
blurred B-PHE
vision I-PHE
. O

-DOCSTART- O


Tiotropium O
is O
a O
muscarinic O
receptor O
antagonist O
, O
often O
referred O
to O
as O
an O
antimuscarinic O
or O
anticholinergic O
agent O
. O

Although O
it O
does O
not O
display O
selectivity O
for O
specific O
muscarinic O
receptors O
, O
on O
topical O
application O
it O
acts O
mainly O
on O
M3 O
muscarinic O
receptors O
located O
in O
the O
airways O
to O
produce O
smooth O
muscle B-PHE
relaxation I-PHE
, O
thus O
producing O
a O
bronchodilatory B-PHE
effect I-PHE
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
dry O
damp B-PHE
, O
check O
dysentery B-PHE
. O

-DOCSTART- O


lumbago B-PHE
due O
to O
strain B-PHE
and O
contusion B-PHE

-DOCSTART- O


stiffness B-PHE
of O
four O
ends O

-DOCSTART- O


This O
is O
a O
syndrome O
with O
ooze O
from O
a O
sore B-PHE
. O

-DOCSTART- O


a O
disease O
that O
difficult O
to O
sleep O
, O
beating O
fast O
in O
the O
chest O
, O
feel O
anxiety B-PHE
, O
sometimes O
frightening B-PHE
well O
due O
to O
cold B-PHE
of O
gallbladder B-PHE
meridian I-PHE

-DOCSTART- O


Airway O
Reflexes O
, O
Protective O

-DOCSTART- O


the O
symptom O
caused O
by O
stagnation O
of O
phlegm-heat B-PHE

-DOCSTART- O


For O
acute O
and O
long-term O
management O
of O
signs O
and O
symptoms O
of O
osteoarthritis B-PHE
and O
rheumatoid B-PHE
arthritis I-PHE
, O
as O
well O
as O
for O
the O
management O
of O
pain B-PHE
. O

-DOCSTART- O


Used O
in O
the O
treatment O
of O
relapsing O
forms O
of O
multiple B-PHE
sclerosis I-PHE
( O
MS B-PHE
) O
. O

-DOCSTART- O


Treatment O
of O
cough B-PHE
, O
asthma B-PHE
and O
distending B-PHE
pain I-PHE
of O
the O
chest O
caused O
by O
cold B-PHE
phlegm I-PHE
, O
arthralgia B-PHE
accompanied O
by O
numbness B-PHE
due O
to O
obstruction O
of O
collaterals O
by O
phlegm B-PHE
, O
deep O
abscess B-PHE
. O

-DOCSTART- O


Exposure O
to O
Hepatitis B-PHE
B I-PHE
Virus I-PHE

-DOCSTART- O


alleviate O
edema B-PHE
and O
relieve O
toxicity B-PHE

-DOCSTART- O


Proellex O
selectively O
blocks O
the O
progesterone O
receptor O
thus O
avoiding O
the O
adverse O
effects O
of O
GnRH O
agonists O
associated O
with O
the O
induction O
of O
a O
low O
estrogen B-PHE
, O
menopausal-like B-PHE
state O
in O
women O
. O

-DOCSTART- O


reinforce O
bone B-PHE
marrow I-PHE

-DOCSTART- O


a O
symptom O
of O
not B-PHE
vomiting I-PHE
despite O
nausea B-PHE

-DOCSTART- O


To O
remove O
blood B-PHE
stasis I-PHE
and O
promote O
the O
blood B-PHE
flow I-PHE
, O
to O
stimulate O
menstrual B-PHE
discharge I-PHE
, O
and O
to O
induce O
labour O
. O

-DOCSTART- O


a O
disease B-PHE
with O
pain B-PHE
and O
cold B-PHE
in O
the O
joints O

-DOCSTART- O


To O
expel O
wind B-PHE
from O
the O
body O
surface O
, O
clear O
away O
heat B-PHE
and O
promote O
bowel B-PHE
movement I-PHE
. O

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Overall O
CVD B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
quicken O
blood B-PHE
and O
resolve O
toxin B-PHE
. O

-DOCSTART- O


For O
for O
use O
with O
insulin O
for O
the O
treatment O
of O
noninsulin-dependent O
( O
type O
2 O
) O
diabetes B-PHE
mellitus I-PHE
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Eldery O
, O
Endocrine B-PHE
system I-PHE
, O
Intelligence B-PHE
, O
Others O
, O
Memory B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


To O
stimulate O
digestion B-PHE
and O
promote O
the O
functional O
activity B-PHE
of I-PHE
the I-PHE
stomach I-PHE
; O
to O
improve O
the O
normal O
flow O
of O
qi O
and O
dissipate O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
angioedema B-PHE
. O

-DOCSTART- O


Kidney O
Transplant O

-DOCSTART- O


pectoral B-PHE
pain I-PHE
with O
stuffiness B-PHE
; O
chest B-PHE
impediment I-PHE
; O
chest B-PHE
blockage I-PHE
; O
obstruction O
of O
Gi O
in O
the O
chest O
( O
1 O
) O
a O
morbid B-PHE
condition I-PHE
due O
to O
stagnation B-PHE
of B-PHE
dampness B-PHE
and O
phlegm B-PHE
, O
marked O
by O
choking B-PHE
pain I-PHE
in O
the O
chest O
, O
sometimes O
referring O
to O
the O
back B-PHE
, O
usually O
accompanied O
by O
shortness B-PHE
of I-PHE
breath I-PHE
, O
cough B-PHE
. O
( O

2 O
) O
obstruction O
of O
Gi O
in O
the O
stomach O
, O
chest B-PHE
pain I-PHE
that O
occurs O
immediately O
after O
eating O
, O
accompanied O
by O
difficulty B-PHE
in I-PHE
swallowing I-PHE
and O
frequent O
vomiting B-PHE
. O

-DOCSTART- O


phlegm B-PHE
; O
sputum B-PHE
pathologic O
mucoid O
substances O
collected O
in O
a O
diseased O
organ O
or O
tissue O
. O

-DOCSTART- O


IMC-A12 O
is O
a O
fully O
human O
monoclonal O
antibody O
that O
specifically O
targets O
the O
type O
1 O
human O
insulin-like O
growth O
factor O
receptor O
( O
IGF-IR O
) O
. O

Tumors B-PHE
have O
receptors O
for O
the O
insulin-like O
growth O
factor-1 O
( O
IGF-I O
) O
, O
and O
it O
is O
thought O
that O
the O
presence O
of O
these O
receptors O
cause O
tumors B-PHE
to O
grow O
. O

IMC-A12 O
attaches O
to O
the O
receptors O
and O
may O
inhibit O
the O
growth B-PHE
of I-PHE
cancer I-PHE
cells I-PHE
. O

-DOCSTART- O


epidemic B-PHE
smallpox I-PHE

-DOCSTART- O


scabies B-PHE

-DOCSTART- O


Urinary B-PHE
Bladder I-PHE
, I-PHE
Overactive I-PHE

-DOCSTART- O


Neurological B-PHE
systems I-PHE
health I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Memory B-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


cough B-PHE
due O
to O
pulmonary B-PHE
flaccidity I-PHE

-DOCSTART- O


cough B-PHE
due O
to O
phlegm-damp B-PHE
due O
to O
lung-heat B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Monocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


Proteinuria B-PHE

-DOCSTART- O


Overactive B-PHE
Bladder I-PHE

-DOCSTART- O


chronic B-PHE
cough I-PHE
due O
to O
deficiency B-PHE
of I-PHE
the I-PHE
lung I-PHE

-DOCSTART- O


Purging B-PHE
by O
aggression O

-DOCSTART- O


Enfuvirtide O
binds O
to O
the O
first O
heptad-repeat B-PHE
( O
HR1 O
) O
in O
the O
gp41 O
subunit O
of O
the O
viral O
envelope O
glycoprotein O
and O
prevents O
the O
conformational B-PHE
changes I-PHE
required O
for O
the O
fusion O
of O
viral O
and O
cellular B-PHE
membranes I-PHE
. O

It O
works O
by O
disrupting O
the O
HIV-1 B-PHE
molecular I-PHE
machinery I-PHE
at O
the O
final O
stage O
of O
fusion O
with O
the O
target O
cell O
, O
preventing O
uninfected B-PHE
cells I-PHE
from O
becoming O
infected O
. O

Enfuvirtide O
is O
a O
biomimetic O
peptide O
that O
was O
rationally O
designed O
to O
mimic O
components O
of O
the O
HIV-1 B-PHE
fusion I-PHE
machinery O
and O
displace O
them O
, O
preventing O
normal O
fusion B-PHE
. O

-DOCSTART- O


Rituximab O
binds O
to O
the O
CD20 O
antigen O
on O
B O
lymphocytes O
, O
while O
the O
Fc O
domain O
recruits O
antibodies B-PHE
and O
complements O
to O
mediate O
cell B-PHE
lysis I-PHE
and O
interferes O
with O
the O
growth O
and O
spread O
of O
cancer B-PHE
cells I-PHE
in O
the O
body O
. O

-DOCSTART- O


For O
palliative O
, O
not O
definitive O
, O
therapy O
to O
temporarily O
maintain O
the O
patency B-PHE
of I-PHE
the I-PHE
ductus I-PHE
arteriosus I-PHE
until O
corrective O
or O
palliative O
surgery O
can O
be O
performed O
in O
neonates O
who O
have O
congenital B-PHE
heart I-PHE
defects I-PHE
and O
who O
depend O
upon O
the O
patent O
ductus O
for O
survival O
. O

Also O
for O
the O
treatment O
of O
erectile B-PHE
dysfunction I-PHE
due O
to O
neurogenic O
, O
vasculogenic O
, O
psychogenic O
, O
or O
mixed O
etiology O
. O

-DOCSTART- O


to O
have O
skin B-PHE
rashes I-PHE
due O
to O
epidemic B-PHE
febrile I-PHE

-DOCSTART- O


Treatment O
of O
ulcer B-PHE
difficulty O
to O
heal O
, O
wounds B-PHE
, O
burns B-PHE
and O
scalds B-PHE
. O

-DOCSTART- O


reinforce O
the O
spleen B-PHE

-DOCSTART- O


This O
means O
no O
rash B-PHE
formation O
after O
days O
of O
fever B-PHE
. O

-DOCSTART- O


constipation B-PHE
and O
dry B-PHE
stool I-PHE

-DOCSTART- O


relieve O
spasm B-PHE

-DOCSTART- O


moisten O
the O
lung B-PHE

-DOCSTART- O


Hepatitis B-PHE
C I-PHE
, I-PHE
Chronic I-PHE

-DOCSTART- O


convulsive B-PHE
seizure I-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
stuffiness B-PHE
and O
hot B-PHE
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O


Treatment O
of O
thrist O
in O
febrile B-PHE
disease I-PHE
, O
dry B-PHE
cough I-PHE
due O
to O
heat B-PHE
in O
the O
lung O
, O
diabetes B-PHE
caused O
by O
internal O
heat B-PHE
, O
sores B-PHE
and O
abscess B-PHE
. O

-DOCSTART- O


Stage O
II O
Childhood B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


reinforce O
Gi(Qi O
) O
and O
blood B-PHE

-DOCSTART- O


The O
so O
called O
renin-angiotensin B-PHE
system I-PHE
( O
RAS B-PHE
) O
is O
an O
important O
regulator O
of O
blood B-PHE
pressure I-PHE
and O
has O
already O
been O
successfully O
targeted O
by O
three O
major O
classes O
of O
antihypertensive O
drugs O
: O
by O
ACE O
inhibitors O
, O
by O
ARBs O
and O
by O
renin O
inhibitors O
. O
QQQQQ O
-DOCSTART- O


lack O
of O
Gi O
; O

asthenic B-PHE
breathing I-PHE
a O
morbid B-PHE
condition I-PHE
chiefly O
manifested O
as O
disinclination B-PHE
ta1k O
, O
low B-PHE
voice I-PHE
, O
listlessness B-PHE
and O
asthenia B-PHE
, O
lack B-PHE
of I-PHE
strength I-PHE
in O
speaking O
, O
weak O
pulse B-PHE

-DOCSTART- O


Lung B-PHE
cancer I-PHE

-DOCSTART- O


Myocardial B-PHE
Reperfusion I-PHE
Injury I-PHE

-DOCSTART- O


Therapeutic O
effect O
of O
Kakkonto O
in O
a O
mouse O
model O
of O
food B-PHE
allergy I-PHE
with O
gastrointestinal O
symptoms O
. O

-DOCSTART- O


Heroin O
is O
a O
mu-opioid O
agonist O
. O

It O
acts O
on O
endogenous O
mu-opioid O
receptors O
that O
are O
spread O
in O
discrete O
packets O
throughout O
the O
brain O
, O
spinal O
cord O
and O
gut O
in O
almost O
all O
mammals O
. O

Heroin O
, O
along O
with O
other O
opioids B-PHE
, O
are O
agonists O
to O
four O
endogenous B-PHE
neurotransmitters I-PHE
. O

They O
are O
beta-endorphin B-PHE
, O
dynorphin B-PHE
, O
leu-enkephalin B-PHE
, O
and O
met-enkephalin B-PHE
. O

The O
body O
responds O
to O
heroin O
in O
the O
brain O
by O
reducing O
( O
and O
sometimes O
stopping O
) O
production B-PHE
of I-PHE
the I-PHE
endogenous I-PHE
opioids I-PHE
when O
heroin O
is O
present O
. O

Endorphins B-PHE
are O
regularly O
released O
in O
the O
brain B-PHE
and O
nerves B-PHE
, O
attenuating O
pain B-PHE
. O

Their O
other O
functions O
are O
still O
obscure O
, O
but O
are O
probably O
related O
to O
the O
effects O
produced O
by O
heroin O
besides O
analgesia B-PHE
( O
antitussin O
, O
anti-diarrheal O
) O
. O

-DOCSTART- O


Liver B-PHE
health I-PHE
, O
Liver B-PHE

-DOCSTART- O


the O
ulcerated B-PHE
mouth I-PHE
turns O
to O
the O
aphtha B-PHE

-DOCSTART- O


Stage O
III O
Adult B-PHE
T-Cell I-PHE
Leukemia/Lymphoma I-PHE

-DOCSTART- O


recurrent B-PHE
fever I-PHE
by O
the O
exhaustion B-PHE
after O
healing O
from O
pyogenic B-PHE
febrile I-PHE
disease I-PHE
. O

-DOCSTART- O


Used O
mainly O
in O
female B-PHE
infertility I-PHE
due O
to O
anovulation B-PHE
( O
e.g O
. O
due O
to O
polycystic B-PHE
ovary I-PHE
syndrome I-PHE
) O
to O
induce O
ovulation B-PHE
. O

-DOCSTART- O


lingual B-PHE
pustule I-PHE
; O
boil B-PHE
of O
the O
tongue O

-DOCSTART- O


harmonize O
blood B-PHE

-DOCSTART- O


refers O
to O
the O
heavy B-PHE
coughing I-PHE
and O
shortness B-PHE
of I-PHE
breath I-PHE
due O
to O
the O
heat B-PHE
In I-PHE
the I-PHE
lung I-PHE

-DOCSTART- O


destroy O
intestinal B-PHE
parasites I-PHE

-DOCSTART- O


dissipate O
blood B-PHE

-DOCSTART- O


Breast B-PHE
Pain I-PHE

-DOCSTART- O


Abscess B-PHE

-DOCSTART- O


Gastric B-PHE
Varices I-PHE

-DOCSTART- O


Carpal B-PHE
Tunnel I-PHE
Syndrome I-PHE

-DOCSTART- O


malignant B-PHE
furuncle I-PHE
due O
to O
scrofula B-PHE
. O

-DOCSTART- O


relieve O
fever B-PHE

-DOCSTART- O


hemoptysis B-PHE
; O
coughing B-PHE
up I-PHE
blood I-PHE

-DOCSTART- O


Treament O
of O
arthritis B-PHE
with O
ankylosis B-PHE
, O
aching B-PHE
and I-PHE
heaviness I-PHE
sensation I-PHE
of O
the O
loins O
and O
knees O
, O
systremma B-PHE
due O
to O
vomiting B-PHE
and O
diarrhea B-PHE
, O
edema B-PHE
and O
weakness B-PHE
of I-PHE
the I-PHE
legs I-PHE
. O

-DOCSTART- O


absorption B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
motility O

-DOCSTART- O


To O
eliminate O
blood B-PHE
stasis I-PHE
, O
arrest O
bleeding B-PHE
, O
cause O
subsidence O
of O
swelling B-PHE
and O
alleviate O
pain B-PHE
. O

-DOCSTART- O


clear O
the O
heart B-PHE
and O
relieve O
vexation B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
absorption B-PHE
, O
Lipid O
profile O
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Strength B-PHE
and O
power B-PHE
, O
Others O
, O
motility B-PHE

-DOCSTART- O


S B-PHE
. I-PHE
Aureus I-PHE
Bacteremia I-PHE

-DOCSTART- O


damp-warm B-PHE
disease I-PHE
febrile B-PHE
disease I-PHE
often O
occurring O
around O
mid-summer O
, O
July O
, O
caused O
by O
damp-heat B-PHE
pathogene I-PHE
, O
which O
mainly O
involves O
the O
gastro-intestinal B-PHE
tract I-PHE
often O
in O
a O
protracted O
course O
. O

It O
may O
sometimes O
be O
seen O
in O
diseases O
such O
as O
typhoid B-PHE
fever I-PHE
. O

-DOCSTART- O


Exciting O
the O
intestinal B-PHE
smooth I-PHE
muscles I-PHE
in O
vivo O
or O
in O
vitro O
, O
and O
relaxing O
the O
uterus B-PHE
of O
guinea-pigs O
in O
vitro O
. O

-DOCSTART- O


To O
supplement O
kidney B-PHE
and O
boost O
essence O
, O
warm O
lung B-PHE
and O
settle O
asthma B-PHE
, O
moisten O
intestines B-PHE
and O
free O
stool B-PHE
. O

-DOCSTART- O


To O
promote O
blood B-PHE
circulation I-PHE
to O
remove O
blood B-PHE
stasis I-PHE
, O
soothe O
the O
liver B-PHE
and O
remove O
the O
obstruction B-PHE
in O
the O
channels O
. O

-DOCSTART- O


Protective B-PHE
immunity I-PHE
, O
Others O
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Others O
health B-PHE
and O
immunity B-PHE
, O
Metabolism B-PHE

-DOCSTART- O


Hepatitis B-PHE
B I-PHE
Virus I-PHE

-DOCSTART- O


1 O
nocturnal O
enuresis O
; O
bed-wetting O
2 O
incontinence O
of O
urine O

-DOCSTART- O


Deficiency B-PHE
of O
both O
qi O
and O
blood B-PHE
marked O
by O
pallor B-PHE
, O
shortness B-PHE
of I-PHE
breath I-PHE
, O
cardiac B-PHE
palpitation I-PHE
, O
dizziness B-PHE
, O
spontaneous B-PHE
sweating I-PHE
, O
lassitude B-PHE
and O
cold B-PHE
extremities I-PHE
, O
or O
excessive O
menstrual B-PHE
discharge I-PHE
. O

-DOCSTART- O


Solid B-PHE
Tumors I-PHE

-DOCSTART- O


asthma B-PHE
and O
cough B-PHE

-DOCSTART- O


This O
means O
urolithiasis B-PHE
made O
of O
coagulation B-PHE
of I-PHE
phlegm I-PHE
. O

-DOCSTART- O


Erlotinib O
inhibits O
the O
intracellular B-PHE
phosphorylation I-PHE
of I-PHE
tyrosine I-PHE
kinase I-PHE
associated O
with O
the O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
which O
is O
expressed O
on O
the O
cell O
surface O
of O
normal O
cells B-PHE
and O
cancer B-PHE
cells I-PHE
. O

-DOCSTART- O


metrorrhagia B-PHE

-DOCSTART- O


1 O
Applicable O
to O
edema B-PHE
of I-PHE
wind I-PHE
type O
attributive O
to O
attack O
of O
dampness B-PHE
and O
heat B-PHE
, O
which O
is O
manifested O
as O
general O
edema B-PHE
beginning O
from O
the O
eyelids O
, O
dyuria B-PHE
, O
fever B-PHE
, O
chilliness B-PHE
, O
white B-PHE
and I-PHE
greasy I-PHE
fur I-PHE
on O
the O
tongue O
and O
slow B-PHE
pulse I-PHE
. O
2 O
Also O
applicable O
to O
urinar B-PHE

-DOCSTART- O


headache B-PHE
due O
to O
cold B-PHE
affection O

-DOCSTART- O


This O
is O
damp-arthritis B-PHE
caused O
by O
apoplectoid B-PHE
syndrome I-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption B-PHE
, O
Lipid O
profile O
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
motility B-PHE
, O
Evacuation B-PHE

-DOCSTART- O


tinea B-PHE
favosa I-PHE
; O
mouth-corner B-PHE
ulcer I-PHE

-DOCSTART- O


Chlorambucil O
alkylates O
and O
cross-links O
DNA O
during O
all O
phases O
of O
the O
cell O
cycle O
, O
resulting O
in O
disruption B-PHE
of I-PHE
DNA I-PHE
function I-PHE
, O
cell B-PHE
cycle I-PHE
arrest I-PHE
, O
and O
apoptosis O
. O

-DOCSTART- O


infantile B-PHE
convulsion I-PHE
; O
child O
fright O
epilepsy B-PHE

-DOCSTART- O


sore B-PHE
throat I-PHE
; O
swollen B-PHE
and I-PHE
pailful I-PHE
throat I-PHE

-DOCSTART- O


replenish O
Gi O
( O
Qi O
) O
and O
invigorate O
the O
spleen B-PHE

-DOCSTART- O


brighten O
the O
eyes B-PHE

-DOCSTART- O


A O
symptom O
that O
Gi O
gets O
together O
and O
blood B-PHE
does O
not O
circulate O
well O
. O

An O
affected O
part O
has O
abdominal B-PHE
distension I-PHE
or O
a O
sore B-PHE
. O

If O
it O
keeps O
long O
, O
it O
becomes O
blood B-PHE
stagnation I-PHE
, O
and O
causes O
a O
hard B-PHE
swelling I-PHE
and O
a O
serious B-PHE
pain I-PHE
on O
the O
part O
. O

-DOCSTART- O


all O
kinds O
of O
disease O
due O
to O
wind B-PHE

-DOCSTART- O


Treatment O
of O
deficient O
yin O
of O
the O
liver O
and O
kidneys O
and O
hyperactivity O
of O
liver O
yang O
manifested O
as O
distension B-PHE
and I-PHE
pain B-PHE
in I-PHE
the I-PHE
head I-PHE
and I-PHE
eyes I-PHE
, O
dizziness B-PHE
and O
vertigo B-PHE
. O

Red O
ochre O
( O
Daizheshi O
) O
is O
used O
with O
Dragon's O
bone O
( O
Longgu O
) O
, O
Oyster O
shell O
( O
Muli O
) O
, O
White O
peony O
root O
( O
Bais O

-DOCSTART- O


Promoting O
bile B-PHE
secretion I-PHE
. O

-DOCSTART- O


SR O
58611 O
has O
positive B-PHE
chronotropic I-PHE
effect I-PHE
which O
is O
mainly O
of O
peripheral O
origin O
and O
can O
be O
attributed O
to O
a O
baroreceptor-mediated B-PHE
reflex I-PHE
due O
to O
the O
beta3-adrenoceptor B-PHE
mediated I-PHE
vasodilation I-PHE
with O
an O
increase O
in O
sympathetic B-PHE
tone I-PHE
and O
a O
reduction B-PHE
in I-PHE
vagal I-PHE
tone I-PHE
to I-PHE
the O
heart O
. O

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Blood B-PHE
pressure I-PHE

-DOCSTART- O


abdominal B-PHE
distension I-PHE
; O
distension B-PHE
of I-PHE
abdomen I-PHE
with O
a O
gas O
or O
fluid O

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE
short O
, O
rapid B-PHE
and I-PHE
interrupted I-PHE
breathing I-PHE
, O
and O
anguish B-PHE
with O
chest B-PHE
congestion I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
chronic B-PHE
gouty I-PHE
arthritis I-PHE
when O
complicated O
by O
frequent O
, O
recurrent O
acute O
attacks O
of O
gout B-PHE
. O

-DOCSTART- O


For O
malaria B-PHE
, O
applying O
crushed O
product O
on O
Neiguan O
( O
P.6 O
) O
and O
Dazhui O
( O
Du' O
14 O
) O
2 O
hours O
before O
the O
episode O
; O
alos O
used O
for O
dyspnea B-PHE
due O
to O
the O
retention B-PHE
of I-PHE
phlegm I-PHE
. O

-DOCSTART- O


Woman O
, O
Mood O
, O
Menopausal B-PHE
woman I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
General O
woman O
, O
General O
skin B-PHE
health I-PHE
, O
Others O
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


calm O
the O
fetus O

-DOCSTART- O


To O
relieve O
dyspnea B-PHE
and O
cough B-PHE
by O
eliminating O
cold-phlegm B-PHE
, O
to O
reduce O
modulation O
, O
and O
to O
relieve O
pain B-PHE
by O
removing O
the O
obstruction O
of O
collateral O
. O

-DOCSTART- O


To O
dispel O
cold B-PHE
, O
eliminate O
damp B-PHE
and O
phlegm B-PHE
, O
and O
to O
arrest O
emesis B-PHE
or O
nausea B-PHE
. O

-DOCSTART- O


epilepsy B-PHE
induced O
by O
frightening B-PHE
and O
mania-withdrawal B-PHE

-DOCSTART- O


join O
cutting B-PHE
wound I-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
relieve O
pain B-PHE
, O
soothe O
sinews B-PHE
and O
quicken O
network O
vessels B-PHE
. O

-DOCSTART- O


Treatment O
of O
epistaxis B-PHE
, O
spitting B-PHE
of I-PHE
blood I-PHE
, O
hematuria B-PHE
, O
hematochezia B-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
, O
carbuncles B-PHE
and O
sores B-PHE
. O

-DOCSTART- O


To O
remove O
heat O
from O
the O
lung B-PHE
, O
and O
to O
relieve O
cough B-PHE
and O
dyspnea B-PHE
. O

-DOCSTART- O


exhaustion B-PHE
syndrome I-PHE
; O

consumption B-PHE
; O

exhaustion B-PHE
of I-PHE
strength I-PHE
; O

overstrain B-PHE
; O

asthenic B-PHE
disease I-PHE
; O

weakness B-PHE
and O
fatigue B-PHE

-DOCSTART- O


free O
the O
kidney B-PHE
and O
water O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Inflammation B-PHE
, O
Others O

-DOCSTART- O


postpartum B-PHE
anemic I-PHE
faintness I-PHE
; O
faint B-PHE
after O
childbirth O

-DOCSTART- O


cosolidate O
the O
kidney B-PHE

-DOCSTART- O


eczema B-PHE

-DOCSTART- O


Kidney B-PHE
Cancer I-PHE

-DOCSTART- O


Dimethindene O
is O
also O
indicated O
for O
pruritus B-PHE
in O
eruptive B-PHE
skin I-PHE
diseases I-PHE
such O
as O
chicken-pox B-PHE
. O

-DOCSTART- O


The O
hormones O
, O
T O
4 O
and O
T O
3, O
are O
tyrosine-based O
hormones O
produced O
by O
the O
thyroid O
gland O
. O

Iodine O
is O
an O
important O
component O
in O
their O
synthesis O
. O

The O
major O
secreted O
form O
of O
thyroid O
hormone O
is O
T4 O
. O

T4 O
is O
converted O
T3 O
, O
the O
more O
active O
thyroid O
hormone O
, O
by O
deiodinases O
in O
peripheral O
tissues O
. O

T3 O
acts O
in O
the O
body O
to O
increase O
basal B-PHE
metabolic I-PHE
rate I-PHE
, O
alter O
protein B-PHE
synthesis I-PHE
and O
increase O
the O
body's B-PHE
sensitivity I-PHE
to O
catecholamines O
( O
such O
as O
adrenaline O
) O
. O

Thyroid O
hormones O
are O
essential O
for O
proper O
development O
and O
differentiation O
of O
all O
cells O
of O
the O
human O
body O
. O

T O
4 O
and O
T O
3 O
regulate O
protein O
, O
fat O
and O
carbohydrate O
metabolism O
to O
varying O
extents O
. O

The O
most O
pronounced O
effect O
of O
the O
hormones O
is O
in O
altering O
how O
human O
cells O
use O
energetic O
compounds O
. O

The O
thyroid O
hormone O
derivatives O
bind O
to O
the O
thyroid O
hormone O
receptors O
initially O
to O
initiate O
their O
downstream B-PHE
effects I-PHE
. O

-DOCSTART- O


N(omega)-Nitro-L-arginine O
methyl O
ester O
( O
L-NAME O
) O
induces O
a O
pre-eclampsia-like B-PHE
syndrome I-PHE
in O
pregnant O
rats O
. O

We O
have O
previously O
reported O
the O
anti-hypertensive B-PHE
effects I-PHE
of O
several O
Japanese O
traditional O
( O
Kampo O
) O
medicines O
in O
this O
model O
, O
and O
one O
of O
these O
, O
Tokishakuyakusan O
( O
TS O
) O
, O
also O
improved O
intrauterine B-PHE
growth I-PHE
retardation I-PHE
( O
IUGR O
) O
. O

In O
the O
present O
study O
, O
we O
characterized O
the O
effect O
of O
TS O
on O
IUGR O
. O

TS O
administration O
reversed O
the O
decrease O
in O
fetal O
body B-PHE
weight I-PHE
and O
fetal O
blood B-PHE
glucose I-PHE
concentration I-PHE
induced O
by O
the O
infusion O
of O
L-NAME O
. O

Growth O
hormone O
( O
GH O
) O
levels O
in O
the O
fetal O
blood B-PHE
, O
which O
were O
decreased O
by O
L-NAME O
infusion O
, O
were O
also O
significantly O
elevated O
by O
TS O
; O

however O
, O
levels O
of O
GH O
releasing O
hormone O
( O
GHRH O
) O
and O
insulin-like O
growth O
factor O
I O
( O
IGF-I O
) O
were O
unchanged O
and O
only O
slightly O
changed O
, O
respectively O
. O

Treatment O
with O
L-NAME O
with O
or O
without O
TS O
had O
no O
apparent O
effect O
on O
GH O
, O
GHRH O
, O
and O
IGF-I O
levels O
of O
dams O
. O

In O
an O
immunocytochemical O
study O
, O
the O
number O
of O
GH-positive O
cells O
in O
the O
fetal O
pituitary O
gland O
was O
significantly O
increased O
in O
TS-treated O
rats O
. O

These O
data O
suggest O
that O
enhanced O
proliferation O
of O
somatotrope O
cells O
of O
the O
pituitary O
gland O
and O
the O
resultant O
increase O
in O
GH O
secretion O
in O
the O
fetus O
may O
be O
involved O
in O
the O
improvement O
of O
IUGR O
by O
TS O
. O

-DOCSTART- O


External O
use O
for O
vitiligo B-PHE
and O
alpecia B-PHE
areata I-PHE
. O

-DOCSTART- O


To O
replenish O
the O
liver B-PHE
and O
the O
kidney B-PHE
, O
and O
to O
arrest O
bleeding B-PHE
by O
removing O
heat B-PHE
from I-PHE
blood I-PHE
. O

-DOCSTART- O


Infertility B-PHE

-DOCSTART- O


Hyperuricemia B-PHE

-DOCSTART- O


Traumatic B-PHE
injury I-PHE
with O
ecchymosis B-PHE
, O
swelling B-PHE
and O
pain B-PHE
. O

-DOCSTART- O


thirst B-PHE
with O
fever B-PHE

-DOCSTART- O


invigorate O
the O
spleen B-PHE
and O
disperse O
food O

-DOCSTART- O


deficiency B-PHE
syndrome I-PHE
after O
delivery O

-DOCSTART- O


Prednisone O
enters O
the O
nucleus O
where O
it O
binds O
to O
and O
activates O
specific O
nuclear O
receptors O
, O
resulting O
in O
an O
altered O
gene B-PHE
expression I-PHE
and O
inhibition O
of O
proinflammatory B-PHE
cytokine I-PHE
production I-PHE
. O

-DOCSTART- O


To O
replenish O
blood B-PHE
, O
activate O
circulation B-PHE
and O
regulate O
menstruation B-PHE
. O

-DOCSTART- O


pain B-PHE
and I-PHE
swelling I-PHE
of I-PHE
testis I-PHE

-DOCSTART- O


Nephrolithiasis B-PHE

-DOCSTART- O


Treatment O
of O
consumptive B-PHE
diseases I-PHE
, O
impotence B-PHE
, O
cold B-PHE
sperm I-PHE
, O
lassitude B-PHE
in O
the O
loins O
and O
legs O
due O
to O
deficiency O
of O
the O
kidney-yang O
, O
etc O
. O

-DOCSTART- O


Used O
in O
the O
treatment O
of O
rheumatoid B-PHE
arthritis I-PHE
. O

-DOCSTART- O


breast B-PHE
abscess I-PHE
; O
abscess B-PHE
of I-PHE
breast I-PHE
; O
acute B-PHE
mastitis I-PHE

-DOCSTART- O


three O
Eum O
syndrome O
of O
cold O
attack O

-DOCSTART- O


1 O
Its O
decoction O
acts O
as O
an O
antitussive O
and O
expectorant O
in O
mice O
. O

2 O
Inhibiting O
the O
growth B-PHE
of I-PHE
pneumococcus B-PHE
and O
beta-streptococcus B-PHE
in O
vitro O
. O

-DOCSTART- O


sore B-PHE
; O
pain B-PHE
; O
to O
ache B-PHE

-DOCSTART- O


To O
eliminate O
phlegm B-PHE
( O
Powder O
insufflation O
for O
pharyngitis B-PHE
and O
diphtheria B-PHE
) O
. O

-DOCSTART- O


NRP409 O
is O
presumed O
to O
work O
like O
the O
endogenous O
thyroid B-PHE
hormone I-PHE
thyroxine B-PHE
( O
T O
4 O
, O
a O
tetra-iodinated O
tyrosine O
derivative O
) O
. O

In O
the O
liver B-PHE
and O
kidney B-PHE
, O
T O
4 O
is O
converted O
to O
T O
3, O
the O
active O
metabolite B-PHE
. O

In O
order O
to O
increase O
solubility O
, O
the O
thyroid B-PHE
hormones I-PHE
attach O
to O
thyroid O
hormone O
binding O
proteins O
, O
thyroxin-binding B-PHE
globulin I-PHE
, O
and O
thyroxin-binding B-PHE
prealbumin I-PHE
( O
transthyretin B-PHE
) O
. O

Transport O
and O
binding O
to O
thyroid O
hormone O
receptors O
in O
the O
cytoplasm O
and O
nucleus O
then O
takes O
place O
. O

Thus O
by O
acting O
as O
a O
replacement O
for O
natural O
thyroxine B-PHE
, O
symptoms O
of O
thyroxine B-PHE
deficiency I-PHE
are O
relieved O
. O

-DOCSTART- O


cold B-PHE
sweating I-PHE
at O
night O

-DOCSTART- O


To O
lower O
blood B-PHE
pressure I-PHE
, O
supplement O
liver B-PHE
and O
kidney B-PHE
, O
strengthen O
sinews B-PHE
and O
bones B-PHE
, O
quiet O
fetus O
. O

-DOCSTART- O


edema B-PHE

-DOCSTART- O


high B-PHE
fever I-PHE
due O
to O
shaking B-PHE
chills I-PHE
during O
fever B-PHE

-DOCSTART- O


pain B-PHE
with O
1 O
hernia B-PHE
2 O
diseases B-PHE
of I-PHE
genitalia I-PHE
3 O
. O
severe O
pain B-PHE
in I-PHE
the I-PHE
lower I-PHE
abdomen I-PHE

-DOCSTART- O


Both O
tolterodine O
and O
its O
active O
metabolite O
, O
5-hydroxymethyltolterodine O
, O
act O
as O
competitive O
antagonists O
at O
muscarinic O
receptors O
. O

This O
antagonism O
results O
in O
inhibition O
of O
bladder B-PHE
contraction I-PHE
, O
decrease O
in O
detrusor B-PHE
pressure I-PHE
, O
and O
an O
incomplete O
emptying O
of O
the O
bladder B-PHE
. O

-DOCSTART- O


regulate O
menstruation B-PHE

-DOCSTART- O


To O
promote O
contraction O
and O
stem O
desertion O
, O
disperse O
swelling B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


smallpox B-PHE

-DOCSTART- O


profuse B-PHE
metrorrhagia I-PHE

-DOCSTART- O


Treatment O
of O
bdominal O
pain B-PHE
and O
constipation B-PHE
due O
to O
cold B-PHE
or O
retention B-PHE
of I-PHE
food I-PHE
in O
the O
intestines O
. O

-DOCSTART- O


suffering B-PHE
from O
diarrhea B-PHE
and O
having O
a O
stomachache B-PHE

-DOCSTART- O


To O
regulate O
cold B-PHE
and O
heat B-PHE
, O
regulate O
the O
functions B-PHE
of I-PHE
the I-PHE
stomach I-PHE
and O
lower O
down O
the O
adverse O
rising O
energy O
. O

-DOCSTART- O


cataract B-PHE
and O
nebula B-PHE

-DOCSTART- O


Used O
principally O
as O
an O
analgesic O
. O

-DOCSTART- O


Retention O
of O
moisture O
, O
dermatological B-PHE
systems I-PHE
health I-PHE

-DOCSTART- O


swelling B-PHE
of I-PHE
carbuncle I-PHE
caused O
by O
heat B-PHE
toxin I-PHE

-DOCSTART- O


dispel O
wind B-PHE

-DOCSTART- O


General O
woman O
, O
Woman O
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


Leukemia B-PHE

-DOCSTART- O


injury B-PHE
by I-PHE
knife I-PHE

-DOCSTART- O


Atopic B-PHE
Dermatitis I-PHE

-DOCSTART- O


Chinese O
herbal O
medicine O
( O
CHM O
) O
, O
either O
in O
single O
herb O
or O
in O
herbal O
formula O
, O
has O
been O
used O
to O
treat O
insomnia B-PHE
for O
more O
than O
2000 O
years O
. O

A O
systematic O
review O
including O
Chinese O
and O
English O
literature O
of O
randomized O
controlled O
trials O
was O
conducted O
to O
examine O
the O
efficacy O
, O
safety O
, O
and O
composition O
of O
CHM O
for O
insomnia B-PHE
. O

Among O
the O
217 O
studies O
we O
have O
reviewed O
, O
only O
eight O
had O
a O
Jadad O
score O
>= O
3, O
and O
seven O
out O
of O
these O
eight O
studies O
had O
at O
least O
one O
domain O
with O
high O
risks O
of O
bias O
. O

Meta-analyses O
of O
the O
studies O
with O
Jadad O
score O
>= O
3 O
found O
that O
CHM O
was O
similar O
to O
Western O
medication O
( O
three O
studies O
) O
and O
placebo O
( O
three O
studies O
) O
in O
treating O
insomnia B-PHE
. O

Due O
to O
the O
poor O
methodological O
quality O
of O
the O
studies O
and O
the O
small O
number O
of O
trials O
included O
in O
meta-analyses O
, O
the O
current O
evidence O
is O
insufficient O
to O
support O
the O
efficacy O
of O
CHM O
for O
insomnia B-PHE
. O

The O
frequency O
of O
adverse O
events O
associated O
with O
CHM O
was O
similar O
to O
that O
of O
placebo O
, O
but O
lower O
than O
with O
Western O
medication O
. O

Gui O
Pi O
Tang O
was O
the O
most O
commonly O
used O
standardized O
formula O
, O
while O
Suan O
Zao O
Ren O
( O
Ziziphus O
jujuba O
) O
was O
the O
most O
frequently O
used O
single O
herb O
. O

Further O
studies O
with O
a O
double-blind O
placebo-controlled O
design O
are O
needed O
to O
accurately O
determine O
the O
benefits O
and O
risks O
of O
CHM O
for O
insomnia B-PHE
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
disinhibit O
water O
and O
harmonize O
center O
, O
quicken O
blood B-PHE
and O
resolve O
toxin B-PHE
. O

-DOCSTART- O


disharmony B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
the I-PHE
stomach I-PHE
a O
morbid B-PHE
condition I-PHE
marked O
by O
poor B-PHE
appetite I-PHE
, O
loose B-PHE
stools I-PHE
and O
other O
symptoms O
of O
indigestion B-PHE
. O

-DOCSTART- O


For O
stablizing O
period O
, O
controlling O
urine B-PHE
and O
reducing O
heavy B-PHE
blood-flow I-PHE

-DOCSTART- O


refers O
to O
the O
dream-disturbed O
sleep O

-DOCSTART- O


Enzalutamide O
is O
indicated O
for O
the O
treatment O
of O
patients O
with O
metastatic B-PHE
castration-resistant I-PHE
prostate I-PHE
cancer I-PHE
who O
have O
previously O
received O
docetaxel O
. O

-DOCSTART- O


protracted O
dysentery B-PHE
; O
chronic B-PHE
dysentery I-PHE
; O
prolonged O
dysentery B-PHE

-DOCSTART- O


Chronic B-PHE
Renal I-PHE
Failure I-PHE

-DOCSTART- O


Respiratory B-PHE
Distress I-PHE

-DOCSTART- O


infraumbilical B-PHE
cold I-PHE
pain I-PHE

-DOCSTART- O


It O
means O
not O
shiny O
hair O

-DOCSTART- O


Malaria B-PHE
infection I-PHE

-DOCSTART- O


ulcerative B-PHE
gingivitis I-PHE

-DOCSTART- O


Asthma B-PHE

-DOCSTART- O


vomiting B-PHE
due O
to O
heat B-PHE
in O
the O
stomach O

-DOCSTART- O


To O
tonify O
Qi O
and O
strengthen O
the O
spleen B-PHE
. O

To O
consolidate O
the O
Chong B-PHE
channel I-PHE
and O
control O
the O
blood B-PHE
. O

-DOCSTART- O


ETI-204 O
is O
an O
affinity-enhanced O
, O
de-immunized O
antibody O
, O
which O
means O
that O
its O
ability O
to O
bind O
to O
its O
target O
pathogen O
has O
been O
strengthened O
and O
that O
elements O
that O
might O
cause O
an O
immune B-PHE
response I-PHE
have O
been O
removed O
. O

ETI-204 O
targets O
and O
binds O
to O
Protective O
Antigen O
, O
which O
prevents O
the O
anthrax B-PHE
toxins I-PHE
from O
binding O
to O
and O
entering O
the O
cells O
in O
the O
body O
, O
thereby O
preventing O
death B-PHE
. O

-DOCSTART- O


Emergence B-PHE
Agitation I-PHE

-DOCSTART- O


Muscle B-PHE
Weakness I-PHE

-DOCSTART- O


Didanosine O
is O
converted O
to O
the O
active O
triphosphate O
form O
, O
which O
is O
incorporated O
into O
DNA O
and O
inhibits O
DNA B-PHE
elongation I-PHE
. O

-DOCSTART- O


Colonic B-PHE
Cancer I-PHE
. O

-DOCSTART- O


menorrhagia B-PHE
; O
abnormally O
profuse B-PHE
menstruation I-PHE

-DOCSTART- O


Lymphoma B-PHE
, I-PHE
Non-Hodgkin I-PHE

-DOCSTART- O


Cholangiocarcinoma B-PHE

-DOCSTART- O


affection O
due O
to O
wind-heat B-PHE
; O
common O
cold B-PHE
of O
the O
wind-heat B-PHE
type O
; O
flu B-PHE
caused O
by O
wind B-PHE
and O
heat B-PHE

-DOCSTART- O


Pralnacasan O
inhibits O
interleukin-1beta B-PHE
converting I-PHE
enzyme I-PHE
( O
ICE B-PHE
) O
, O
an O
enzyme B-PHE
that O
regulates O
the O
production B-PHE
of I-PHE
IL-1 I-PHE
and I-PHE
IFN I-PHE
gamma I-PHE
- I-PHE
intercellular I-PHE
mediators I-PHE
that O
initiate O
and O
sustain O
the O
process O
of O
inflammation B-PHE
. O

Inhibiting O
ICE B-PHE
may O
be O
an O
effective O
strategy O
for O
curtailing O
damaging O
inflammatory O
processes O
common O
to O
a O
number O
of O
acute O
and O
chronic O
conditions O
, O
such O
as O
rheumatoid B-PHE
arthritis I-PHE
( O
RA B-PHE
) O
and O
osteoarthritis B-PHE
. O

-DOCSTART- O


Treatment O
of O
edema B-PHE
, O
oliguria B-PHE
, O
arthritis B-PHE
with O
contracture B-PHE
of O
joints O
, O
diarrhea B-PHE
due O
to O
diminished B-PHE
function I-PHE
of I-PHE
the I-PHE
spleen I-PHE
, O
lung B-PHE
abscess I-PHE
, O
appendicitis B-PHE
, O
verruca B-PHE
plana I-PHE
. O

-DOCSTART- O


Epinastine O
has O
a O
multiaction O
effect O
that O
inhibits O
the O
allergic B-PHE
response I-PHE
in O
3 O
ways O
: O
1 O
stabilizes O
mast B-PHE
cells I-PHE
by O
preventing O
mast B-PHE
cell I-PHE
degranulation I-PHE
to O
control O
the O
allergic B-PHE
response I-PHE
, O
2 O
prevents O
histamine B-PHE
binding O
to O
both O
the O
H1- O
and O
H O
2-receptors O
to O
stop O
itching B-PHE
and O
provide O
lasting B-PHE
protection I-PHE
, O
and O
3 O
prevents O
the O
release B-PHE
of I-PHE
proinflammatory I-PHE
chemical I-PHE
mediators I-PHE
from O
the O
blood B-PHE
vessel I-PHE
to O
halt O
progression O
of O
the O
allergic B-PHE
response I-PHE
. O

-DOCSTART- O


Parkinsons B-PHE
Disease I-PHE

-DOCSTART- O


1 O
For O
cases O
with O
paralysis B-PHE
of I-PHE
lower I-PHE
limbs I-PHE
and O
feverish B-PHE
sensation I-PHE
of O
joints O
, O
which O
are O
attritbutive O
to O
deficiency O
of O
kidney-yin O
, O
omit O
menthae O
, O
Ziziphi O
jujubae O
and O
add O
carapax O
trionycis O
and O
ramulus O
mori O
to O
benefit O
kidney-yin O
and O
eliminate O
asthenic B-PHE
heat I-PHE
. O

-DOCSTART- O


cold B-PHE
and O
heat B-PHE
; O

cold B-PHE
syndrome I-PHE
and O
heat B-PHE
syndrome I-PHE
two O
of O
the O
eight O
principles O
in O
analysing O
and O
differentiating O
pathological O
conditions O
; O

cold B-PHE
caused O
by O
excess O
of O
Eum O
, O
and O
heat B-PHE
caused O
by O
excess O
of O
Yang O
. O

chills B-PHE
and O
fever B-PHE

cold B-PHE
pathogene I-PHE
and O
heat B-PHE
pathogene I-PHE

-DOCSTART- O


retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
; O
dyspepsia B-PHE

-DOCSTART- O


Adult B-PHE
B I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


promote O
menstruation B-PHE

-DOCSTART- O


stop O
thirst B-PHE

-DOCSTART- O


weakness B-PHE
of O
the O
waist O

-DOCSTART- O


terminate O
lactation B-PHE

-DOCSTART- O


To O
relieve O
cough B-PHE
and O
promote O
expectoration B-PHE
, O
to O
promote O
digestion B-PHE
and O
remove O
stagnancy B-PHE
of I-PHE
food I-PHE
, O
and O
to O
promote O
blood B-PHE
circulation I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


Metformin O
acts O
by O
the O
initial O
activation B-PHE
of I-PHE
AMP-activated I-PHE
protein I-PHE
kinase I-PHE
( O
AMPK O
) O
, O
a O
liver B-PHE
enzyme I-PHE
that O
plays O
an O
important O
role O
in O
insulin B-PHE
signaling I-PHE
, O
whole B-PHE
body I-PHE
energy I-PHE
balance I-PHE
, O
and O
the O
metabolism B-PHE
of I-PHE
glucose I-PHE
and I-PHE
fats I-PHE
. O

Pioglitazone O
activates O
peroxisome B-PHE
proliferator-activated I-PHE
receptor I-PHE
gamma I-PHE
( O
PPAR-gamma B-PHE
) O
, O
a O
ligand-activated B-PHE
transcription I-PHE
factor I-PHE
, O
thereby O
inducing O
cell B-PHE
differentiation I-PHE
and O
inhibiting O
cell B-PHE
growth I-PHE
and O
angiogenesis B-PHE
. O

-DOCSTART- O


food B-PHE
damage I-PHE
; O

injury B-PHE
due O
to O
improper O
diet O
; O

eating O
food O
much O
injury B-PHE
of O
spleen O
and O
stomach O

-DOCSTART- O


The O
authors O
report O
the O
3 O
months O
treatment O
of O
51 O
cases O
of O
breast B-PHE
proliferation I-PHE
disease I-PHE
with O
modified O
Xiao O
Yao O
San O
and O
Er O
Chen O
decoction O
, O
an O
effective O
rate O
being O
0.961 O
. O

In O
each O
patient O
before O
and O
after O
treatment O
, O
saliva B-PHE
estradiol I-PHE
( O
SE2 B-PHE
) O
, O
saliva B-PHE
progesterone I-PHE
( O
SP B-PHE
) O
, O
saliva B-PHE
testosterone I-PHE
( O
ST B-PHE
) O
and O
plasma B-PHE
prolactin I-PHE
( O
PRL B-PHE
) O
concentrations O
were O
monitored O
and O
breast O
molybdenum O
- O
target O
X O
- O
ray O
films O
were O
taken O
. O

The O
results O
showed O
that O
after O
treatment O
, O
SE2 B-PHE
concentrations I-PHE
declined O
very O
significantly O
( O
P O
less O
than O
0.001 O
) O
; O
SP B-PHE
concentrations I-PHE
declined O
significantly O
( O
P O
less O
than O
0.05 O
) O
; O
PRL B-PHE
concentrations I-PHE
declined O
very O
significantly O
( O
P O
less O
than O
0.005 O
) O
, O
but O
ST B-PHE
concentrations I-PHE
did O
not O
change O
significantly O
. O

Breast O
molybdenum O
- O
target O
X O
- O
ray O
films O
showed O
absorption O
of O
proliferation O
masses O
in O
21 O
cases O
. O

These O
indicated O
that O
the O
medicine O
could O
regulate O
endocrine B-PHE
system I-PHE
, O
perhaps O
through O
suppressing O
secretion B-PHE
of I-PHE
PRL I-PHE
, O
decreasing O
prolactin B-PHE
antagonist I-PHE
action I-PHE
to O
follicular B-PHE
stimulating I-PHE
hormone I-PHE
so O
as O
to O
restore O
follicle B-PHE
function I-PHE
, O
and O
could O
regulate O
pituitary O
- O
follicle O
axis O
and O
make O
the O
axis O
normal O
. O

-DOCSTART- O


To O
enrich O
yin O
and O
supplement O
kidney B-PHE
, O
clear O
lung B-PHE
and O
moisten O
dryness B-PHE
, O
resolve O
toxin B-PHE
and O
disperse O
swelling B-PHE
. O

-DOCSTART- O


stomachache B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Megakaryoblastic I-PHE
Leukemia I-PHE
( O
M7 B-PHE
) O

-DOCSTART- O


To O
transform O
dampness B-PHE
and O
promote O
water B-PHE
metabolism I-PHE
. O

-DOCSTART- O


yellowish B-PHE
complexion I-PHE

-DOCSTART- O


Seasonal B-PHE
Allergic I-PHE
Rhinitis I-PHE

-DOCSTART- O


relieve O
Clonorchiasis B-PHE
toxin I-PHE

-DOCSTART- O


wind-toxic B-PHE
pathogen O

-DOCSTART- O


Binding O
of O
dalbavancin O
to O
the O
D-Ala-D-Ala O
prevents O
the O
incorporation O
of O
the O
NAM/NAG-peptide O
subunits O
into O
the O
peptidoglycan O
matrix O
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
remove O
obstruction O
of O
the O
collaterals O
, O
and O
relieve O
spasms B-PHE
and O
convulsions B-PHE
. O

-DOCSTART- O


a O
symptom O
of O
fingers B-PHE
being I-PHE
cold I-PHE
although O
the O
temperature O
is O
not O

-DOCSTART- O


disperse O
carbuncle B-PHE
swelling B-PHE

-DOCSTART- O


For O
bacterial B-PHE
infections I-PHE
of O
eyes O

-DOCSTART- O


function O

-DOCSTART- O


Reserpine's O
mechanism O
of O
action O
is O
through O
inhibition O
of O
the O
ATP/Mg2+ O
pump O
responsible O
for O
the O
sequestering O
of O
neurotransmitters B-PHE
into O
storage O
vesicles O
located O
in O
the O
presynaptic B-PHE
neuron I-PHE
. O

Trichlormethiazide O
appears O
to O
block O
the O
active O
reabsorption O
of O
chloride O
and O
possibly O
sodium O
in O
the O
ascending O
loop B-PHE
of I-PHE
Henle I-PHE
, O
altering O
electrolyte O
transfer O
in O
the O
proximal B-PHE
tubule I-PHE
. O

-DOCSTART- O


Pain B-PHE
Due O
to O
Certain O
Specified O
Procedures O

-DOCSTART- O


Juvenile B-PHE
Idiopathic I-PHE
Arthritis I-PHE

-DOCSTART- O


To O
transform O
water O
and O
reduce O
edema B-PHE

-DOCSTART- O


dispel O
wind B-PHE
and O
eliminate O
dampness B-PHE

-DOCSTART- O


Treatment O
of O
deficiency B-PHE
condition I-PHE
of I-PHE
the I-PHE
kidney I-PHE
marked O
by O
lumbago B-PHE
and O
lack B-PHE
of I-PHE
strength I-PHE
, O
threatened B-PHE
abortion I-PHE
, O
hypertension B-PHE
. O

-DOCSTART- O


pain B-PHE
of O
genitals O
among O
men O
and O
women O

-DOCSTART- O


Heat B-PHE
vexation I-PHE
, O
diabetes B-PHE
mellitus I-PHE
, O
vomiting B-PHE
nausea I-PHE
, O
vacuity B-PHE
heat I-PHE
cough I-PHE
, O
dry B-PHE
stool I-PHE
, O
swelling B-PHE
of I-PHE
welling I-PHE
abscess I-PHE
, O
welling B-PHE
abscess I-PHE
and O
flat B-PHE
abscess I-PHE
with O
swelling B-PHE
sore I-PHE
. O

-DOCSTART- O


Treament O
of O
edema B-PHE
or O
retained O
fluid O
with O
abdominal B-PHE
distension I-PHE
, O
oliguria B-PHE
and O
constipation B-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
external O
use O
for O
ringworm B-PHE
and O
verrucous B-PHE
vegetations I-PHE
. O

-DOCSTART- O


1 O
An O
active O
component O
, O
anisaldehyde O
, O
increases O
the O
effect O
of O
streptomycin B-PHE
on O
experimental O
tuberculosis B-PHE
in O
mice O
. O
Accelerating O
gastrointestinal B-PHE
peristalsis I-PHE
, O
and O
promoting O
eliminating B-PHE
of I-PHE
flatus I-PHE
. O
Eliminating O
phlegm B-PHE
. O

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE
short B-PHE
, I-PHE
rapid I-PHE
and I-PHE
interrupted I-PHE
breathing I-PHE
. O

-DOCSTART- O


neck B-PHE
stiffness I-PHE
; O
neck B-PHE
rigidity I-PHE
; O
rigidity B-PHE
of I-PHE
the I-PHE
neck I-PHE
; O
rigid B-PHE
neck I-PHE

-DOCSTART- O


Beginning O
stage O
of O
rash B-PHE
, O
fever B-PHE
, O
cough B-PHE
, O
alternating O
cold B-PHE
and I-PHE
hot I-PHE
feeling I-PHE

-DOCSTART- O


mania-withdrawal B-PHE
; O

mania B-PHE
; O

manic-depressive B-PHE
psychosis I-PHE

-DOCSTART- O


Yokukansan O
inhibits O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
: O
the O
role O
of O
a O
A-adrenoceptor B-PHE
. O

-DOCSTART- O


Milnacipran O
is O
used O
to O
treat O
moderate O
to O
severe O
clinical B-PHE
depression I-PHE
but O
this O
indication O
is O
not O
yet O
FDA-approved O
in O
the O
USA O
. O

Milnacipran O
is O
labelled O
for O
the O
treatment O
of O
fibromyalgia B-PHE
pain I-PHE
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
soothe O
sinews O
and O
quicken O
blood B-PHE
, O
relieve O
cough B-PHE
, O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Neuromyelitis B-PHE
Optica I-PHE
( O
NMO B-PHE
) O

-DOCSTART- O


Treatment O
of O
pains B-PHE
caused O
by O
blood B-PHE
stagnation I-PHE
. O

-DOCSTART- O


Berberine O
inhibits O
the O
cellular O
growht O
of O
ascitic B-PHE
cancer I-PHE
and O
lymphoma B-PHE
. O

-DOCSTART- O


Rikkunshito O
improves O
globus B-PHE
sensation I-PHE
in O
patients O
with O
proton-pump O
inhibitor-refractory O
laryngopharyngeal B-PHE
reflux I-PHE
. O

-DOCSTART- O


Treatment O
of O
stagnation O
of O
qi O
in O
the O
liver B-PHE
and O
stomach B-PHE
manifested O
by O
distending O
pain B-PHE
in O
the O
chest O
and O
hypochodria B-PHE
, O
fullness B-PHE
and O
stuffiness B-PHE
sensation O
in O
the O
epigastrium O
, O
vomiting B-PHE
and O
belching B-PHE
, O
cough B-PHE
with O
copious O
expectoration B-PHE
. O

-DOCSTART- O


To O
induce O
subsidence O
of O
swelling B-PHE
and O
remove O
toxic B-PHE
substances O
, O
to O
cause O
purgation B-PHE
. O

-DOCSTART- O


papule B-PHE

-DOCSTART- O


stop O
itching B-PHE

-DOCSTART- O


Parkinson B-PHE
Disease I-PHE

-DOCSTART- O


Treatment O
of O
impotence B-PHE
and O
seminal O
emission O
, O
mass B-PHE
in O
the O
abdomen B-PHE
, O
scrofula B-PHE
, O
traumatic B-PHE
injuries I-PHE
, O
external O
use O
for O
carbuncles B-PHE
and O
boils O
. O

-DOCSTART- O


This O
is O
a O
syndrome O
with O
palpitation B-PHE
and O
severe O
palpitation B-PHE
. O

-DOCSTART- O


harmonize O
acute B-PHE
and I-PHE
chronic I-PHE
disease I-PHE
of O
center O

-DOCSTART- O


epigastric O
fullness O
; O
stuffiness B-PHE
in O
the O
gastric O
region O

-DOCSTART- O


In O
order O
to O
investigate O
the O
characteristic O
of O
optical O
properties O
of O
Asian O
dust O
particles O
, O
the O
atmospheric O
aerosol O
vertical O
profile O
was O
measured O
with O
the O
multi-wavelength O
LIDAR O
system O
, O
at O
the O
Gosan O
super O
site O
( O
33 O
degrees O
17'N O
, O
126 O
degrees O
10'E O
) O
in O
Jeju O
Island O
, O
Korea O
, O
during O
the O
ACE-Asia O
intensive O
observation O
period O
, O
11 O
42798 O
May O
2001 O
. O

An O
air O
mass O
backward O
trajectory O
analysis O
, O
using O
Hysplit-4 O
, O
was O
carried O
out O
to O
track O
the O
aerosol O
plume O
, O
with O
high O
mass O
loading O
, O
from O
the O
Chinese O
desert O
regions O
during O
the O
period O
of O
Asian O
dust O
storm O
events O
. O

Vertical O
atmospheric O
aerosol O
profiles O
on O
three O
major O
Asian O
dust O
storm O
event O
days O
, O
22 O
March O
and O
13 O
and O
26 O
April O
2001 O
, O
have O
been O
analyzed O
. O

The O
LIDAR-derived O
aerosol O
optical O
depth O
values O
were O
compared O
with O
those O
measured O
by O
a O
collocated O
sunphotometer O
. O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
cataracts B-PHE
, O
eye B-PHE
disorders I-PHE
/ I-PHE
infections I-PHE
, O
glaucoma B-PHE
, O
and O
macular B-PHE
degeneration I-PHE
. O

-DOCSTART- O


Baker's B-PHE
Cyst I-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Others O

-DOCSTART- O


prolapse B-PHE
of I-PHE
uterus I-PHE

-DOCSTART- O


the O
disease B-PHE
that O
liver O
and O
spleen O
become O
swollen B-PHE
and O
enlarged B-PHE

-DOCSTART- O


release O
muscles B-PHE

-DOCSTART- O


arthralgia B-PHE
and O
myalgia B-PHE
; O
pain B-PHE
in O
the O
muscles O
and O
bones O

-DOCSTART- O


the O
heat B-PHE
syndrome I-PHE
syndrome O
due O
to O
attack O
of O
pathogenic O
heat B-PHE
or O
hyperactivity B-PHE
of O
Yanggi O
, O
usually O
seen O
in O
infectious B-PHE
disease I-PHE
and O
those O
caused O
by O
abnormal O
hyperactivity I-PHE
of O
the O
body O
, O
with O
manifestation O
such O
as O
fever B-PHE
, O
fidgets B-PHE
, O
flushed B-PHE
face I-PHE
, O
congested B-PHE
eyes I-PHE
dry B-PHE
mouth I-PHE
and I-PHE
throat I-PHE
, O
red O
and O
dry B-PHE
lip I-PHE
thirst B-PHE
with O
preference O
for O
cold O
drink O
, O
constipation B-PHE
, O
scanty O
dark B-PHE
urine I-PHE
reddened B-PHE
tongue I-PHE
with O
dry B-PHE
brow I-PHE
or O
black O
coating O
, O
and O
rapid B-PHE
pulse I-PHE
. O

-DOCSTART- O


spitting B-PHE
pus I-PHE
and I-PHE
blood I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
obesity B-PHE
. O

-DOCSTART- O


the O
low B-PHE
back I-PHE
and I-PHE
knees I-PHE
being I-PHE
aching I-PHE
and I-PHE
limp I-PHE
( O
i O
. O
e O
. O
, O
weak O
) O

-DOCSTART- O


To O
dispel O
damp B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


SP-01A O
is O
an O
HIV B-PHE
oral O
entry O
inhibitor O
drug O
. O

In O
order O
for O
viruses B-PHE
to O
reproduce O
, O
they O
must O
infect O
or O
hi-jack O
a O
cell O
, O
and O
use O
it O
to O
make O
new O
viruses B-PHE
. O

Just O
as O
your O
body O
is O
constantly O
making O
new O
skin B-PHE
cells I-PHE
, O
or O
new O
blood B-PHE
cells I-PHE
, O
each O
cell O
often O
makes O
new O
proteins O
in O
order O
to O
stay O
alive O
and O
to O
reproduce O
itself O
. O

Viruses B-PHE
hide O
their O
own O
DNA O
in O
the O
DNA O
of O
the O
cell O
, O
and O
then O
, O
when O
the O
cell O
tries O
to O
make O
new O
proteins O
, O
it O
accidentally O
makes O
new O
viruses B-PHE
as O
well O
. O

HIV B-PHE
mostly O
infects O
cells O
in O
the O
immune B-PHE
system I-PHE
. O

-DOCSTART- O


Arrhythmia B-PHE

-DOCSTART- O


As O
an O
anthelmintic O
for O
tapeworm O
and O
hookworm O
, O
more O
effective O
than O
that O
of O
tetrachloroethylene O
. O

-DOCSTART- O


conjunctival B-PHE
congestion I-PHE

-DOCSTART- O


night B-PHE
blindness I-PHE
. O
Visual B-PHE
disorder I-PHE
at O
night O
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
motility B-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE

-DOCSTART- O


bruise B-PHE

-DOCSTART- O


incised B-PHE
wound I-PHE

-DOCSTART- O


To O
relieve O
rheumatic B-PHE
conditions I-PHE
, O
to O
strengthen O
the O
tendons B-PHE
and O
bones B-PHE
, O
and O
to O
arrest O
bleeding B-PHE
. O

-DOCSTART- O


promote O
all O
vessels B-PHE

-DOCSTART- O


constrain O
the O
lung B-PHE

-DOCSTART- O


Phenylpropanolamine O
acts O
directly O
on O
alpha- O
and O
, O
to O
a O
lesser O
degree O
, O
beta-adrenergic O
receptors O
in O
the O
mucosa B-PHE
of I-PHE
the I-PHE
respiratory I-PHE
tract I-PHE
. O

-DOCSTART- O


promote O
the O
stomach B-PHE
and O
increase O
food B-PHE
intake I-PHE

-DOCSTART- O


Adult B-PHE
B I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE
With O
t(9;22)(q34;q11.2 O
) O
; O
BCR-ABL1 O

-DOCSTART- O


Uncomplicated B-PHE
Falciparum I-PHE
Malaria I-PHE

-DOCSTART- O


Myelodysplastic B-PHE
Syndromes I-PHE

-DOCSTART- O


restlessness B-PHE
and O
thirst B-PHE
; O

polydipsia B-PHE

-DOCSTART- O


Saengmaeksan O
inhibits O
inflammatory B-PHE
mediators I-PHE
by O
suppressing O
RIP-2 B-PHE
/ I-PHE
caspase-1 I-PHE
activation I-PHE
. O

-DOCSTART- O


general O
weakness B-PHE
and O
weight B-PHE
loss I-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
free O
network B-PHE
vessels I-PHE
, O
disperse O
swelling B-PHE
and O
relieve O
pain B-PHE
, O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
. O

-DOCSTART- O


cooling O
throat B-PHE

-DOCSTART- O


Relief O
of O
mild O
to O
moderate O
pain B-PHE

-DOCSTART- O


Despite O
the O
development O
of O
radiotherapy O
machines O
and O
technologies O
, O
a O
proportion O
of O
patients O
suffer O
from O
radiation-induced B-PHE
lymphedema I-PHE
. O

Saireito O
( O
SRT O
) O
is O
a O
traditional O
Japanese O
herbal O
medicine O
that O
has O
been O
used O
for O
treating O
edema B-PHE
and O
inflammation B-PHE
in O
conditions O
such O
as O
nephritic B-PHE
disease I-PHE
. O

This O
study O
investigated O
the O
effect O
of O
SRT O
on O
lymphedema B-PHE
caused O
by O
radiotherapy O
. O

Four O
patients O
were O
treated O
with O
SRT O
at O
a O
dose O
of O
9 O
g/day O
. O

The O
severity O
of O
lymphedema B-PHE
was O
evaluated O
using O
the O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
version O
4 O
and O
Numerical O
Rating O
Scale O
before O
and O
after O
SRT O
treatment O
. O

After O
the O
treatment O
with O
SRT O
, O
2 O
of O
4 O
patients O
( O
0.5 O
) O
showed O
apparent O
improvement O
in O
lymphedema B-PHE
. O

One O
of O
the O
cases O
had O
difficulty O
in O
wearing O
the O
custom-made O
thermoplastic O
cast O
, O
but O
after O
SRT O
administration O
, O
he O
could O
wear O
the O
mask O
easily O
. O

One O
case O
decided O
to O
stop O
taking O
SRT O
3 O
days O
after O
initiation O
because O
cough B-PHE
and O
fever B-PHE
appeared O
. O

In O
conclusion O
, O
it O
is O
important O
to O
control O
the O
side O
effects O
of O
radiotherapy O
, O
which O
leads O
to O
improved O
tumor B-PHE
control I-PHE
rates I-PHE
. O

Prospective O
randomized O
studies O
are O
necessary O
to O
confirm O
the O
findings O
of O
this O
case O
series O
study O
. O

-DOCSTART- O


Zuo O
Jin O
Wan O
( O
ZJW O
) O
, O
a O
typical O
traditional O
Chinese O
medicine O
( O
TCM O
) O
formula O
, O
has O
been O
identified O
to O
have O
anticancer B-PHE
activity I-PHE
in O
recent O
studies O
. O

In O
this O
study O
, O
we O
determined O
the O
underlying O
mechanism O
of O
ZJW O
in O
the O
reversal O
effect O
of O
multidrug O
resistance O
on O
colorectal B-PHE
cancer I-PHE
in O
vitro O
and O
in O
vivo O
. O

Our O
results O
showed O
that O
ZJW O
significantly O
enhanced O
the O
sensitivity O
of O
chemotherapeutic O
drugs O
in O
HCT116/L-OHP O
, O
SGC7901/DDP O
, O
and O
Bel/Fu O
MDR O
cells O
. O

Moreover O
, O
combination O
of O
chemotherapy O
with O
ZJW O
could O
reverse O
the O
drug O
resistance O
of O
HCT116/L-OHP B-PHE
cells I-PHE
, O
increase O
the O
sensitivity O
of O
HCT116/L-OHP B-PHE
cells I-PHE
to O
L-OHP O
, O
DDP O
, O
5-Fu O
, O
and O
MMC O
in O
vitro O
, O
and O
inhibit O
the O
tumor B-PHE
growth I-PHE
in O
the O
colorectal O
MDR O
cancer O
xenograft O
model O
. O

ICP-MS O
results O
showed O
that O
ZJW O
could O
increase O
the O
concentration O
of O
chemotherapeutic O
drugs O
in O
HCT116/L-OHP O
cells O
in O
a O
dose-dependent O
manner O
. O

Furthermore O
, O
we O
showed O
that O
ZJW O
could O
reverse O
drug O
resistance O
of O
colorectal B-PHE
cancer I-PHE
cells O
by O
decreasing O
P-gp B-PHE
level I-PHE
in O
vitro O
and O
in O
vivo O
, O
which O
has O
been O
represented O
as O
one O
of O
the O
major O
mechanisms O
that O
contribute O
to O
the O
MDR O
phenotype O
. O

Our O
study O
has O
provided O
the O
first O
direct O
evidence O
that O
ZJW O
plays O
an O
important O
role O
in O
reversing O
multidrug O
resistance O
of O
human B-PHE
colorectal I-PHE
cancer I-PHE
and O
may O
be O
considered O
as O
a O
useful O
target O
for O
cancer O
therapy O
. O

-DOCSTART- O


To O
arrest O
bleeding B-PHE
by O
reducing O
heat B-PHE
in O
blood O
, O
to O
remove O
heat B-PHE
, O
and O
to O
cause O
diuresis B-PHE
. O

-DOCSTART- O


syphilis B-PHE
; O
strawberry O
sores B-PHE
; O
syphilitic B-PHE
skin I-PHE
disease I-PHE

-DOCSTART- O


Appears O
to O
preferentially O
bind O
to O
mycobacterial B-PHE
DNA I-PHE
leading O
to O
disruption B-PHE
of I-PHE
the I-PHE
cell I-PHE
cycle I-PHE
and O
eventually O
kills O
the O
bacterium B-PHE
. O

-DOCSTART- O


hemiplegia B-PHE

-DOCSTART- O


the O
body O
is O
fatigued O
and O
cannot O
walk O
because O
of O
a O
flaccidity B-PHE
of I-PHE
lower I-PHE
limbs I-PHE

-DOCSTART- O


To O
warm O
the O
kidney B-PHE
and O
promote O
virility B-PHE
, O
to O
reduce O
modulation O
, O
and O
to O
induce O
subsidence O
of O
swelling B-PHE
. O

-DOCSTART- O


Croton O
seed O
( O
Badou O
) O
is O
used O
externally O
. O

-DOCSTART- O


Warfarin O
inhibits O
vitamin B-PHE
K I-PHE
reductase I-PHE
, O
resulting O
in O
depletion O
of O
the O
reduced O
form O
of O
vitamin B-PHE
K I-PHE
which O
reduces O
the O
thrombogenicity B-PHE
of I-PHE
clots I-PHE
. O

Heparin O
binds O
to O
antithrombin O
III O
to O
form O
a O
heparin-antithrombin O
III O
complex O
. O

The O
complex O
binds O
to O
and O
irreversibly O
inactivates O
thrombin B-PHE
and O
other O
activated O
clotting B-PHE
factors I-PHE
, O
such O
as O
factors O
IX O
, O
X, O
XI O
, O
and O
XII O
, O
thereby O
preventing O
the O
polymerization B-PHE
of I-PHE
fibrinogen I-PHE
to O
fibrin O
and O
the O
subsequent O
formation B-PHE
of I-PHE
clots I-PHE
. O

-DOCSTART- O


Cholelithiasis B-PHE
, O
infection B-PHE
of I-PHE
the I-PHE
biliary I-PHE
tract I-PHE
, O
cholecystitis B-PHE
. O

-DOCSTART- O


Dermatitis B-PHE
, I-PHE
Atopic I-PHE

-DOCSTART- O


As O
GABA B-PHE
is O
an O
inhibitory O
neurotransmitter O
, O
this O
results O
in O
increased O
inhibition O
of O
the O
ascending O
reticular B-PHE
activating I-PHE
system I-PHE
. O

-DOCSTART- O


Pemetrexed O
binds O
to O
and O
inhibits O
the O
enzyme O
thymidylate B-PHE
synthase I-PHE
which O
catalyses O
the O
substrate O
to O
an O
essential O
precursor O
in O
DNA B-PHE
synthesis I-PHE
. O

ABT-751 O
binds O
to O
the O
colchicine-binding O
site O
on O
beta-tubulin O
and O
inhibits O
the O
polymerization O
of O
microtubules O
, O
thereby O
preventing O
tumor B-PHE
cell I-PHE
replication I-PHE
. O

-DOCSTART- O


Bacterial B-PHE
infections I-PHE
of I-PHE
the I-PHE
eyes I-PHE
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE

-DOCSTART- O


Acute B-PHE
Adrenal I-PHE
Insufficiency I-PHE

-DOCSTART- O


Inecalcitol O
is O
an O
analogue O
of O
calcitriol O
, O
the O
naturally O
active O
metabolite O
of O
vitamin O
D O
. O

Calcitriol O
and O
their O
analogues O
activate O
the O
vitamin O
D O
receptor O
( O
VDR O
) O
. O

Vitamin O
D O
has O
a O
major O
role O
in O
regulating O
calcium B-PHE
absorption I-PHE
from O
the O
gut O
, O
storage O
in O
mineral O
form O
in O
the O
bones O
, O
and O
excretion B-PHE
by O
the O
kidney O
and O
effectively O
prevents O
rickets B-PHE
in O
infants O
. O

Vitamin O
D O
and O
calcitriol O
can O
cause O
hypercalcemia B-PHE
at O
high O
or O
frequently O
repeated O
doses O
; O
in O
turn O
, O
hypercalcemia B-PHE
can O
cause O
kidney B-PHE
toxicity I-PHE
by O
accumulation O
of O
calcium-containing O
micro-crystals O
and O
heart B-PHE
and I-PHE
muscle I-PHE
dysfunction I-PHE
by O
impairing O
contractions O
. O

The O
mechanism O
of O
action O
is O
currently O
unknown O
, O
but O
it O
is O
proposed O
that O
inecalcitol O
exerts O
its O
superagonistic O
action O
through O
enhancing O
coactivator O
binding O
by O
the O
VDR O
. O

-DOCSTART- O


The O
herbal O
medicine O
Tokishakuyakusan O
increases O
fetal O
blood B-PHE
glucose I-PHE
concentrations I-PHE
and O
growth B-PHE
hormone I-PHE
levels I-PHE
and O
improves O
intrauterine B-PHE
growth I-PHE
retardation I-PHE
induced O
by O
N(omega)-nitro-L-arginine O
methyl O
ester O
. O

-DOCSTART- O


1 O
Interrupting O
pregnancy B-PHE
. O

2 O
Its O
active O
component O
, O
trichosanthin O
, O
is O
effective O
on O
placental B-PHE
trophocytic I-PHE
tumor I-PHE
. O

3 O
. O
Bacteriostatic B-PHE
. O

-DOCSTART- O


Endometrial B-PHE
Cancer I-PHE

-DOCSTART- O


promote O
the O
stomach B-PHE
and O
increased O
food B-PHE
intake I-PHE

-DOCSTART- O


Weak B-PHE
and I-PHE
reduced I-PHE
yin I-PHE
blood I-PHE
after O
treatment O
, O
exterior B-PHE
evil I-PHE
, O
loss B-PHE
of I-PHE
blood I-PHE
, O
cold B-PHE
and O
period O
, O
headache B-PHE
, O
hot B-PHE
body I-PHE
, O
feeling O
slightly O
cold B-PHE
, O
no B-PHE
sweating I-PHE
. O

-DOCSTART- O


Treatment O
of O
deficiency B-PHE
syndrome I-PHE
of O
the O
kidney O
marked O
by O
back B-PHE
pain I-PHE
, O
tinnitus B-PHE
, O
impairment B-PHE
of I-PHE
hearing I-PHE
and O
looseness B-PHE
of I-PHE
teeth I-PHE
, O
traumatic B-PHE
injury I-PHE
, O
bone B-PHE
fracture I-PHE
, O
external O
use O
for O
alopecia B-PHE
areata I-PHE
, O
vitiligo B-PHE
. O

-DOCSTART- O


major O
red O
and O
white O
dysentery B-PHE

-DOCSTART- O


1 O
Hypotensive B-PHE
2 O
Promoting O
phagocytosis B-PHE
of I-PHE
mononuclear I-PHE
phagocytes I-PHE
. O

Sedative O
and O
diuretic O
. O

-DOCSTART- O


To O
remove O
heat B-PHE
from I-PHE
the I-PHE
lung I-PHE
, O
relieve O
cough B-PHE
and O
resolve O
phlegm B-PHE
. O

-DOCSTART- O


1)a O
disease O
due O
to O
reducing O
wind B-PHE
pathogen O
of O
the O
heart B-PHE
2) O
mental B-PHE
problem I-PHE
due O
to O
disorder O
of O
opening O
the O
heart O
by O
phlegm B-PHE
. O

-DOCSTART- O


upper O
diabetes B-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
colorectal B-PHE
cancer I-PHE
. O

-DOCSTART- O


linear O
lump B-PHE
of I-PHE
scrofula I-PHE

-DOCSTART- O


settle O
the O
pain B-PHE
and O
tranquilize O

-DOCSTART- O


Enteritis B-PHE
, O
dysentery B-PHE
, O
prolapse B-PHE
of O
rectum O
, O
emission O
, O
knocks O
and O
falls O
. O

-DOCSTART- O


Zidovudine O
inhibits O
the O
activity B-PHE
of I-PHE
HIV-1 I-PHE
reverse I-PHE
transcriptase I-PHE
( O
RT O
) O
via O
DNA B-PHE
chain I-PHE
termination I-PHE
after O
incorporation O
of O
the O
nucleotide B-PHE
analogue I-PHE
. O

-DOCSTART- O


Saireito O
(a O
Chinese O
herbal O
drug O
) O
decreases O
inhibitory O
effect O
of O
prednisolone O
and O
accelerates O
the O
recovery O
of O
rat O
hypothalamic-pituitary-adrenal O
axis O
. O

-DOCSTART- O


Tropicamide O
acts O
by O
blocking O
the O
responses O
of O
the O
iris B-PHE
sphincter I-PHE
muscle I-PHE
to O
the O
iris B-PHE
and I-PHE
ciliary I-PHE
muscles I-PHE
to O
cholinergic B-PHE
stimulation I-PHE
, O
producing O
dilation B-PHE
of O
the O
pupil O
and O
paralysis B-PHE
of O
the O
ciliary O
muscle O
. O

Hydroxyamphetamine O
is O
a O
sympathomimetic O
drug O
, O
that O
is O
, O
a O
drug O
that O
stimulates O
the O
sympathetic B-PHE
nervous I-PHE
system I-PHE
as O
an O
agonist O
of O
human O
TAAR1 O
. O

-DOCSTART- O


Cetuximab O
competitively O
inhibits O
epidermal O
growth O
factor O
and O
TGF B-PHE
alpha I-PHE
, O
thereby O
reducing O
their O
effects O
on O
cell B-PHE
growth I-PHE
and O
metastatic B-PHE
spread I-PHE
. O

Fluorouracil O
metabolites O
incorporate O
into O
both O
RNA B-PHE
and O
DNA B-PHE
; O
inhibits O
synthesis B-PHE
of I-PHE
DNA I-PHE
, O
incorporation O
into O
RNA B-PHE
results O
in O
major O
effects O
on O
both O
RNA B-PHE
processing O
and O
functions O
. O

Carboplatin O
is O
activated O
intracellularly O
to O
form O
reactive O
platinum O
complexes O
that O
bind O
to O
nucleophilic O
groups O
such O
as O
GC-rich O
sites O
in O
DNA B-PHE
, O
thereby O
inducing O
intrastrand O
and O
interstrand O
DNA B-PHE
cross-links O
, O
as O
well O
as O
DNA-protein B-PHE
cross-links O
. O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
Maturation B-PHE

-DOCSTART- O


swelling B-PHE
of O
the O
lips O
; O
swollen B-PHE
lips I-PHE

-DOCSTART- O


Breech B-PHE
Presentation I-PHE
in O
Pregnancy O

-DOCSTART- O


HIV B-PHE
Infection I-PHE

-DOCSTART- O


Neurological B-PHE
systems I-PHE
health I-PHE
, O
DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
Memory B-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


dyspnea B-PHE
due O
to O
the O
kidney B-PHE
deficiency I-PHE

-DOCSTART- O


Reproductive B-PHE
systems I-PHE
, O
Mood O
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Memory B-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Quality O
of O
life O
, O
UV B-PHE
protection I-PHE
, O
Others O
, O
Man O
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Motivation O
, O
Strength B-PHE
and O
power B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
, O
Hemostatic B-PHE
function I-PHE
, O
effort O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Intelligence B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Overall O
CVD B-PHE
, O
dermatological B-PHE
systems I-PHE
health I-PHE
, O
Protective B-PHE
immunity I-PHE

-DOCSTART- O


1.To O
promote O
blood B-PHE
circulation I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
, O
expel O
wind B-PHE
and O
alleviate O
pain B-PHE
. O

2 O
. O
To O
relieve O
asthma B-PHE
. O

-DOCSTART- O


Pulmonary B-PHE
Disease I-PHE
, I-PHE
Chronic I-PHE
Obstructive I-PHE

-DOCSTART- O


Diminshing O
the O
toxicity B-PHE
of I-PHE
kanamycin I-PHE
to O
guinea-pig's O
cochlea B-PHE
. O

the O
levels O
of O
serum B-PHE
cholesterol I-PHE
and O
triglyceride B-PHE
. O

Hindering O
the O
formation O
of O
arteriosclerotic B-PHE
deposits O
in O
the O
vessels O
. O

-DOCSTART- O


protracted O
diarrhea B-PHE
; O
chronic B-PHE
diarrhea I-PHE
; O
prolonged O
diarrhea B-PHE

-DOCSTART- O


Tourette B-PHE
Disorder I-PHE

-DOCSTART- O


Fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

Prazosin O
acts O
by O
inhibiting O
the O
postsynaptic O
alpha(1)-adrenoceptors O
on O
vascular B-PHE
smooth I-PHE
muscle I-PHE
. O

This O
inhibits O
the O
vasoconstrictor B-PHE
effect I-PHE
of O
circulating O
and O
locally O
released O
catecholamines B-PHE
, O
resulting O
in O
peripheral B-PHE
vasodilation I-PHE
. O

Oxymetazoline O
is O
a O
direct O
acting O
sympathomimetic O
amine O
, O
which O
acts O
on O
alpha-adrenergic O
receptors O
in O
the O
arterioles O
of O
the O
conjunctiva O
and O
nasal O
mucosa O
. O

-DOCSTART- O


Cyclosporine O
binds O
to O
cyclophilin O
which O
inhibits O
lymphokine B-PHE
production I-PHE
and O
interleukin B-PHE
release I-PHE
, O
shows O
potent O
immunosuppressant O
medication O
. O

-DOCSTART- O


Repeated O
administration O
of O
Yokukansan O
inhibits O
DOI B-PHE
- I-PHE
induced I-PHE
head I-PHE
- I-PHE
twitch I-PHE
response I-PHE
and O
decreases O
expression O
of O
5 O
- O
hydroxytryptamine O
( O
5 O
- O
HT O
) O
2A O
receptors O
in O
the O
prefrontal O
cortex O
. O

-DOCSTART- O


abdominal B-PHE
pain I-PHE
and O
tenesmus B-PHE

-DOCSTART- O


stroke B-PHE
; O
sudden B-PHE
wind-stroke I-PHE
a O
sudden O
and O
severe O
attack O
, O
as O
of O
apoplexy B-PHE

-DOCSTART- O


Glucagon O
binds O
the O
glucagon O
receptor O
, O
a O
G O
protein-coupled O
receptor O
located O
in O
the O
plasma B-PHE
membrane I-PHE
, O
which O
then O
initiates O
a O
dual O
signaling O
pathway O
using O
both O
adenylate O
cyclase O
activation O
and O
increased O
intracellular B-PHE
calcium I-PHE
. O

Adenylate O
cyclase O
manufactures O
cAMP O
( O
cyclic O
AMP O
) O
, O
which O
activates O
protein B-PHE
kinase I-PHE
A I-PHE
( O
cAMP-dependent B-PHE
protein I-PHE
kinase I-PHE
) O
. O

This O
enzyme B-PHE
, O
in O
turn O
, O
activates O
phosphorylase B-PHE
kinase I-PHE
, O
which O
, O
in O
turn O
, O
phosphorylates O
glycogen B-PHE
phosphorylase I-PHE
, O
converting O
into O
the O
active O
form O
called O
phosphorylase B-PHE
A I-PHE

Phosphorylase O
A O
is O
the O
enzyme O
responsible O
for O
the O
release O
of O
glucose-1-phosphate O
from O
glycogen O
polymers O
. O

This O
yields O
glucose O
molecules O
to O
be O
released O
into O
the O
blood O
. O

Glucagon O
receptors O
are O
found O
in O
the O
liver B-PHE
, O
kidney B-PHE
, O
brain B-PHE
and O
pancreatic B-PHE
islet I-PHE
cells I-PHE
. O

The O
glucagon O
mediated O
signals O
lead O
to O
an O
increase O
in O
insulin B-PHE
excretion I-PHE

-DOCSTART- O


Acute B-PHE
Myelogenous I-PHE
Leukemia I-PHE

-DOCSTART- O


miasma O
1 O
pestilential B-PHE
pathogene I-PHE
2 O
malaria B-PHE

-DOCSTART- O


disliking O
wind B-PHE
syndrome I-PHE
due O
to O
external B-PHE
and I-PHE
internal I-PHE
injury I-PHE
. O

-DOCSTART- O


Therapeutic O
effects O
of O
Saireito O
( O
chai-ling-tang O
) O
, O
a O
traditional O
Japanese O
herbal O
medicine O
, O
on O
lymphedema B-PHE
caused O
by O
radiotherapy O
: O
a O
case O
series O
study O
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
relieve O
pain B-PHE
, O
kill O
worms B-PHE
and O
relieve O
itch B-PHE
, O
resolve B-PHE
toxin I-PHE
and O
close O
sores B-PHE
. O

-DOCSTART- O


restore O
depression B-PHE
and O
dissipate O
bind O

-DOCSTART- O


dispel O
the O
effects O
of O
alcohol O

-DOCSTART- O


Symptoms O
associated O
with O
stagnation O
of O
liver O
qi O
, O
stagnated O
qi O
truned O
into O
fire O
, O
insufficient O
yin O
blood O

-DOCSTART- O


Allosteric O
interactions O
between O
central O
benzodiazepine O
receptors O
and O
gamma-aminobutyric O
acid O
( O
GABA O
) O
receptors O
potentiate O
the O
effects O
of O
GABA O
. O

-DOCSTART- O


OBJECTIVE O
: O
The O
aim O
of O
this O
study O
was O
to O
analyse O
the O
value O
of O
intraoperative O
micro-Doppler O
in O
stereotactic O
brain O
biopsy O
( O
SBB O
) O
. O

So O
far O
, O
only O
a O
few O
studies O
have O
reported O
about O
the O
usefulness O
of O
micro-Doppler O
in O
stereotactic O
brain O
biopsy O
. O

METHODS O
: O
Between O
1998 O
and O
2003 O
, O
155 O
SBBs O
were O
performed O
in O
153 O
patients O
with O
micro-Doppler O
( O
81 O
males O
, O
72 O
females O
, O
mean O
age O
: O
59 O
years O
) O
. O

All O
operations O
were O
performed O
using O
a O
ZD-frame O
and O
a O
multiplanar O
computer O
tomography-guided O
trajectory O
planning O
system O
( O
Leibinger O
SPP O
) O
. O

A O
16 O
MHz O
micro-Doppler O
probe O
( O
diameter O
1 O
mm O
, O
DWL O
) O
was O
used O
in O
all O
cases O
to O
explore O
the O
area O
of O
biopsy O
before O
the O
tissue O
probes O
were O
taken O
. O

Serial O
biopsies O
( O
mean O
, O
6 O
samples O
) O
were O
taken O
with O
the O
Sedan O
side-cutting O
cannula O
(n O
= O
145 O
) O
or O
the O
small O
forceps O
(n O
= O
10 O
) O
. O

We O
evaluated O
the O
number O
of O
intraoperative O
detectable O
vessel O
signals O
by O
micro-Doppler O
, O
intraoperative O
bleedings B-PHE
as O
well O
as O
bleedings B-PHE
detected O
by O
postoperative O
CT O
( O
which O
was O
performed O
in O
all O
cases O
) O
. O

We O
compared O
our O
results O
according O
to O
bleeding B-PHE
- O
related O
complications O
with O
the O
data O
of O
stereotactic O
biopsy O
series O
from O
the O
recent O
literature O
. O

RESULTS O
: O
A O
conclusive O
histopathological O
diagnosis O
was O
achieved O
in O
150/153 O
patients O
( O
98 O
% O
) O
. O

A O
re-biopsy O
had O
to O
be O
undertaken O
in O
2 O
cases O
. O

In O
98 O
biopsies O
( O
63 O
% O
) O
, O
no O
vessel O
could O
be O
detected O
with O
the O
micro-Doppler O
. O

In O
the O
remainder O
, O
a O
signal O
of O
arterial B-PHE
vessels I-PHE
was O
detected O
in O
22 O
( O
14 O
%) O
and O
a O
signal O
of O
venous B-PHE
vessels I-PHE
in O
35 O
cases O
( O
23 O
% O
) O
. O

Detection O
of O
a O
vessel B-PHE
in O
the O
micro-Doppler O
led O
to O
a O
change O
of O
the O
biopsy O
site O
in O
each O
case O
within O
the O
same O
trajectory O
. O

Biopsy-related O
bleedings B-PHE
were O
detected O
in O
4 O
cases O
( O
2.6 O
% O
) O
. O

Among O
these O
, O
the O
only O
bleeding B-PHE
which O
occurred O
without O
any O
signs O
of O
vessels B-PHE
in O
the O
micro-Doppler O
happened O
in O
a O
case O
of O
a O
melanoma B-PHE
. O

The O
overall O
biopsy-related O
permanent O
morbidity O
was O
0.6 O
% O
(n O
= O
1 O
) O
. O

The O
biopsy-related O
mortality O
was O
0 O

CONCLUSIONS O
: O
Despite O
the O
overall O
high O
security O
of O
SBB O
, O
the O
use O
of O
intraoperative O
micro-Doppler O
may O
lead O
to O
an O
additional O
reduction O
of O
the O
risk O
for O
a O
biopsy-related O
bleeding B-PHE
without O
enormous O
expense O
. O

-DOCSTART- O


cold O
dysentery B-PHE

-DOCSTART- O


Antiviral O
Treatment O
of O
Chronic B-PHE
Hepatitis I-PHE
B I-PHE

-DOCSTART- O


dispel O
cold B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


For O
the O
prophylaxis O
of O
organ B-PHE
rejection I-PHE
in O
patients O
receiving O
renal O
transplants O
. O

-DOCSTART- O


Purging B-PHE
by O
moisterizing O

-DOCSTART- O


Zidovudine O
inhibits O
the O
activity B-PHE
of I-PHE
HIV-1 I-PHE
reverse I-PHE
transcriptase I-PHE
( O
RT B-PHE
) O
via O
DNA B-PHE
chain I-PHE
termination I-PHE
after O
incorporation O
of O
the O
nucleotide O
analogue O
. O

Efavirenz O
inhibits O
the O
activity B-PHE
of I-PHE
viral I-PHE
RNA-directed I-PHE
DNA I-PHE
polymerase I-PHE
. O

Lamivudine O
is O
a O
synthetic O
nucleoside O
analogue O
and O
this O
nucleoside O
analogue O
is O
incorporated O
into O
viral O
DNA O
by O
HIV B-PHE
reverse I-PHE
transcriptase I-PHE
and O
HBV B-PHE
polymerase I-PHE
, O
resulting O
in O
DNA B-PHE
chain I-PHE
termination I-PHE
. O

-DOCSTART- O


10-Gingerol O
, O
a O
component O
of O
Rikkunshito O
, O
improves O
cisplatin-induced B-PHE
anorexia I-PHE
by O
inhibiting O
acylated B-PHE
ghrelin I-PHE
degradation I-PHE
. O

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
t(8;21)(q22;q22 O
) O
; O
RUNX1-RUNX1T1 O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Monoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Intraocular B-PHE
Melanoma I-PHE

-DOCSTART- O


Hepatitis B-PHE
B I-PHE
Reactivation I-PHE

-DOCSTART- O


Sudden O
stroke O
and O
fulminant O
reversal O
, O
pain B-PHE
in O
heart O
and O
abdomen B-PHE
, O
postpartum O
blood B-PHE
dizziness I-PHE
, O
child O
fright B-PHE
epilepsy I-PHE
, O
wind B-PHE
impediment O
and O
lumbago B-PHE
. O

-DOCSTART- O


Rhizoma O
Coptidis O
( O
processed O
with O
ginger O
) O
Stuffiness B-PHE
and O
fullness B-PHE
sensation O
in O
the O
abdomen O
with O
nausea B-PHE
and O
vomiting B-PHE
caused O
by O
damp-heat B-PHE
in O
combination O
with O
cold B-PHE
. O

-DOCSTART- O


Gallbladder B-PHE
Neoplasms I-PHE

-DOCSTART- O


Urinary B-PHE
tract I-PHE
stone I-PHE
marked O
by O
paroxysmal B-PHE
lumbago I-PHE
or O
pain B-PHE
in O
one O
side O
of O
the O
abdomen O
often O
radiating O
to O
pudendum O
, O
or O
accompanied O
by O
fever B-PHE
, O
hematuria B-PHE
, O
urodynia B-PHE
, O
dysuria B-PHE
, O
discontinuance B-PHE
of O
urination O
, O
yellow B-PHE
fur I-PHE
of I-PHE
the I-PHE
tongue I-PHE
and O
taut B-PHE
pulse I-PHE
. O

-DOCSTART- O


Food O
accumulation O
, O
stomachache B-PHE
, O
abdomin B-PHE
al I-PHE
pain I-PHE
. O

-DOCSTART- O


break O
blood B-PHE

-DOCSTART- O


The O
itching B-PHE
sensation I-PHE
due O
to O
eczema B-PHE

-DOCSTART- O


( O
1) O
wind-warm B-PHE
; O
wind-warm B-PHE
pathogen I-PHE
( O
1 O
) O
wind B-PHE
and O
warm O
blended O
as O
a O
pathogenic O
factor O
. O

( O
2 O
) O
wind-warm B-PHE
syndrome I-PHE
acute O
febrile B-PHE
diseases I-PHE
caused O
by O
wind-warm B-PHE
pathogene I-PHE
occurring O
in O
winter O
and O
spring O
, O
characterized O
by O
chills B-PHE
and O
fever B-PHE
, O
thirst B-PHE
sweating I-PHE
, O
cough B-PHE
and O
headache B-PHE
in O
the O
initial O
stage O
, O
and O
then O
, O
delirium B-PHE
and O
maculation B-PHE
in O
the O
following O
stage O
. O

-DOCSTART- O


fever B-PHE
and O
aversion O
to O
cold B-PHE

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE

-DOCSTART- O


pyogenic B-PHE
infections I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
the O
signs O
and O
symptoms O
of O
idiopathic O
Parkinson's B-PHE
disease I-PHE
. O

Also O
used O
for O
the O
treatment O
of O
restless B-PHE
legs I-PHE
syndrome I-PHE
. O

-DOCSTART- O


soothe O
the O
sinews B-PHE
and O
the O
network B-PHE
vessels I-PHE

-DOCSTART- O


acute B-PHE
arthritis I-PHE
; O
gout B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Quality O
of O
life O
, O
absorption O
, O
Liver B-PHE
health I-PHE
, O
motility O
, O
Liver B-PHE
, O
Others O

-DOCSTART- O


Methyclothiazide O
appears O
to O
block O
the O
active O
reabsorption B-PHE
of I-PHE
chloride I-PHE
and O
possibly O
sodium O
in O
the O
ascending O
loop O
of O
Henle O
, O
altering O
electrolyte O
transfer O
in O
the O
proximal O
tubule O
. O

Pargyline O
is O
a O
monoamine O
oxidase O
B O
( O
MAO-B O
) O
inhibitor O
with O
antihypertensive O
properties O
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Woman O
, O
Quality O
of O
life O
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
General O
woman O
, O
Inflammation B-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE

-DOCSTART- O


Grepafloxacin O
exerts O
its O
antibacterial B-PHE
activity I-PHE
by O
inhibiting O
bacterial B-PHE
topoisomerase I-PHE
II I-PHE
( O
DNA B-PHE
gyrase I-PHE
) O
and O
topoisomerase B-PHE
IV I-PHE
, O
essential O
enzymes O
for O
duplication O
, O
transcription O
, O
and O
repair O
of O
bacterial B-PHE
DNA I-PHE
. O

-DOCSTART- O


Other O
system B-PHE
health I-PHE
, O
Others O

-DOCSTART- O


To O
remove O
heat B-PHE
and O
counteract O
toxicity B-PHE
, O
to O
expel O
intestinal B-PHE
worms I-PHE
, O
stanch O
bleeding B-PHE
. O

-DOCSTART- O


Beta-Thalassemia B-PHE

-DOCSTART- O


constipation B-PHE

-DOCSTART- O


Methotrexate O
anti-tumor O
activity O
is O
a O
result O
of O
the O
inhibition O
of O
folic B-PHE
acid I-PHE
reductase I-PHE
, O
leading O
to O
inhibition O
of O
DNA B-PHE
synthesis I-PHE
and O
inhibition O
of O
cellular B-PHE
replication I-PHE
. O

Golimumab O
inhibits O
the O
activity B-PHE
of I-PHE
the I-PHE
cytokine I-PHE
, O
tumor B-PHE
necrosis I-PHE
factor I-PHE
alpha I-PHE
. O

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Lipid O
profile O

-DOCSTART- O


Untreated O
Childhood B-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


The O
precise O
mechanism O
of O
action O
has O
not O
been O
fully O
determined O
, O
but O
the O
main O
mechanism O
of O
fluorouracil O
is O
thought O
to O
be O
the O
binding O
of O
the O
deoxyribonucleotide O
of O
the O
drug O
( O
FdUMP O
) O
and O
the O
folate O
cofactor O
, O
N50-methylenetetrahydrofolate O
, O
to O
thymidylate O
synthase O
( O
TS O
) O
to O
form O
a O
covalently O
bound O
ternary O
complex O
. O

This O
results O
in O
the O
inhibition O
of O
the O
formation B-PHE
of I-PHE
thymidylate I-PHE
from O
uracil O
, O
which O
leads O
to O
the O
inhibition O
of O
DNA B-PHE
and I-PHE
RNA I-PHE
synthesis I-PHE
and O
cell B-PHE
death I-PHE
. O

Fluorouracil O
can O
also O
be O
incorporated O
into O
RNA B-PHE
in O
place O
of O
uridine O
triphosphate O
( O
UTP O
) O
, O
producing O
a O
fraudulent B-PHE
RNA I-PHE
and O
interfering O
with O
RNA B-PHE
processing I-PHE
and O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


yellow B-PHE
or I-PHE
reddish I-PHE
urine I-PHE
; O
dark B-PHE
urine I-PHE

-DOCSTART- O


Postpartum B-PHE
bleeding I-PHE
, O
migraine B-PHE
. O

-DOCSTART- O


penis B-PHE
ulceration I-PHE

-DOCSTART- O


Cardiac B-PHE
carbuncle I-PHE
has O
half O
conscious O
, O
stuffiness B-PHE
in O
the O
heart O
, O
and O
forgetting O
well O
when O
something O
occurred O
. O

-DOCSTART- O


Adult B-PHE
Pure I-PHE
Erythroid I-PHE
Leukemia I-PHE

-DOCSTART- O


Quality O
of O
life O

-DOCSTART- O


phlegmy B-PHE
fire O
a O
morbid O
condition O
produced O
by O
long-standing O
depression B-PHE
of O
Gi O
which O
turns O
into O
fire O
and O
changes O
the O
body O
fluid O
into O
phlegm B-PHE
, O
usually O
causing B-PHE
mental I-PHE
disturbances O
such O
as O
hysteria B-PHE
, O
mania B-PHE
. O

-DOCSTART- O


AIM O
: O
Zhi O
Zhu O
Wan O
( O
ZZW O
) O
is O
a O
classical O
Chinese O
medical O
formulation O
used O
for O
the O
treatment O
of O
functional O
dyspepsia B-PHE
that O
attributed O
to O
Spleen B-PHE
- I-PHE
deficiency I-PHE
Syndrome I-PHE
. O

ZZW O
contains O
Atractylodes O
Rhizome O
and O
Fructus O
Citrus O
Immaturus O
, O
the O
later O
originates O
from O
both O
Citrus O
aurantium O
L. O
( O
BZZW O
) O
and O
Citrus O
sinensis O
Osbeck O
( O
RZZW O
) O
. O

The O
present O
study O
is O
designed O
to O
elucidate O
disparities O
in O
the O
clinical O
efficacy O
of O
two O
ZZW O
varieties O
based O
on O
the O
pharmacokinetics O
of O
naringenin O
and O
hesperetin O
. O

MEHTOD O
: O
After O
oral O
administration O
of O
ZZWs O
, O
blood O
sample O
was O
collected O
from O
healthy O
volunteers O
at O
designed O
time O
points O
. O

Naringenin O
and O
hesperetin O
were O
detected O
in O
plasma O
by O
RP-HPLC O
, O
pharmacokinetic O
parameters O
were O
processed O
using O
mode-independent O
methods O
with O
WINNONLIN O
. O

RESULTS O
: O
After O
oral O
administration O
of O
BZZW O
, O
both O
naringenin O
and O
hesperetin O
were O
detected O
in O
plasma O
, O
and O
demonstrated O
similar O
pharmacokinetic O
parameters O
. O

Ka O
was O
0.384+/-0.165 O
and O
0.401+/-0.159 O
, O
T(1/2(ke))(h O
) O
was O
5.491+/-3.926 O
and O
5.824+/-3.067 O
, O
the O
AUC O
( O
mg/Lh O
) O
was O
34.886+/-22.199 O
and O
39.407+/-19.535 O
for O
naringenin O
and O
hesperetin O
, O
respectively O
. O

However O
, O
in O
the O
case O
of O
RZZW O
, O
only O
hesperetin O
was O
found O
in O
plasma O
, O
but O
the O
pharmacokinetic O
properties O
for O
hesperetin O
in O
RZZW O
was O
different O
from O
that O
in O
BZZW O
. O

T(max O
) O
for O
hesperetin O
in O
RZZW O
is O
about O
8.515h O
, O
and O
its O
C(max O
) O
is O
much O
larger O
than O
that O
of O
BZZW O
. O

Moreover O
, O
it O
was O
eliminated O
slowly O
as O
it O
possessed O
a O
much O
larger O
AUC O
value O
. O

CONCLUSION O
: O
The O
distinct O
therapeutic O
orientations O
of O
the O
Chinese O
medical O
formula O
ZZWs O
with O
different O
Fructus O
Citrus O
Immaturus O
could O
be O
elucidated O
based O
on O
the O
pharmacokinetic O
parameters O
of O
constituents O
after O
oral O
administration O
. O

-DOCSTART- O


Eye B-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness O
, O
Eye B-PHE
health I-PHE
, O
Eye B-PHE
health I-PHE
, O
Others O
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Strength O
and O
power O
, O
Intelligence B-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


dizziness B-PHE
and O
palpitation B-PHE
due O
to O
congested B-PHE
fluids I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation O
, O
Fat B-PHE
storage I-PHE
and O
oxidation O

-DOCSTART- O


inner O
impairment B-PHE

-DOCSTART- O


Reproductive B-PHE
systems I-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Menopausal B-PHE
woman I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery O
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Metabolism B-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Woman O
, O
Quality O
of O
life O
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Liver B-PHE
, O
Others O
, O
Kids O
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Liver B-PHE
health I-PHE
, O
Strength B-PHE
and O
power B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Intelligence B-PHE
, O
Overall O
CVD B-PHE
, O
General O
woman O
, O
Body B-PHE
weight I-PHE
, O
Protective B-PHE
immunity I-PHE

-DOCSTART- O


tonify O
the O
kidney B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Inflammation B-PHE
, O
Other O
system O
health O
, O
Others O

-DOCSTART- O


The O
anti-inflammatory B-PHE
effects I-PHE
of O
diclofenac O
are O
believed O
to O
be O
due O
to O
inhibition O
of O
both O
leukocyte B-PHE
migration I-PHE
and O
the O
enzyme B-PHE
cylooxygenase I-PHE
( O
COX-1 B-PHE
and O
COX-2 B-PHE
) O
, O
leading O
to O
the O
peripheral O
inhibition O
of O
prostaglandin B-PHE
synthesis I-PHE
. O

-DOCSTART- O


To O
promote O
blood B-PHE
circulation I-PHE
, O
strengthen O
the O
muscles B-PHE
and O
tendon B-PHE
, O
regulate O
the O
function O
between O
qi O
and O
blood O
. O

-DOCSTART- O


promote O
blood B-PHE
vessel I-PHE

-DOCSTART- O


For O
appendicitis B-PHE
, O
used O
together O
with O
same O
dose O
of O
pills O
of O
Radix O
et O
Rhizoma O
Rhei O
and O
Rhizoma O
Coptidis O
, O
or O
mixed O
with O
same O
dose O
of O
Cinnabaris O
, O
applying O
on O
point O
Lanwei O
( O
Extra33 O
) O
. O

-DOCSTART- O


Heavy B-PHE
flow I-PHE
in I-PHE
period I-PHE
due O
to O
blood B-PHE
stagnation I-PHE

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
liver B-PHE
cancer I-PHE
. O

-DOCSTART- O


Hyperactivity B-PHE
of O
the O
liver-yang O
, O
hypertension B-PHE
, O
dizziness B-PHE
, O
vertigo B-PHE
, O
insomnia B-PHE
, O
amnesia B-PHE
. O

-DOCSTART- O


moisten B-PHE
face I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Mood O
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Intelligence B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Inflammation B-PHE
, O
Others O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


diarrhea B-PHE
due O
to O
dysfunction B-PHE
of I-PHE
the I-PHE
spleen I-PHE

-DOCSTART- O


harmonize O
the O
stomach B-PHE

-DOCSTART- O


To O
warm O
the O
kidney B-PHE
, O
invigorate O
yang O
, O
replenish O
the O
vital B-PHE
essence I-PHE
and O
reinforce O
the O
marrow B-PHE

-DOCSTART- O


To O
benefit O
qi O
and O
revitalize O
blood B-PHE
; O
To O
nourish O
yin O
and O
tonify O
yang O

-DOCSTART- O


For O
the O
treatment O
of O
essential B-PHE
hypertension I-PHE
, O
alone O
or O
as O
an O
adjunct O
. O

Also O
for O
the O
management O
of O
severe B-PHE
hypertension I-PHE
when O
the O
drug O
cannot O
be O
given O
orally O
or O
when O
blood B-PHE
pressure I-PHE
must O
be O
lowered O
immediately O
, O
congestive B-PHE
heart I-PHE
failure I-PHE
( O
in O
combination O
with O
cardiac O
glycosides O
and O
diuretics O
and O
/ O
or O
with O
isosorbide O
dinitrate O
) O
, O
and O
hypertension B-PHE
secondary I-PHE
to O
pre-eclampsia B-PHE
/ O
eclampsia B-PHE
. O

-DOCSTART- O


the O
stagnation B-PHE
of O
Gi O
a O
morbid B-PHE
condition I-PHE
due O
to O
impeded B-PHE
circulation I-PHE
of O
Gi O
that O
leads O
to O
a O
local B-PHE
obstruction I-PHE
, O
manifested O
by O
distension B-PHE
or O
pain B-PHE
in O
the O
affected O
part O
. O

-DOCSTART- O


facial B-PHE
hemiparalysis I-PHE
due O
to O
wind B-PHE
stroke I-PHE

-DOCSTART- O


The O
complex O
binds O
to O
and O
irreversibly O
inactivates O
thrombin O
and O
other O
activated O
clotting O
factors O
, O
such O
as O
factors O
IX O
, O
X, O
XI O
, O
and O
XII O
, O
thereby O
preventing O
the O
polymerization O
of O
fibrinogen O
to O
fibrin O
and O
the O
subsequent O
formation B-PHE
of I-PHE
clots I-PHE
. O

-DOCSTART- O


This O
is O
a O
syndrome O
that O
the O
both O
cheeks O
of O
children O
turn O
red O
. O

-DOCSTART- O


exogenous B-PHE
febrile I-PHE
disease I-PHE
of O
four O
seasons O

-DOCSTART- O


To O
quicken O
blood B-PHE
and O
dispel O
stasis B-PHE
, O
regulate O
menstruation B-PHE
and O
relieve O
pain B-PHE
, O
nourish O
blood B-PHE
and O
quiet O
spirit O
, O
cool O
blood B-PHE
and O
disperse O
welling O
abscess B-PHE
. O

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
to O
counteract O
toxicity B-PHE
, O
to O
kill O
parasites B-PHE
, O
and O
to O
relieve O
itching B-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Quality O
of O
life O
, O
Inflammation B-PHE
, O
Protective O
immunity B-PHE
, O
Others O

-DOCSTART- O


invigorate O
the O
spleen B-PHE

-DOCSTART- O


Alzheimer's B-PHE
Disease I-PHE

-DOCSTART- O


Quality O
of O
life O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Mood O

-DOCSTART- O


spitting O
bloody B-PHE
pus I-PHE
; O

cough B-PHE
with O
bloody B-PHE
pus I-PHE

-DOCSTART- O


stop O
dysentery B-PHE

-DOCSTART- O


palpitation B-PHE

-DOCSTART- O


Hochuekkito O
, O
a O
Kampo O
( O
Traditional O
Japanese O
Herbal O
) O
Medicine O
, O
and O
its O
Polysaccharide O
Portion O
Stimulate O
G B-PHE
- I-PHE
CSF I-PHE
Secretion I-PHE
from O
Intestinal O
Epithelial O
Cells O
. O

-DOCSTART- O


stranguria B-PHE
due O
to O
heat B-PHE
; O
heat-type B-PHE
stranguria I-PHE

-DOCSTART- O


old O
ulceration B-PHE

-DOCSTART- O


1 O
To O
relieve O
carbuncle B-PHE
and O
drain B-PHE
pus I-PHE
. O

For O
the O
early O
stage O
of O
carbuncle B-PHE
or O
carbuncle B-PHE
with O
unruptured O
abscess B-PHE
. O

2 O
To O
expel O
wind B-PHE
and O
kill O
parasites B-PHE
. O

For O
tinea B-PHE
infection I-PHE
and O
leprosy B-PHE
. O

-DOCSTART- O


For O
tonifying O
blood B-PHE

-DOCSTART- O


Anti-inflammatory B-PHE
activity I-PHE
of O
Gumiganghwaltang O
through O
the O
inhibition O
of O
nuclear B-PHE
factor-kappa I-PHE
B I-PHE
activation I-PHE
in O
peritoneal O
macrophages O
. O

-DOCSTART- O


pain B-PHE
from I-PHE
cramped I-PHE
tendons I-PHE
and I-PHE
bones I-PHE

-DOCSTART- O


a O
stomachache B-PHE
due O
to O
exhaustion O
of O
vital O
energy O

-DOCSTART- O


deficiency O
of O
the O
Yang O
of O
the O
spleen B-PHE
and O
the O
kidney B-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
remove O
toxic B-PHE
materials I-PHE
; O
To O
tonify O
kidney B-PHE
and O
revitalize O
blood B-PHE

-DOCSTART- O


Blood B-PHE
activation I-PHE
and O
injury B-PHE
healing I-PHE

-DOCSTART- O


hemicrania B-PHE
; O
migraine B-PHE
; O
megrim B-PHE

-DOCSTART- O


1 O
For O
cases O
of O
menorrhagia B-PHE
accompanied O
with O
listlessness B-PHE
and O
pale B-PHE
complexion I-PHE
due O
to O
deficiency B-PHE
of I-PHE
vital I-PHE
energy I-PHE
Radix O
Ginseng O
Jilin O
to O
invigorate O
vital B-PHE
energy I-PHE
and O
control O
blood B-PHE
of O
profuse O
uterine B-PHE
bleeding I-PHE
leading O
to O
deadly O
coldness B-PHE
of I-PHE
limbs I-PHE
and O

-DOCSTART- O


Fructus O
Crataegi O
( O
charred O
) O
: O
Has O
more O
digestant O
action O
and O
is O
particularly O
useful O
for O
stagnation B-PHE
of I-PHE
undigested I-PHE
meat I-PHE
and O
diarrhea B-PHE
with O
inadequate B-PHE
discharge I-PHE
from I-PHE
the I-PHE
bowels I-PHE
. O

-DOCSTART- O


Woman O
, O
Eldery O
, O
menopausal B-PHE
woman I-PHE
, O
Others O

-DOCSTART- O


Rapamycin O
binds O
to O
the O
immunophilin B-PHE
FK I-PHE
Binding I-PHE
Protein-12 I-PHE
( O
FKBP-12 B-PHE
) O
to O
generate O
an O
immunosuppressive B-PHE
complex I-PHE
that O
binds O
to O
and O
inhibits O
the O
activation B-PHE
of I-PHE
the I-PHE
mammalian I-PHE
Target I-PHE
Of I-PHE
Rapamycin I-PHE
( O
mTOR B-PHE
) O
, O
a O
key O
regulatory O
kinase B-PHE
. O

This O
results O
in O
inhibition O
of O
T B-PHE
lymphocyte I-PHE
activation I-PHE
and I-PHE
proliferation I-PHE
that O
occurs O
in O
response O
to O
antigenic O
and O
cytokine B-PHE
( O
IL-2 B-PHE
, O
IL-4 B-PHE
, O
and O
IL-15 B-PHE
) O
stimulation O
and O
inhibition O
of O
antibody B-PHE
production I-PHE
. O

Imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine B-PHE
kinases I-PHE
( O
TK B-PHE
) O
, O
thereby O
inhibiting O
ATP B-PHE
binding I-PHE
and O
preventing O
phosphorylation B-PHE
and O
the O
subsequent O
activation O
of O
growth O
receptors O
and O
their O
downstream O
signal B-PHE
transduction I-PHE
pathways I-PHE
. O

This O
agent O
inhibits O
TK B-PHE
encoded O
by O
the O
bcr-abl O
oncogene O
as O
well O
as O
receptor O
TKs O
encoded O
by O
the O
c-kit O
and O
platelet-derived O
growth O
factor O
receptor O
( O
PDGFR O
) O
oncogenes O
. O

Biochemical O
analyses O
raise O
the O
possibility O
that O
inhibition O
of O
4E-BP1 B-PHE
phosphorylation I-PHE
may O
be O
particularly O
important O
for O
the O
synergistic O
effects O
of O
PTK O
inhibitor O
/ O
rapamycin O
combinations O
. O

-DOCSTART- O


convulsion B-PHE
; O

epilepsy B-PHE

-DOCSTART- O


general O
edema B-PHE
with O
abdominal B-PHE
distension I-PHE

-DOCSTART- O


nourish O
Gi O
( O
Qi O
) O
and O
blood B-PHE

-DOCSTART- O


Acne B-PHE
Vulgaris I-PHE

-DOCSTART- O


Gramicidin O
D O
binds O
and O
inserts O
itself O
into O
bacterial B-PHE
membranes I-PHE
and O
results O
in O
membrane B-PHE
disruption I-PHE
and O
permeabilization O
, O
which O
leads O
to O
cell B-PHE
death I-PHE
. O

Polymyxin O
B O
sulfate O
interacts O
with O
the O
lipopolysaccharide O
of O
the O
cytoplasmic O
outer O
membrane O
of O
Gram-negative O
bacteria O
, O
altering O
membrane O
permeability O
and O
causing O
cell B-PHE
death I-PHE
. O

Neomycin O
is O
a O
bactericidal O
aminoglycoside O
antibiotic O
that O
binds O
to O
the O
30S O
ribosome O
of O
susceptible O
organisms O
. O

Binding O
interferes O
with O
mRNA B-PHE
binding I-PHE
and O
acceptor B-PHE
tRNA I-PHE
sites I-PHE
and O
results O
in O
the O
production O
of O
non-functional O
or O
toxic B-PHE
peptides I-PHE
. O

-DOCSTART- O


To O
dispel O
phlegm B-PHE
, O
to O
restore O
consciousness B-PHE
, O
and O
to O
reduce O
modulation B-PHE
and O
cause O
the O
subsidence B-PHE
of I-PHE
swelling I-PHE
. O

-DOCSTART- O


To O
warm O
the O
kidney B-PHE
and O
cause O
diuresis B-PHE
. O

-DOCSTART- O


Chronic B-PHE
hepatitis I-PHE

-DOCSTART- O


This O
paper O
was O
designed O
to O
study O
metabonomic O
characters O
of O
the O
hepatotoxicity O
induced O
by O
alcohol O
and O
the O
intervention O
effects O
of O
Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
, O
a O
classic O
traditional O
Chinese O
medicine O
formula O
for O
treatment O
of O
jaundice B-PHE
and O
liver B-PHE
disorders I-PHE
in O
China O
. O

Urinary O
samples O
from O
control O
, O
alcohol- O
and O
YCHT-treated O
rats O
were O
analyzed O
by O
ultra-performance O
liquid O
chromatography O
/ O
electrospray O
ionization O
quadruple O
time-of-flight O
mass O
spectrometry O
( O
UPLC/ESI-QTOF-MS O
) O
in O
positive O
ionization O
mode O
. O

The O
total O
ion O
chromatograms O
obtained O
from O
the O
control O
, O
alcohol- O
and O
YCHT-treated O
rats O
were O
easily O
distinguishable O
using O
a O
multivariate O
statistical O
analysis O
method O
such O
as O
the O
principal O
components O
analysis O
( O
PCA O
) O
. O

The O
greatest O
difference O
in O
metabolic O
profiling O
was O
observed O
from O
alcohol-treated O
rats O
compared O
with O
the O
control O
and O
YCHT-treated O
rats O
. O

The O
positive O
ions O
m/z O
664.3126 O
( O
9 O
min O
) O
was O
elevated O
in O
urine O
of O
alcohol-treated O
rats O
, O
whereas O
, O
ions O
m/z O
155.3547 O
( O
10.96 O
min O
) O
and O
708.2932 O
( O
9.01 O
min O
) O
were O
at O
a O
lower O
concentration O
compared O
with O
that O
in O
urine O
of O
control O
rats O
, O
however O
, O
these O
ions O
did O
not O
indicate O
a O
statistical O
difference O
between O
control O
rats O
and O
YCHT-treated O
rats O
. O

The O
ion O
m/z O
664.3126 O
was O
found O
to O
correspond O
to O
ceramide O
( O
d18:1/25:0 O
) O
, O
providing O
further O
support O
for O
an O
involvement O
of O
the O
sphingomyelin O
signaling O
pathway O
in O
alcohol B-PHE
hepatotoxicity I-PHE
and O
the O
intervention O
effects O
of O
YCHT O
. O

-DOCSTART- O


abdominal B-PHE
pain I-PHE
due O
to O
intestinal B-PHE
parasitosis I-PHE
; O
abdominal B-PHE
pain I-PHE
due O
to O
intestinal B-PHE
ascariasis I-PHE

-DOCSTART- O


deficiency B-PHE
of I-PHE
the I-PHE
heart I-PHE
; O
deficiency B-PHE
syndrome I-PHE
of I-PHE
the I-PHE
heart I-PHE
including O
deficiency B-PHE
of I-PHE
blood I-PHE
and O
Eum O
, O
and O
insufficiency O
of O
Gi O
and O
Yang O
of O
the O
heart O

-DOCSTART- O


galactostasis B-PHE
; O
hypogalactia B-PHE
; O
scant B-PHE
breast I-PHE
; O
inadequacy B-PHE
of I-PHE
lactation I-PHE

-DOCSTART- O


Pregnancy B-PHE
Outcome O

-DOCSTART- O


disperse O
wart B-PHE

-DOCSTART- O


Follitropin O
alpha O
is O
a O
recombinant O
form O
of O
endogenous O
follicle O
stimulating O
hormone O
( O
FSH O
) O
. O

FSH O
binds O
to O
the O
follicle O
stimulating O
hormone O
receptor O
which O
is O
a O
G-coupled O
transmembrane O
receptor O
. O

Binding O
of O
the O
FSH O
to O
its O
receptor O
seems O
to O
induce O
phosphorylation B-PHE
and O
activation B-PHE
of I-PHE
the I-PHE
PI3K I-PHE
( O
Phosphatidylinositol-3-kinase O
) O
and O
Akt O
signaling O
pathway O
, O
which O
is O
known O
to O
regulate O
many O
other O
metabolic O
and O
related O
survival/maturation O
functions O
in O
cells O
. O

-DOCSTART- O


Vaginitis B-PHE

-DOCSTART- O


Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Mood O

-DOCSTART- O


invigorate O
the O
spleen B-PHE
and O
promote O
the O
stomach B-PHE

-DOCSTART- O


nocturnal B-PHE
enuresis I-PHE
and O
frequency B-PHE
of I-PHE
micturition I-PHE

-DOCSTART- O


jaundice B-PHE
related O
to O
immoderate O
drinking O
; O
alcoholic B-PHE
jaundice I-PHE
one O
of O
the O
five O
types O
of O
jaundice B-PHE
. O

jaundice B-PHE
caused O
by O
endogenous O
damp-heat B-PHE
due O
to O
indulging O
in O
alcohol O
, O
manifested O
as O
yellowish B-PHE
pigmentation I-PHE
of I-PHE
the I-PHE
skin I-PHE
and I-PHE
sclera I-PHE
, O
chest B-PHE
distress I-PHE
, O
anorexia B-PHE
, O
nausea B-PHE
and O
vomiting B-PHE

-DOCSTART- O


Treatment O
of O
fever B-PHE
with O
constipation B-PHE
, O
retention O
of O
the O
feces O
and O
abdominal B-PHE
pain I-PHE
, O
dysentery B-PHE
with O
inadequate O
discharge O
from O
the O
bowels B-PHE
, O
jaundice B-PHE
caused O
by O
damp-heat B-PHE
, O
haematemesis B-PHE
, O
epistaxis B-PHE
, O
inflammation B-PHE
of O
eye O
and O
swelling B-PHE
of O
the O
throat O
due O
to O
heat B-PHE
in O
the O
blood O
, O
appendicitis B-PHE
with O
abdominal B-PHE
pain I-PHE
, O
boils B-PHE
, O
sores B-PHE
and O
abscess B-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
traumatic B-PHE
injuries I-PHE
, O
hemorrhage B-PHE
from O
the O
upper B-PHE
gastrointestinal I-PHE
tract I-PHE
. O

External O
use O
for O
scalds B-PHE
and O
burns.Radixet O
Rhizoma O
Rhei O
( O
stir-fried O
with O
wine O
) O
Inflammation B-PHE
of O
the O
eye O
, O
swelling B-PHE
of O
the O
throat O
and O
painful O
swelling B-PHE
of O
the O
gums O
. O

Radix O
et O
Rhizoma O
Rhei O
( O
prepared O
) O
Boils B-PHE
, O
sores B-PHE
and O
abscess B-PHE
. O

Radix O
et O
Rhizoma O
Rhei O
( O
carbonized O
) O
Hemorrhage B-PHE
with O
blood B-PHE
stasis I-PHE
due O
to O
heat B-PHE
in O
the O
blood O
. O

-DOCSTART- O


Diarrhea B-PHE
, O
Malnutrition B-PHE

-DOCSTART- O


Menstrual B-PHE
discomfort I-PHE
, O
feelings O
of O
heat B-PHE
, O
flushed B-PHE
face I-PHE
, O
irritability B-PHE

-DOCSTART- O


Schizophrenia B-PHE

-DOCSTART- O


regurgitation B-PHE
; O
frequent B-PHE
vomiting I-PHE

-DOCSTART- O


For O
promoting O
diuresis B-PHE
and O
desolving O
inflammation B-PHE
. O

-DOCSTART- O


jaundice B-PHE
a O
morbid O
condition O
clinically O
characterized O
by O
yellow-brown B-PHE
pigmentation I-PHE
of I-PHE
the I-PHE
skin I-PHE
and I-PHE
sclera I-PHE
and O
dark B-PHE
yellow I-PHE
colored I-PHE
urine I-PHE
, O
and O
classified O
into O
two O
types O
, O
Yang B-PHE
jaundice I-PHE
and O
Eum B-PHE
jaundice I-PHE
; O

one O
of O
the O
five O
types O
of O
jaundice B-PHE
. O

-DOCSTART- O


Post-operative B-PHE
Pain I-PHE

-DOCSTART- O


Angiotensin B-PHE
II I-PHE
is O
a O
small O
hormone O
in O
the O
body O
and O
part O
of O
the O
RAS B-PHE
. O

-DOCSTART- O


Treatment O
of O
deficiency B-PHE
of I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE
, O
lassitude B-PHE
, O
palpitation B-PHE
, O
arrhythmia B-PHE
. O

-DOCSTART- O


tenesmus B-PHE

-DOCSTART- O


To O
quicken O
blood B-PHE
and O
free O
menstruation B-PHE
( O
raw O
) O
, O
transform O
stasis B-PHE
and O
stanch O
bleeding B-PHE
( O
scorch-fry O
) O
. O

-DOCSTART- O


Bradycardia B-PHE
, O
sick B-PHE
sinus I-PHE
syndrome I-PHE
, O
angina B-PHE
and O
cardiac B-PHE
insufficiency I-PHE
, O
arrhythmia B-PHE
. O

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
pain B-PHE
in O
lumbus O
and O
legs O
, O
numbness B-PHE
of I-PHE
limbs I-PHE
, O
sprain B-PHE
from O
knocks B-PHE
and O
falls B-PHE
, O
sequel O
of O
poliomyelitis B-PHE
. O

-DOCSTART- O


Fenretinide O
treatment O
may O
cause O
ceramide B-PHE
to O
build O
up O
in O
tumor B-PHE
cells I-PHE
and O
is O
associated O
with O
the O
accumulation O
of O
reactive B-PHE
oxygen I-PHE
species I-PHE
, O
resulting O
in O
cell B-PHE
death I-PHE
through O
apoptosis B-PHE
and/or O
necrosis B-PHE
. O

Sodium O
butyrate O
( O
NaB O
) O
, O
a O
short O
chain O
fatty O
acid O
, O
is O
a O
HDAC O
inhibitor O
and O
induces O
growth B-PHE
arrest I-PHE
and O
apoptosis B-PHE
in O
a O
variety O
of O
human O
cancer O
cells O
. O

-DOCSTART- O


Treatment O
of O
rheumatic B-PHE
or I-PHE
rheumatoid I-PHE
arthrits I-PHE
with O
muscular B-PHE
contracture I-PHE
and O
severe O
joint B-PHE
pain I-PHE
, O
fever B-PHE
recurring O
daily O
in O
the O
afternoon O
, O
fever B-PHE
in O
infants O
with O
malnutrition B-PHE
. O

-DOCSTART- O


headache B-PHE
due O
to O
adverse O
rising O
of O
phlegm B-PHE

-DOCSTART- O


To O
relax O
the O
bowels B-PHE
, O
and O
to O
cause O
diuresis B-PHE
. O

-DOCSTART- O


To O
benefit O
vital B-PHE
energy I-PHE
to O
control O
blood B-PHE
. O

-DOCSTART- O


Graft B-PHE
Versus I-PHE
Host I-PHE
Disease I-PHE

-DOCSTART- O


To O
regulate O
the O
flow O
of O
qi O
in O
the O
liver O
and O
the O
stomach O
, O
and O
to O
remove O
the O
retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
. O

-DOCSTART- O


Rheumatoid B-PHE
Arthritis I-PHE

-DOCSTART- O


Type B-PHE
1 I-PHE
Diabetes I-PHE
Mellitus I-PHE

-DOCSTART- O


This O
is O
carbuncle B-PHE
and O
cellulites B-PHE
occurred I-PHE
on I-PHE
the I-PHE
back I-PHE
. O

-DOCSTART- O


Hypoglycemia B-PHE

-DOCSTART- O


swelling B-PHE
and O
pain B-PHE
of O
the O
anus O

-DOCSTART- O


Neostigmine O
is O
used O
for O
the O
symptomatic O
treatment O
of O
myasthenia B-PHE
gravis I-PHE
by O
improving O
muscle B-PHE
tone I-PHE
. O

-DOCSTART- O


Vaginal B-PHE
discharge I-PHE
, O
strangury B-PHE
syndrome I-PHE
, O
swelling B-PHE
toxin I-PHE
of O
clove B-PHE
sore I-PHE
, O
parotitis B-PHE
, O
mastitis B-PHE
, O
lymphrnoditis B-PHE
. O

-DOCSTART- O


Chunghyuldan O
( O
Daio-Orengedokuto O
in O
Japanese O
) O
( O
CHD O
) O
has O
been O
used O
as O
an O
antihyperlipidemic B-PHE
and O
antiischemic B-PHE
agent I-PHE
in O
Korea O
. O

To O
evaluate O
in O
vitro O
the O
efficacy O
of O
Chunghyuldans O
( O
CHDs O
) O
metabolized O
with O
and O
without O
human B-PHE
intestinal I-PHE
microflora I-PHE
against O
brain B-PHE
ischemia I-PHE
, O
we O
investigated O
its O
anti-inflammatory B-PHE
effect I-PHE
on O
LPS-induced O
RAW264.7 O
cells O
. O

Both O
metabolized O
CHD O
( O
MCHD O
) O
and O
CHD O
showed O
antioxidant B-PHE
activities I-PHE
in O
vitro O
, O
and O
inhibited O
nitric O
oxide O
( O
NO O
) O
and O
prostaglandin B-PHE
E2 I-PHE
( O
PGE2 B-PHE
) O
productions O
in O
lipopolysaccharide O
( O
LPS)-induced O
RAW264.7 O
cells O
. O

These O
also O
inhibited O
enzyme B-PHE
activities I-PHE
and O
protein B-PHE
expressions I-PHE
of O
inducible O
NO B-PHE
synthase I-PHE
and O
cyclooxygenase-2 B-PHE
in O
LPS-induced O
RAW264.7 O
cells O
. O

MCHD-inhibitory O
activity O
against O
NO B-PHE
and I-PHE
PGE2 I-PHE
productions I-PHE
in O
LPS-induced O
RAW264.7 O
cells O
was O
more O
potent O
than O
those O
of O
CHD O
. O

These O
results O
suggest O
that O
CHD O
may O
show O
potent O
anti-inflammatory B-PHE
activity I-PHE
in O
vivo O
and O
can O
improve O
brain B-PHE
ischemia I-PHE
. O

-DOCSTART- O


relieve O
throat B-PHE

-DOCSTART- O


a O
disease O
that O
menstruation B-PHE
is O
not O
even O
due O
to O
coldness B-PHE

-DOCSTART- O


1 O
Sennoside O
A O
is O
the O
component O
for O
purgation O
. O

2 O
. O
Promoting O
biliary B-PHE
secretion I-PHE
and O
enhancing O
the O
amount O
of O
bilirubin B-PHE
and O
bile B-PHE
acid I-PHE
. O

3 O
. O
Rhein O
and O
Emodin O
exert O
bacteriostatic O
effect O
by O
inhibting O
the O
synthesis B-PHE
of I-PHE
DNA I-PHE
, O
RNA O
and O
protein O
in O
bacteria O

4 O
. O
Emodin O
is O
a O
component O
for O
hypotensive B-PHE

5 O
. O
Oral O
use O
of O
its O
extract O
reduces O
the O
raio O
of O
serum B-PHE
cholesterol I-PHE
and O
total O
phospholipid B-PHE
in O
rabbits O
with O
hypercholesterolemia B-PHE
. O

6 O
. O
Chrysophanol O
, O
an O
other O
active O
component O
, O
exerts O
a O
hemostatic B-PHE
effect I-PHE
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
engender O
liquid O
, O
moisten O
dryness B-PHE
and O
harmonize O
center O
, O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Ulcerative B-PHE
Colitis I-PHE

-DOCSTART- O


1 O
Its O
aqueous O
infusion O
exerts O
a O
significant O
diuretic B-PHE
effect I-PHE
in O
experimental O
animals O
. O

2 O
Shortening O
clotting B-PHE
time O
and O
bleeding B-PHE
time O
, O
and O
decreasing O
the O
permeability O
of O
blood O
vessels O
. O

3 O
Inhibiting O
the O
growth O
of O
Staphylococcus B-PHE
aureus I-PHE
and O
Bacillus B-PHE
dysenteriae I-PHE
. O

-DOCSTART- O


discharge O
heat B-PHE
and O
cool O
blood B-PHE

-DOCSTART- O


Its O
decoction O
inhibits O
the O
development O
of O
egg-white O
induced O
arthritis B-PHE
in O
mice O
. O

-DOCSTART- O


calm O
five B-PHE
viscera I-PHE

-DOCSTART- O


Stage O
IV O
Childhood B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


move O
wind B-PHE
Gi(Qi O
) O

-DOCSTART- O


nocturnal B-PHE
emission I-PHE
; O
emission B-PHE
; O
spermatorrhea B-PHE
; O
seminal B-PHE
emission I-PHE

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Body O
weight O
regulation O
, O
Woman O
, O
Reproductive B-PHE
systems I-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Endocrine O
& O
reproductive B-PHE
systems I-PHE
, O
Intelligence O
, O
Dermatological B-PHE
systems I-PHE
health O
, O
Eldery O
, O
Overall O
CVD O
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
General O
woman O
, O
General O
skin B-PHE
health I-PHE
, O
menopausal B-PHE
woman I-PHE
, O
Others O
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


To O
reinforce O
qi O
and O
invigorate O
the O
function O
of O
the O
spleen B-PHE
and O
the O
lung B-PHE
. O

-DOCSTART- O


To O
remove O
damp-heat B-PHE
, O
quench O
fire B-PHE
and O
counteract O
toxicity B-PHE
. O

-DOCSTART- O


Treatment O
of O
mass B-PHE
in O
the O
abdomen O
, O
goitre B-PHE
with O
pain B-PHE
, O
epigastric B-PHE
pain I-PHE
and O
distension B-PHE
due O
to O
indigestion B-PHE
. O

-DOCSTART- O


The O
ingredients O
of O
this O
prescription O
are O
all O
bitter O
in O
taste O
and O
cold O
in O
nature O
, O
so O
that O
the O
fire O
purging O
and O
detoxifying O
effect O
is O
very O
strong O
. O

Since O
the O
bitter-cold O
drugs O
are O
liable O
to O
damage O
yin-energy O
, O
the O
prescription O
is O
only O
used O
for O
cases O
when O
the O

-DOCSTART- O


relaxing O
apoplexy B-PHE

-DOCSTART- O


invigorate O
blood B-PHE
and O
resolve O
stasis B-PHE

-DOCSTART- O


Woman O
, O
Eye B-PHE
, O
Mood O
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE
, O
Menopausal B-PHE
woman I-PHE
, O
Eye B-PHE
health I-PHE
, O
Lipid B-PHE
profile I-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
sleep B-PHE
, O
Inflammation B-PHE
, O
Other O
system B-PHE
health I-PHE
, O
Memory B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
post O
delivery O
, O
Hypersensitivity B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Quality O
of O
life O
, O
Eye B-PHE
health I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Blood B-PHE
pressure I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Diet B-PHE
cardiovascular I-PHE
disease I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Liver B-PHE
, O
Others O
, O
vigilance B-PHE
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Homocysteine B-PHE
metabolism I-PHE
, O
Bone B-PHE
metabolism I-PHE
/ I-PHE
density I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
activation B-PHE
, O
attention B-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Liver B-PHE
health I-PHE
, O
Eldery O
, O
Strength B-PHE
and O
power B-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Intelligence B-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Overall O
CVD B-PHE
, O
General O
woman O
, O
General O
skin B-PHE
health I-PHE
, O
Strength B-PHE
and O
power B-PHE
Reproductive I-PHE
systems I-PHE
, O
Arousal B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Man O
, O
sleep B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
stanch O
bleeding B-PHE
and O
disperse O
swelling B-PHE
, O
kill O
worms B-PHE
. O

-DOCSTART- O


CYT006-AngQb O
is O
a O
therapeutic O
vaccine O
designed O
to O
instruct O
the O
patient's O
immune B-PHE
system I-PHE
to O
produce O
a O
specific O
anti-angiotensin B-PHE
II I-PHE
antibody I-PHE
response I-PHE
. O

-DOCSTART- O


Metabolic O
urinary O
profiling O
of O
alcohol B-PHE
hepatotoxicity I-PHE
and I-PHE
intervention I-PHE
effects O
of O
Yin O
Chen O
Hao O
Tang O
in O
rats O
using O
ultra O
- O
performance O
liquid O
chromatography O
/ O
electrospray O
ionization O
quadruple O
time O
- O
of O
- O
flight O
mass O
spectrometry O
. O

-DOCSTART- O


Insulin O
glargine O
is O
is O
a O
long-acting O
basal O
insulin O
analogue O
and O
binds O
to O
the O
insulin O
receptor O
, O
the O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-PHE
kinase I-PHE
activity O
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

Insulin O
glulisine O
is O
a O
biosynthetic O
, O
rapid-acting O
human O
insulin O
analogue O
which O
differs O
from O
native O
human O
insulin O
in O
that O
the O
amino O
acid O
arginine O
at O
position O
B3 O
is O
replaced O
by O
lysine O
and O
the O
lysine O
at O
position O
B29 O
is O
replaced O
by O
glutamic O
acid O
. O

-DOCSTART- O


Menstrual B-PHE
disorder I-PHE
, O
postpartum B-PHE
abdominal I-PHE
pain I-PHE
due O
to O
stasis B-PHE
obstruction I-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
wind-damp B-PHE
impediment I-PHE
pain I-PHE
. O

-DOCSTART- O


To O
dissipate O
cold B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
and O
disinhibit O
damp B-PHE
. O

-DOCSTART- O


the O
upper O
emaciation B-PHE
; O
lung B-PHE
diabetes I-PHE

-DOCSTART- O


wind B-PHE
Pi I-PHE
syndrome I-PHE
; O
arthralgia B-PHE
due O
to O
wind B-PHE
arthritis I-PHE
mainly O
due O
to O
pathogenic B-PHE
wind I-PHE
, O
marked O
by O
swelling B-PHE
and O
migratory B-PHE
pain I-PHE
in O
the O
joints O
of O
the O
limbs O
. O

-DOCSTART- O


reinforce O
the O
kidney B-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
pricking B-PHE
pain I-PHE
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O


Complicated O
Skin O
and O
Skin B-PHE
Structure I-PHE
Infections I-PHE

-DOCSTART- O


Macular B-PHE
Degeneration I-PHE

-DOCSTART- O


For O
the O
treatment O
and O
management O
of O
congestive B-PHE
cardiac I-PHE
insufficiency I-PHE
, O
arrhythmias B-PHE
and O
heart B-PHE
failure I-PHE
. O

-DOCSTART- O


Pseudoephedrine O
relaxes O
bronchial B-PHE
smooth I-PHE
muscle I-PHE
by O
stimulating O
beta2-adrenergic O
receptors O
. O

-DOCSTART- O


Treament O
of O
looseness B-PHE
of I-PHE
teeth I-PHE
, O
premature B-PHE
greying I-PHE
of I-PHE
hair I-PHE
and I-PHE
beard I-PHE
, O
dizziness B-PHE
, O
tinnitus B-PHE
, O
aching B-PHE
and I-PHE
weakness I-PHE
of I-PHE
the I-PHE
loins I-PHE
and I-PHE
knees I-PHE
, O
spitting B-PHE
of I-PHE
blood I-PHE
, O
epistaxis B-PHE
, O
hematuria B-PHE
and O
diarrhea B-PHE
with O
bloody B-PHE
stools I-PHE
due O
to O
heat B-PHE
in I-PHE
the I-PHE
blood I-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
. O

-DOCSTART- O


reinforce O
blood B-PHE

-DOCSTART- O


Serious O
heat B-PHE
in O
lung O
and O
stomach O
, O
epidemic B-PHE
infectious I-PHE
diseases I-PHE
, O
fever B-PHE
, O
dizziness B-PHE
, O
aching B-PHE
of O
limbs O
, O
cough B-PHE
with O
copious B-PHE
phlegm I-PHE
, O
sore B-PHE
throat I-PHE
, O
epistaxis B-PHE
, O
haemoptysis B-PHE
, O
dryness B-PHE
of I-PHE
mouth I-PHE
and I-PHE
tongue I-PHE
. O

-DOCSTART- O


This O
is O
a O
symptom O
with O
a O
pain B-PHE
in O
a O
waist O
and O
the O
side O
. O

-DOCSTART- O


( O
1 O
) O
precordial B-PHE
pain I-PHE
; O
intermittent O
cardiac B-PHE
pain I-PHE
( O
2 O
) O
epigastric B-PHE
pain I-PHE

-DOCSTART- O


fluid B-PHE
retention I-PHE
; O

phlegm B-PHE
and O
retained B-PHE
fluid I-PHE
; O

congested B-PHE
fluids I-PHE

-DOCSTART- O


hematuria B-PHE
with I-PHE
pain I-PHE
; O
stranguria B-PHE
with I-PHE
hematuria I-PHE
; O
painful O
urination B-PHE
with I-PHE
blood I-PHE

-DOCSTART- O


abortion B-PHE

-DOCSTART- O


Purging O
by O
pressure O
and O
by O
removing O
liquid O

-DOCSTART- O


1 O
Application O
to O
cass O
of O
early O
stage O
of O
superficial O
pyogenic O
infection O
with O
local O
signs O
of O
inflammation B-PHE
, O
chilliness B-PHE
, O
fever B-PHE
, O
bitter B-PHE
mouth I-PHE
, O
constipation B-PHE
, O
oliguria B-PHE
, O
red B-PHE
tongue I-PHE
with O
white O
fur O
and O
rapid B-PHE
pulse I-PHE
. O
2 O
Also O
indicated O
for O
cases O
of O
urticaria B-PHE
and O
e O

-DOCSTART- O


To O
activate O
blood B-PHE
circulation I-PHE
, O
eliminate O
stasis B-PHE
, O
promote O
the O
subsidence B-PHE
of I-PHE
swelling I-PHE
and O
alleviate O
pain B-PHE
. O

-DOCSTART- O


To O
clear O
liver B-PHE
and O
brighten O
eyes B-PHE
. O

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
cardiovascular B-PHE
disorders I-PHE
and O
inflammatory B-PHE
disorders I-PHE
( O
unspecified O
) O
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


pricking B-PHE
pain I-PHE

-DOCSTART- O


Weak O
stomach O
qi O
, O
noise B-PHE
in I-PHE
stomach I-PHE
, O
diarrhea B-PHE
, O
stagnation B-PHE
of I-PHE
water I-PHE
, O
dry B-PHE
vomiting I-PHE
, O
annoyment B-PHE

-DOCSTART- O


Infant B-PHE
, I-PHE
Newborn I-PHE
, I-PHE
Diseases I-PHE

-DOCSTART- O


Besifloxacin O
is O
a O
bactericidal O
fluroquinolone-type O
antibiotic O
that O
inhibits O
bacterial B-PHE
enzymes I-PHE
, O
DNA B-PHE
gyrase I-PHE
and O
topoisomerase B-PHE
IV I-PHE
. O

By O
inhibiting O
DNA B-PHE
gyrase I-PHE
, O
DNA B-PHE
replication O
, O
transcription O
, O
and O
repair O
is O
impaired O
. O

By O
inhibiting O
topoisomerase B-PHE
IV I-PHE
, O
decatenation O
during O
cell O
devision O
is O
impaired O
. O

Inhibiting O
these O
two O
targets O
also O
slows O
down O
development O
of O
resistance O
. O

-DOCSTART- O


convulsive B-PHE
disease I-PHE
; O
epilepsy B-PHE
induced O
by O
frightening O

-DOCSTART- O


Specifically O
, O
dalbavancin O
prevents O
incorporation O
of O
N-acetylmuramic B-PHE
acid I-PHE
( O
NAM B-PHE
) O
- O
and O
N-acetylglucosamine B-PHE
( O
NAG B-PHE
) O
- O
peptide O
subunits O
from O
being O
incorporated O
into O
the O
peptidoglycan O
matrix O
; O
which O
forms O
the O
major O
structural O
component O
of O
Gram-positive O
cell O
walls O
. O

-DOCSTART- O


DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Overall O
CVD B-PHE
, O
Others O

-DOCSTART- O


Cyclandelate O
produces O
peripheral B-PHE
vasodilation I-PHE
by O
a O
direct O
effect O
on O
vascular B-PHE
smooth I-PHE
muscle I-PHE
. O

Pharmacological O
action O
may O
be O
due O
to O
calcium-channel O
antagonism O
. O

-DOCSTART- O


Cholestyramine O
binds O
bile B-PHE
in O
the O
gastrointestinal O
tract O
to O
prevent O
its O
reabsorption O
. O

-DOCSTART- O


Yin O
Chen O
Hao O
Tang O
, O
a O
Chinese O
prescription O
, O
inhibits O
both O
herpes B-PHE
simplex I-PHE
virus I-PHE
type-1 I-PHE
and I-PHE
type-2 I-PHE
infections I-PHE
in O
vitro O
. O

-DOCSTART- O


Treatment O
of O
palpitation B-PHE
and O
insomnia B-PHE
, O
convulsion B-PHE
, O
epilepsy B-PHE
, O
nebula B-PHE
, O
skin B-PHE
ulcerations I-PHE
difficult O
to O
heal O
. O

-DOCSTART- O


Used O
in O
the O
treatment O
of O
Kaposi's B-PHE
sarcoma I-PHE
and O
cancer B-PHE
of O
the O
lung O
, O
ovarian O
, O
and O
breast O
. O

Abraxane O
is O
specfically O
indicated O
for O
the O
treatment O
of O
metastatic B-PHE
breast I-PHE
cancer I-PHE
and O
locally O
advanced B-PHE
or I-PHE
metastatic I-PHE
non-small I-PHE
cell I-PHE
lung I-PHE
cancer I-PHE
. O

-DOCSTART- O


Acute B-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Carcinoma B-PHE
of I-PHE
mammary I-PHE
glands I-PHE
, O
nasopharyngeal B-PHE
carcinoma I-PHE
, O
carcinoma B-PHE
of I-PHE
salivary I-PHE
gland I-PHE
, O
scrofula B-PHE
, O
swelling B-PHE
of I-PHE
skin I-PHE
, O
pain B-PHE
wind I-PHE
. O

-DOCSTART- O


To O
cause O
diuresis B-PHE
, O
to O
invigorate O
the O
spleen B-PHE
function I-PHE
, O
and O
to O
calm O
the O
mind B-PHE
. O

-DOCSTART- O


clear O
heat B-PHE
and O
calm O
the O
fetus O

-DOCSTART- O


Damp-heat B-PHE
dysentery I-PHE
, O
enteritis B-PHE
and O
diarrhea B-PHE
. O

-DOCSTART- O


dry B-PHE
cough I-PHE
due O
to O
lung-heat B-PHE

-DOCSTART- O


For O
clearing O
weakness B-PHE
and O
heat B-PHE

-DOCSTART- O


Exenatide O
is O
a O
functional O
analog O
of O
the O
human O
incretin O
Glucagon-Like O
Peptide-1 O
( O
GLP-1 O
) O
. O

Incretins B-PHE
enhance O
glucose-dependent B-PHE
insulin I-PHE
secretion I-PHE
and O
exhibit O
other O
antihyperglycemic B-PHE
actions I-PHE
following O
their O
release O
into O
the O
circulation O
from O
the O
gut O
. O

The O
GLP-1 B-PHE
system I-PHE
increases O
insulin B-PHE
secretion I-PHE
only O
in O
the O
presence O
of O
elevated O
plasma O
glucose O
levels O
, O
avoiding O
inappropriately O
high B-PHE
insulin I-PHE
levels I-PHE
during O
fasting O
. O

The O
drug O
also O
moderates O
peak O
serum B-PHE
glucagon I-PHE
levels I-PHE
during O
hyperglycemic O
periods O
following O
meals O
, O
but O
does O
not O
interfere O
with O
glucagon B-PHE
release I-PHE
in O
response O
to O
hypoglycemia O
. O

Secondary O
effects O
of O
drug O
administration O
reduces O
the O
rate B-PHE
of I-PHE
gastric I-PHE
emptying I-PHE
and O
decreases O
food B-PHE
intake I-PHE
, O
mitigating O
the O
potential O
severity B-PHE
of I-PHE
hyperglycemic I-PHE
events I-PHE
after O
meals O
. O

-DOCSTART- O


Intelligence O
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
parkinson's B-PHE
disease I-PHE
. O

-DOCSTART- O


Good O
evidence O
exists O
that O
this O
drug O
bind O
strongly O
, O
but O
reversibly O
, O
to O
DNA B-PHE
, O
interfering O
with O
synthesis B-PHE
of I-PHE
RNA I-PHE
( O
prevention O
of O
RNA B-PHE
polymerase I-PHE
elongation I-PHE
) O
and O
, O
consequently O
, O
with O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


Wind-cold-damp B-PHE
impediment O
, O
paralysis B-PHE
, O
painful O
wound B-PHE
from O
knocks O
and O
falls O
, O
tetanus O
. O

-DOCSTART- O


Halobetasol O
propionate O
is O
thought O
to O
act O
by O
the O
induction O
of O
phospholipase O
A2 O
inhibitory O
proteins O
, O
collectively O
called O
lipocortins O
. O

It O
is O
postulated O
that O
these O
proteins O
control O
the O
biosynthesis B-PHE
of O
potent O
mediators O
of O
inflammation O
such O
as O
prostaglandins B-PHE
and O
leukotrienes B-PHE
by O
inhibiting O
the O
release O
of O
their O
common O
precursor O
arachidonic B-PHE
acid I-PHE
. O

Arachidonic O
acid O
is O
released O
from O
membrane O
phospholipids O
by O
phospholipase O
A2 O
. O

The O
initial O
interaction O
, O
however O
, O
is O
due O
to O
the O
drug O
binding O
to O
the O
cytosolic O
glucocorticoid O
receptor O
. O

After O
binding O
the O
receptor O
the O
newly O
formed O
receptor-ligand O
complex O
translocates O
itself O
into O
the O
cell O
nucleus O
, O
where O
it O
binds O
to O
many O
glucocorticoid O
response O
elements O
( O
GRE O
) O
in O
the O
promoter O
region O
of O
the O
target O
genes O
. O

The O
DNA O
bound O
receptor O
then O
interacts O
with O
basic O
transcription B-PHE
factors I-PHE
, O
causing O
the O
increase O
in O
expression B-PHE
of I-PHE
specific I-PHE
target I-PHE
genes I-PHE
. O

-DOCSTART- O


fetal B-PHE
irritability I-PHE
; O
threatened B-PHE
abortion I-PHE
; O
excessive O
fetal O
movements O
continuous O
moving O
of O
the O
fetus O
causing O
pain B-PHE
in I-PHE
the I-PHE
lower I-PHE
abdomen I-PHE
. O

-DOCSTART- O


Cisplatin O
complexes O
react O
in O
vivo O
, O
binding O
to O
and O
causing O
crosslinking O
of O
DNA B-PHE
which O
ultimately O
triggers O
apoptosis B-PHE
( O
programmed O
cell B-PHE
death I-PHE
) O
. O

Gemcitabine O
is O
converted O
intracellularly O
to O
the O
active O
metabolites O
difluorodeoxycytidine O
di- O
and O
triphosphate O
( O
dFdCDP O
, O
dFdCTP O
) O
. O

dFdCDP O
inhibits O
ribonucleotide B-PHE
reductase I-PHE
, O
thereby O
decreasing O
the O
deoxynucleotide O
pool O
available O
for O
DNA B-PHE
synthesis I-PHE
; O
dFdCTP O
is O
incorporated O
into O
DNA B-PHE
, O
resulting O
in O
DNA B-PHE
strand I-PHE
termination I-PHE
and O
apoptosis B-PHE
. O

-DOCSTART- O


For O
breaking O
blood B-PHE
and O
desolving O
stasis B-PHE

-DOCSTART- O


A O
high O
performance O
liquid O
chromatography-hydride O
generation-atomic O
fluorescence O
spectrometry O
( O
HPLC-HG-AFS O
) O
method O
was O
developed O
for O
the O
simultaneous O
determination O
of O
four O
arsenic O
species O
( O
As(III) O
) O
, O
dimethylarsinic O
acid O
( O
DMA O
) O
, O
monomethylarsonic O
acid O
( O
MMA O
) O
and O
arsenate O
As(V) O
in O
dog O
plasma O
. O

Good O
separation O
of O
the O
four O
arsenic O
species O
was O
achieved O
within O
15min O
on O
an O
anion-exchange O
column O
with O
isocratic O
elution O
using O
15mmol/L O
KH(2)PO(4 O
) O
( O
pH O
5.9 O
) O
as O
eluent O
at O
a O
flow O
rate O
of O
1.0mL/min O
. O

The O
assay O
was O
linear O
over O
the O
range O
of O
1.25-200 O
, O
1.56-200 O
, O
1.34-172 O
, O
and O
2.50-200ng/mL O
with O
the O
detection O
limits O
of O
0.8 O
, O
1 O
, O
0.86 O
and O
2.00ng/mL O
for O
As O
( O
III O
) O
, O
DMA O
, O
MMA O
and O
As O
( O
V O
) O
, O
respectively O
. O

The O
method O
was O
validated O
for O
selectivity O
, O
precision O
, O
accuracy O
and O
recovery O
and O
then O
applied O
to O
a O
comparative O
pharmacokinetic O
study O
of O
the O
arsenic O
species O
in O
beagle O
dogs O
after O
a O
single O
oral O
administration O
of O
Realgar O
( O
24.32mg/kg O
, O
equivalent O
to O
11.31mgAs/kg O
) O
alone O
or O
Niu O
Huang O
Jie O
Du O
Pian O
(a O
patent O
traditional O
Chinese O
medicine O
( O
TCM O
) O
, O
380mg/kg O
, O
equivalent O
to O
28.45mgAs/kg O
) O
, O
respectively O
. O

DMA O
was O
found O
to O
be O
the O
predominant O
species O
in O
the O
dog O
plasma O
after O
dosing O
, O
with O
As(V O
) O
appeared O
as O
the O
quickly O
eliminating O
one O
. O

No O
traces O
of O
MMA O
and O
As(III O
) O
were O
detected O
at O
any O
sampling O
time O
points O
. O

The O
main O
pharmacokinetic O
parameters O
found O
for O
DMA O
p.o O
. O
administration O
of O
Realgar O
and O
Niu O
Huang O
Jie O
Du O
Pian O
were O
as O
follows O
: O
C(max O
) O
( O
14.7 O
4.2 O
) O
and O
( O
57 O
32.0)ng/mL O
, O
T(max O
) O
( O
2.4 O
0.5 O
) O
and O
( O
2.5 O
0.5)h O
, O
AUC(0-36 O
) O
( O
151.1 O
12.9 O
) O
and O
( O
635.9 O
418.2)ngh/mL O
, O
AUC(0- O
) O
( O
206 O
44.5 O
) O
and O
( O
687.2 O
425.1)ngh/mL O
, O
t(1/2 O
) O
( O
16.2 O
7.9 O
) O
and O
( O
9.4 O
2.2)h O
, O
respectively O
. O

The O
influence O
of O
compounding O
in O
Niu O
Huang O
Jie O
Du O
Pian O
on O
the O
pharmacokinetics O
of O
arsenics O
was O
shown O
with O
increased O
transformation O
of O
DMA O
and O
its O
faster O
elimination O
rate O
. O

-DOCSTART- O


To O
remove O
heat B-PHE
and O
damp B-PHE
, O
to O
counteract O
toxicity B-PHE
, O
and O
to O
cause O
subsidence B-PHE
of I-PHE
swelling I-PHE
. O

-DOCSTART- O


Treatment O
of O
headache B-PHE
and O
dizziness B-PHE
, O
costal B-PHE
and I-PHE
abdomina I-PHE
pain I-PHE
, O
spasmodic B-PHE
pain I-PHE
of O
the O
limbs O
, O
anemia B-PHE
, O
menstrual B-PHE
disorders I-PHE
, O
spontaneous O
sweating B-PHE
and O
night B-PHE
sweating I-PHE
. O

-DOCSTART- O


Mounting O
qi O
( O
hernia B-PHE
) O
, O
profuse B-PHE
menstruation I-PHE
. O

-DOCSTART- O


arrest O
cough B-PHE
and O
relieve O
asthms B-PHE

-DOCSTART- O


acute O
infantile B-PHE
convulsion I-PHE

-DOCSTART- O


cough B-PHE
due O
to O
wind-cold B-PHE

-DOCSTART- O


Cold B-PHE
pain I-PHE
in O
stomach O
duct O
and O
abdomen O
, O
indigestion B-PHE
, O
vomiting B-PHE
nausea B-PHE
, O
diarrhea B-PHE
, O
cold B-PHE
mounting O
, O
dysmenorrhea B-PHE
, O
urethral B-PHE
stone I-PHE
, O
swelling B-PHE
pain I-PHE
of O
sore O
and O
boil O
. O

-DOCSTART- O


To O
reduce O
swelling B-PHE
and O
promote O
healing B-PHE
. O

-DOCSTART- O


Acute B-PHE
Viral I-PHE
Bronchiolitis I-PHE

-DOCSTART- O


AIDS B-PHE
With O
Tuberculosis B-PHE

-DOCSTART- O


Red B-PHE
eyes I-PHE
with O
gall O
, O
pulmonary O
welling O
abscess B-PHE
, O
diarrhea B-PHE
, O
dysentery B-PHE
, O
leukorrhea B-PHE
, O
postpartum O
blood B-PHE
stasis I-PHE
abdominal B-PHE
pain I-PHE
, O
indigestion B-PHE
, O
nephritis B-PHE
with O
edema B-PHE
, O
cirrhosis B-PHE
with O
ascites B-PHE
, O
swelling B-PHE
toxin O
of O
welling B-PHE
abscess I-PHE
and O
sore B-PHE
. O

-DOCSTART- O


promote O
the O
intestine B-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
cool O
blood B-PHE
; O

To O
benefit O
qi O
and O
contain O
blood B-PHE
; O
To O
revitalize O
blood B-PHE
and O
desolve O
stagnation B-PHE

-DOCSTART- O


For O
treatment O
and O
management O
of O
epilepsy B-PHE
and O
seizures B-PHE
associated O
with O
Lennox-Gastaut B-PHE
syndrome I-PHE
, O
a O
difficult-to-treat O
form O
of O
childhood B-PHE
epilepsy I-PHE
. O

-DOCSTART- O


Hemophilia B-PHE
A I-PHE

-DOCSTART- O


sore B-PHE

-DOCSTART- O


general O
swelling B-PHE
and O
small B-PHE
amount I-PHE
urine I-PHE

-DOCSTART- O


1 O
Since O
the O
prescription O
possesses O
a O
hemostatic O
action O
, O
it O
is O
also O
indicated O
for O
incised B-PHE
wounds I-PHE
with O
hemorrhage B-PHE
( O
topical O
use O
) O
. O

2 O
Applicable O
to O
cases O
of O
angina B-PHE
pectoris I-PHE
which O
are O
attributive O
to O
retention O
of O
blood B-PHE
stasis I-PHE
. O

3 O
Also O
applicable O
orally O
or O
topi O

-DOCSTART- O


Hypertension B-PHE
, O
kidney B-PHE
vacuity I-PHE
lumbago I-PHE
, O
weakness B-PHE
in O
sinews O
and O
bones O
, O
stirring O
fetus O
in O
pregnancy O
. O

-DOCSTART- O


ADHD B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Megakaryoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


excessive B-PHE
thought I-PHE
; O
anxiety O

-DOCSTART- O


To O
calm O
the O
liver O
and O
suppress O
the O
asthenic B-PHE
yang O
, O
to O
promote O
the O
restoration O
of O
consciousness O
, O
decrease O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


Urinary B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Liver B-PHE
health I-PHE
, O
Liver B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
chronic B-PHE
coughing I-PHE
and O
inflammation B-PHE
in O
urination O
. O

-DOCSTART- O


Intelligence B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Others O
, O
Protective O
immunity B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


a O
symptom O
of O
having O
muscular B-PHE
flaccidity I-PHE
due O
to O
deficiency O
of O
Gi O
, O
and O
insufficiency B-PHE
of I-PHE
nourishment I-PHE
in O
organs O
due O
to O
deficiency B-PHE
of I-PHE
blood I-PHE

-DOCSTART- O


Decanoyl O
acetaldehyde O
is O
bacteriostatic O
and O
fungistatic O
. O

Its O
decoction O
retards O
the O
progress O
of O
tuberculosis B-PHE
experimentally O
. O

Synthetic O
product O
( O
compound O
of O
decanoyl O
acetaldehyde O
and O
NaHSO3 O
) O
promotes O
white B-PHE
cell I-PHE
phagocytosis I-PHE
. O

Anti-inflammation B-PHE
. O

Quercitrin O
, O
an O
active O
component O
, O
is O
a O
strong O
diuretic O
, O
and O
exerts O
such O
effect O
in O
a O
1 O
: O
10 O
, O
0 O
solution O
. O

-DOCSTART- O


To O
move O
qi O
, O
precipitate O
qi O
, O
relieve O
pain B-PHE
, O
disperse O
distention O
, O
free O
milk O
. O

-DOCSTART- O


Based O
on O
the O
behavior O
of O
protons O
when O
placed O
in O
a O
strong O
magnetic O
field O
, O
which O
is O
interpreted O
and O
transformed O
into O
images O
by O
magnetic O
resonance O
( O
MR O
) O
instruments O
. O

Paramagnetic O
agents O
have O
unpaired O
electrons O
that O
generate O
a O
magnetic O
field O
about O
700 O
times O
larger O
than O
the O
proton's O
field O
, O
thus O
disturbing O
the O
proton's O
local O
magnetic O
field O
. O

When O
the O
local O
magnetic O
field O
around O
a O
proton O
is O
disturbed O
, O
its O
relaxation O
process O
is O
altered O
. O

MR O
images O
are O
based O
on O
proton O
density O
and O
proton O
relaxation O
dynamics O
. O

MR O
instruments O
can O
record O
2 O
different O
relaxation O
processes O
, O
the O
T1 O
( O
spin-lattice O
or O
longitudinal O
relaxation O
time O
) O
and O
the O
T2 O
( O
spin-spin O
or O
transverse O
relaxation O
time O
) O
. O

In O
magnetic O
resonance O
imaging O
( O
MRI O
) O
, O
visualization O
of O
normal O
and O
pathological O
brain O
tissue O
depends O
in O
part O
on O
variations O
in O
the O
radiofrequency O
signal O
intensity O
that O
occur O
with O
changes O
in O
proton O
density O
, O
alteration O
of O
the O
T1 O
, O
and O
variation O
in O
the O
T2 O
. O

When O
placed O
in O
a O
magnetic O
field O
, O
gadodiamide O
shortens O
both O
the O
T1 O
and O
the O
T2 O
relaxation O
times O
in O
tissues O
where O
it O
accumulates O
. O

At O
clinical O
doses O
, O
gadodiamide O
primarily O
affects O
the O
T1 O
relaxation O
time O
, O
thus O
producing O
an O
increase O
in O
signal O
intensity O
. O

Gadodiamide O
does O
not O
cross O
the O
intact O
blood-brain B-PHE
barrier I-PHE
; O
therefore O
, O
it O
does O
not O
accumulate O
in O
normal O
brain O
tissue O
or O
in O
central B-PHE
nervous I-PHE
system I-PHE
( O
CNS B-PHE
) O
lesions B-PHE
that O
have O
not O
caused O
an O
abnormal O
blood-brain B-PHE
barrier I-PHE
( O
e.g O
. O
, O
cysts B-PHE
, O
mature O
post-operative O
scars O
) O
. O

Abnormal B-PHE
vascularity I-PHE
or O
disruption B-PHE
of I-PHE
the I-PHE
blood-brain I-PHE
barrier I-PHE
allows O
accumulation O
of O
gadodiamide B-PHE
in I-PHE
lesions I-PHE
such O
as O
neoplasms B-PHE
, O
abscesses B-PHE
, O
and O
subacute B-PHE
infarcts I-PHE
. O

-DOCSTART- O


vomiting B-PHE
and O
regurgitation B-PHE

-DOCSTART- O


Inhibited O
urination B-PHE
, O
dribbling O
pain B-PHE
of O
urination O
, O
edema B-PHE
, O
bloody B-PHE
urine I-PHE
, O
damp-heat B-PHE
dysentery I-PHE
, O
asthma B-PHE
, O
sore B-PHE
swollen I-PHE
throat I-PHE
, O
toxin B-PHE
swelling I-PHE
of O
sores O
, O
wind-damp B-PHE
pain I-PHE
, O
menstrual B-PHE
disorder I-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
bleeding B-PHE
knife O
wound O
. O

-DOCSTART- O


This O
is O
a O
syndrome B-PHE
with I-PHE
bloat I-PHE
and I-PHE
fullness I-PHE
in I-PHE
abdominal I-PHE
region I-PHE
. O

-DOCSTART- O


swelling B-PHE
and O
bearing-down B-PHE
pain I-PHE
of O
unilateral O
testis O
; O
unilateral O
swelling B-PHE
of I-PHE
the I-PHE
testis I-PHE

-DOCSTART- O


Boils B-PHE
and O
carbuncles B-PHE
. O

-DOCSTART- O


release O
the O
exterior O
and O
dispel O
wind B-PHE

-DOCSTART- O


Treatment O
of O
weakness B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
the I-PHE
lung I-PHE
manifested O
by O
shortness B-PHE
of I-PHE
breath I-PHE
, O
cough B-PHE
, O
palpitation B-PHE
, O
anorexia B-PHE
, O
loose B-PHE
stools I-PHE
, O
diabetes B-PHE
caused O
by O
internal O
heat B-PHE
. O

-DOCSTART- O


inflammation B-PHE
of O
the O
throat O
; O
sore B-PHE
throat I-PHE
; O
hoarse B-PHE
voice I-PHE
; O
aphonia B-PHE

-DOCSTART- O


Its O
aqueous O
infusion O
inhibits O
the O
growth B-PHE
of I-PHE
skin I-PHE
fungi I-PHE
such O
as O
Trichophyton B-PHE
violaceum I-PHE
. O

-DOCSTART- O


To O
enrich O
the O
blood B-PHE
, O
to O
activate O
blood B-PHE
circulation I-PHE
, O
and O
to O
remove O
obstruction O
of O
the O
channels O
and O
collaterals O
. O

-DOCSTART- O


Chronic B-PHE
Fatigue I-PHE

-DOCSTART- O


Endocrine B-PHE
system I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
the O
following O
mild-to-moderate B-PHE
infections I-PHE
caused O
by O
susceptible O
strains O
of O
microorganisms O
: O
acute B-PHE
bacterial I-PHE
exacerbations I-PHE
of I-PHE
chronic I-PHE
bronchitis I-PHE
, O
secondary B-PHE
bacterial I-PHE
infection I-PHE
of O
acute B-PHE
bronchitis I-PHE
, O
community B-PHE
- I-PHE
acquired I-PHE
pneumonia I-PHE
, O
pharyngitis B-PHE
/ O
tonsilitis B-PHE
, O
and O
uncomplicated B-PHE
skin I-PHE
and O
skin B-PHE
structure I-PHE
infections I-PHE
. O

-DOCSTART- O


To O
remove O
heat B-PHE
from O
the O
lung O
and O
relieve O
sore B-PHE
throat I-PHE
, O
and O
to O
regulate O
the O
flow O
of O
qi O
of O
the O
liver O
and O
the O
stomach O
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
, O
disinhibit O
water O
and O
disperse O
edema B-PHE
. O

-DOCSTART- O


To O
clear O
away O
heat B-PHE
and O
toxic B-PHE
materials I-PHE
. O

-DOCSTART- O


post B-PHE
delivery I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Woman O
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Hypersensitivity B-PHE
, O
motility B-PHE
, O
Others O
, O
Body B-PHE
weight I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Quality O
of O
life O
, O
Hemostatic B-PHE
function I-PHE
, O
Inflammation B-PHE

-DOCSTART- O


pull O
up O
toxicity B-PHE
and O
regenerate O
flesh B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
of O
a O
retarded B-PHE
child I-PHE
. O

There O
are O
five O
symptoms O
including O
slow B-PHE
stand I-PHE
, O
delayed O
development O
in O
walking O
, O
retardation O
in O
hair-growing O
, O
delayed B-PHE
development I-PHE
in O
growth O
of O
teeth O
, O
and O
delayed B-PHE
development I-PHE
of O
speech O
in O
an O
infant O
. O

-DOCSTART- O


Pulmonary O
Aspiration O

-DOCSTART- O


nourish O
Eum O
( O
Yin O
) O
and O
reinforce O
blood B-PHE

-DOCSTART- O


stop O
bleeding B-PHE
; O
hemostasis B-PHE

-DOCSTART- O


freckles B-PHE
on O
face O

-DOCSTART- O


Filgrastim O
binds O
to O
the O
G-CSF O
receptor O
and O
stimulates O
the O
production B-PHE
of I-PHE
neutrophils I-PHE
in O
the O
bone O
marrow O
. O

-DOCSTART- O


Tretinoin O
binds O
to O
and O
activates O
retinoic O
acid O
receptors O
( O
RARs O
) O
, O
thereby O
inducing O
changes O
in O
gene B-PHE
expression I-PHE
that O
lead O
to O
cell B-PHE
differentiation I-PHE
, O
decreased B-PHE
cell I-PHE
proliferation I-PHE
, O
and O
inhibition B-PHE
of I-PHE
tumorigenesis I-PHE
. O

-DOCSTART- O


Heart B-PHE
Failure I-PHE
. O

-DOCSTART- O


juvenile O
onset O
smallpox B-PHE
poison O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
Without O
Maturation B-PHE

-DOCSTART- O


pain B-PHE
in O
ear O

-DOCSTART- O


Numbness B-PHE
of I-PHE
the I-PHE
extremities I-PHE
, O
aching B-PHE
of O
the O
joints O
and O
menstrual B-PHE
disorders I-PHE
due O
to O
deficiency B-PHE
of I-PHE
blood I-PHE
. O

-DOCSTART- O


abdominal B-PHE
mass I-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
fullness B-PHE
and I-PHE
pain I-PHE
in I-PHE
the I-PHE
chest I-PHE
and I-PHE
abdomen I-PHE
. O

-DOCSTART- O


To O
dissipate O
cold B-PHE
and O
relieve O
pain B-PHE
, O
rectify O
qi O
and O
regulate O
center O
. O

-DOCSTART- O


Treatment O
of O
hemoptysis B-PHE
, O
hematemesis B-PHE
, O
epistaxis B-PHE
, O
hematochezia B-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
, O
pricking O
pain B-PHE
in O
the O
chest O
and O
abdomen O
, O
traumatic B-PHE
swelling I-PHE
and O
pain B-PHE
. O

-DOCSTART- O


Coronary O
Artery O
Bypass O
Graft O
Redo O

-DOCSTART- O


deficiency B-PHE
and I-PHE
chills I-PHE
of I-PHE
uterus I-PHE

-DOCSTART- O


frequent B-PHE
vomiting I-PHE

-DOCSTART- O


epigastric O
twisting O
pain B-PHE
. O

-DOCSTART- O


Lopinavir O
inhibits O
the O
HIV B-PHE
viral I-PHE
protease I-PHE
enzyme I-PHE
. O

-DOCSTART- O


Statin O
Therapy O

-DOCSTART- O


TBC3711 O
is O
a O
small O
molecule O
that O
blocks O
the O
action O
of O
endothelin O
, O
a O
potent O
mediator O
of O
blood O
vessel O
constriction O
and O
growth O
of O
smooth O
muscle O
in O
vascular B-PHE
walls I-PHE
. O
It O
is O
a O
next-generation O
endothelin O
A O
antagonist O
which O
possesses O
high O
oral O
bioavailability O
and O
is O
more O
selective O
and O
potent O
than O
THELIN(tm O
) O
( O
sitaxsentan O
sodium O
) O
Encysive's O
oral O
treatment O
for O
pulmonary B-PHE
arterial I-PHE
hypertension I-PHE
. O

TBC3711 O
is O
greater O
than O
100,000-fold O
selective O
in O
the O
targeting O
of O
the O
endothelin O
A O
receptor O
versus O
the O
endothelin O
B O
receptor O
. O

-DOCSTART- O


insulin O
sensitivity O
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation O
, O
Woman O
, O
Reproductive B-PHE
systems I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Quality O
of O
life O
, O
Menopausal B-PHE
woman O
, O
Eldery O
, O
Liver B-PHE
health I-PHE
, O
Metabolism B-PHE
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Bone B-PHE
metabolism/density B-PHE
, O
Memory O
, O
Liver O
, O
Others O
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


swelling B-PHE
of O
the O
foot O
; O
edema B-PHE
of O
foot O

-DOCSTART- O


Obesity B-PHE
and O
Obesity-related B-PHE
Medical O
Conditions O

-DOCSTART- O


frost B-PHE
bite I-PHE
; O
chilblain B-PHE
; O
frostbite B-PHE

-DOCSTART- O


Migraine B-PHE

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
taxation O
damage O
in O
lumbar B-PHE
muscle I-PHE
, O
knocks O
and O
falls O
. O

-DOCSTART- O


Stage O
IV O
Adult B-PHE
T-Cell I-PHE
Leukemia/Lymphoma I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
heparin-induced B-PHE
thrombocytopenia I-PHE

-DOCSTART- O


Protective B-PHE
immunity I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


For O
cooling O
blood B-PHE
and O
stopping O
bleeding B-PHE

-DOCSTART- O


Stage O
III O
Adult B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


chest O
and O
hypochondriac O
pain O

-DOCSTART- O


This O
is O
bleeding B-PHE
due O
to O
an O
external B-PHE
wound I-PHE
. O

-DOCSTART- O


glad O
and O
misten B-PHE
complexion I-PHE

-DOCSTART- O


Treatment O
of O
taeniasis B-PHE
, O
ancylostomiasis B-PHE
, O
ascariasis B-PHE
, O
intestinal B-PHE
parasitosis I-PHE
with O
abdominal B-PHE
pain I-PHE
or O
with O
infantile B-PHE
malnutrition I-PHE
. O

-DOCSTART- O


cough B-PHE
due O
to O
lung B-PHE
subcutaneous I-PHE
nodes I-PHE

-DOCSTART- O


For O
desolving O
phlegm B-PHE
, O
stopping O
cougth B-PHE
, O
and O
soothing O
breathing B-PHE

-DOCSTART- O


Roundworm B-PHE

-DOCSTART- O


Liver B-PHE
health I-PHE
, O
Liver B-PHE
, O
Others O

-DOCSTART- O


fever B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
EGFR-expressing O
, O
metastatic B-PHE
colorectal I-PHE
carcinoma I-PHE
that O
is O
refractory O
to O
fluoropyrimidine- O
, O
oxaliplatin- O
, O
and O
irinotecan- O
containing O
chemotherapy O
regimens O
. O

-DOCSTART- O


Rheumatism B-PHE
numbness I-PHE
, O
damp-heat B-PHE
itchy I-PHE
sore I-PHE
, O
clove B-PHE
sore I-PHE
, O
menstruant O
morbidity O
. O

-DOCSTART- O


To O
soothe O
the O
liver B-PHE
and O
regulate O
the O
circulation O
of O
qi O
, O
clear O
away O
heat B-PHE
and O
toxic O
materials O
. O

-DOCSTART- O


new O
and O
old O
cough B-PHE

-DOCSTART- O


To O
supplement O
blood B-PHE
and O
quicken O
blood B-PHE
, O
free O
channels B-PHE
and O
quicken O
network B-PHE
vessels I-PHE
. O

-DOCSTART- O


Untreated O
Adult B-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Edema B-PHE
due O
to O
deficiency B-PHE
in I-PHE
the I-PHE
kidney I-PHE
, O
accompanied O
with O
heaviness O
sensation O
in O
the O
loins O
and O
knees O
and O
oliguria O
; O

retention O
of O
body O
fluid O
with O
dyspnea B-PHE
and O
cough B-PHE
. O

-DOCSTART- O


leukorrhea B-PHE
with O
pruritis B-PHE
vulva I-PHE

-DOCSTART- O


Liver O
Transplantation O

-DOCSTART- O


To O
regulate O
menstruation B-PHE
, O
replenish O
blood B-PHE
and O
regulate O
qi O
to O
relieve O
pain B-PHE
. O

-DOCSTART- O


To O
supplement O
blood B-PHE
, O
quicken B-PHE
blood I-PHE
, O
strengthen O
lumbus B-PHE
and O
knees B-PHE
. O

-DOCSTART- O


Treatment O
of O
mass B-PHE
in O
the O
abdomen O
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
abdominal B-PHE
distension I-PHE
and O
pain B-PHE
caused O
by O
retention O
of O
undigested O
food O
. O

-DOCSTART- O


To O
eliminate O
toxic B-PHE
material I-PHE
, O
promote O
pus B-PHE
drainage I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


Papillary B-PHE
serous I-PHE
endometrial I-PHE
cancer I-PHE

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE
B I-PHE
Virus I-PHE
, O
Pediatric O

-DOCSTART- O


1 O
To O
remove O
blood B-PHE
stasis I-PHE
and O
alleviate O
pain B-PHE
. O

For O
stomachache B-PHE
, O
headache B-PHE
, O
toothache B-PHE
, O
trauma B-PHE
and O
rheumatism O
. O

2 O
To O
clear O
heat B-PHE
and O
toxic B-PHE
material I-PHE
. O

For O
sorethroat B-PHE
, O
aphthae B-PHE
, O
carbuncle B-PHE
, O
burn B-PHE
, O
snake B-PHE
bite I-PHE
, O
dysentery B-PHE
and O
diarrhea B-PHE
. O

3 O
To O
relax O
the O
muscles O
. O

As O
a O
muscle O
relaxant O
for O
restoration O
of O
fracture B-PHE
and O
surgical O
operation O
. O

-DOCSTART- O


Chloramphenicol O
reversibly O
binds O
to O
the O
L16 B-PHE
protein I-PHE
of O
the O
50S B-PHE
subunit I-PHE
of I-PHE
bacterial I-PHE
ribosomes I-PHE
, O
thus O
inhibits O
protein B-PHE
synthesis I-PHE
. O

Desoxyribonuclease O
is O
a O
biosynthetic O
form O
of O
human O
DNase B-PHE
I I-PHE
, O
which O
is O
involved O
in O
endonucleolytic O
cleavage O
of O
extracellular B-PHE
DNA I-PHE
to O
5-phosphodinucleotide O
and O
5-phosphooligonucleotide O
end O
products O
. O

Fibrinolysin O
attacks O
and O
inactivates O
fibrin B-PHE
molecules I-PHE
occurring O
in O
undesirable O
exudates O
on O
the O
surface O
of O
the O
human O
body O
and O
on O
human B-PHE
mucosa I-PHE
. O

-DOCSTART- O


pulmonary B-PHE
carbuncle I-PHE
; O
lung B-PHE
abscess I-PHE

-DOCSTART- O


a O
disease O
that O
tendons B-PHE
and O
bones B-PHE
become O
dry O

-DOCSTART- O


vomiting B-PHE

-DOCSTART- O


Yang O
poison B-PHE
; O
extreme O
heat B-PHE
; O
symptoms O
due O
to O
extreme O
heat B-PHE

-DOCSTART- O


the O
steaming B-PHE
of I-PHE
bone I-PHE
and O
tidal O
fever B-PHE

-DOCSTART- O


1 O
Byak-angelicin O
contained O
in O
its O
root O
can O
dilate O
the O
coronary B-PHE
arteries I-PHE
. O

2 O
Stimulating O
the O
respiratory B-PHE
center I-PHE
, O
vasomotor B-PHE
center I-PHE
and O
nervus B-PHE
vagus I-PHE
. O

3 O
Its O
decoction O
exerts O
bacteriostatic B-PHE
effect I-PHE
. O

4 O
Imperatorin O
, O
another O
active O
component O
, O
is O
effective O
for O
psoriasis B-PHE
. O

-DOCSTART- O


Intelligence B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Others O

-DOCSTART- O


Its O
volatile O
oil O
is O
an O
expectorant O
and O
antiasthmatic. O
. O

-DOCSTART- O


This O
is O
a O
symptom O
that O
the O
body O
becomes O
haggard B-PHE
because O
of O
exhaustion B-PHE
syndrome I-PHE
. O

-DOCSTART- O


To O
pacify O
the O
liver B-PHE
and O
subdue O
the O
yang O
; O

To O
conduct O
rebellious O
qi O
downward O
and O
stop O
vomiting B-PHE
; O

To O
stop O
bleeding B-PHE

-DOCSTART- O


gingivitis B-PHE
; O
epulis B-PHE

-DOCSTART- O


kill O
worms B-PHE

-DOCSTART- O


HER2-overexpressing O
breast B-PHE
cancer I-PHE

-DOCSTART- O


ischuria B-PHE
; O
dysuria B-PHE
; O
retention B-PHE
of I-PHE
urine I-PHE

-DOCSTART- O


Juzentaihoto O
Failed O
to O
Augment O
Antigen-Specific O
Immunity B-PHE
but O
Prevented O
Deterioration B-PHE
of O
Patients' O
Conditions O
in O
Advanced O
Pancreatic B-PHE
Cancer I-PHE
under O
Personalized O
Peptide O
Vaccine O
. O

-DOCSTART- O


To O
break O
blood B-PHE
and O
desolve O
stagnation B-PHE
; O
To O
benefit O
qi O

-DOCSTART- O


Huperzine O
B O
has O
been O
found O
to O
be O
an O
inhibitor O
of O
the O
enzyme B-PHE
acetylcholinesterase I-PHE
. O

This O
is O
the O
same O
mechanism O
of O
action O
of O
pharmaceutical O
drugs O
such O
as O
galantamine O
and O
donepezil O
used O
to O
treat O
Alzheimer's B-PHE
disease I-PHE
. O

-DOCSTART- O


Effects O
of O
Hachimijiogan O
on O
dopamine O
, O
serotonin O
and O
vasoactive O
intestinal O
peptide O
in O
plasma O
and O
hypothalamus O
in O
sulpiride-induced O
hyperprolactinemic O
rats O
. O

-DOCSTART- O


Chronic B-PHE
Heart I-PHE
Failure I-PHE

-DOCSTART- O


Treatment O
of O
carbuncle B-PHE
and O
boil B-PHE
at O
the O
early O
stage O
or O
formation B-PHE
of I-PHE
abscess I-PHE
difficult O
to O
burst B-PHE
, O
external O
use O
for O
scabies B-PHE
and O
leprosy B-PHE
. O

-DOCSTART- O


oppressed B-PHE
feeling I-PHE
and O
fullness B-PHE
in O
the O
chest O
and O
diaphragm O

-DOCSTART- O


Spontaneous O
external B-PHE
bleeding I-PHE
, O
hematochezia B-PHE
, O
headache B-PHE
, O
dizziness B-PHE
and O
dim B-PHE
vision I-PHE
, O
red B-PHE
eyes I-PHE
, O
night B-PHE
blindness I-PHE
, O
diabetes B-PHE
mellitus I-PHE
, O
fecal B-PHE
stoppage I-PHE
, O
hemorrhoids B-PHE
. O

-DOCSTART- O


warm B-PHE
malaria I-PHE
; O

pyrexial B-PHE
malaria I-PHE

-DOCSTART- O


Enduring O
cough B-PHE
and O
asthma B-PHE
, O
bronchitis B-PHE
, O
lumbago B-PHE
and O
limp O
leg B-PHE
, O
frequent O
urination B-PHE
, O
enuresis B-PHE
, O
impotence B-PHE
, O
emission B-PHE
, O
intestinal B-PHE
dry I-PHE
and O
constipation B-PHE
, O
stone B-PHE
strangury I-PHE
, O
sores B-PHE
and O
scrofula B-PHE
. O

-DOCSTART- O


Cancer B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
effuse O
sweat B-PHE
, O
dissipate O
cold B-PHE
and O
dry O
damp B-PHE
. O

-DOCSTART- O


snake-bite B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective O
immunity B-PHE

-DOCSTART- O


To O
astringe O
intestines B-PHE
and O
check O
diarrhea B-PHE
, O
resolve O
toxin B-PHE
, O
relieve O
itch B-PHE
. O

-DOCSTART- O


Ritonavir O
inhibits O
the O
HIV B-PHE
viral I-PHE
proteinase I-PHE
enzyme I-PHE
which O
prevents O
cleavage B-PHE
of I-PHE
the I-PHE
gag-pol I-PHE
polyprotein I-PHE
, O
resulting O
in O
noninfectious O
, O
immature O
viral B-PHE
particles I-PHE
. O

-DOCSTART- O


Wind-cold-damp B-PHE
impediment O
, O
aching B-PHE
pain I-PHE
in O
joints O
, O
arthritis B-PHE
, O
dysmenorrhea B-PHE
, O
skin B-PHE
numbness I-PHE
, O
weakness B-PHE
in I-PHE
limbs I-PHE
, O
jaundice B-PHE
, O
cough B-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
sores B-PHE
, O
zoster B-PHE
, O
scalds B-PHE
. O

-DOCSTART- O


( O
1 O
) O
hemorrhoids B-PHE
( O
2 O
) O
polyp B-PHE

-DOCSTART- O


damp B-PHE
Pi O
arthritis B-PHE
due O
to O
dampness B-PHE
. O

damp B-PHE
stroke I-PHE
; O

attack O
of O
dampness B-PHE
syndrome I-PHE
due O
to O
attack O
of O
pathogenic B-PHE
factors I-PHE
. O

-DOCSTART- O


1 O
Inhibiting O
the O
growth O
of O
leukemia615 B-PHE
, O
sarcoma180 B-PHE
and O
cervial B-PHE
carcinoma14 I-PHE
in O
mice O
. O
2 O
Relieving O
iodine B-PHE
deficiency I-PHE
and O
goiter B-PHE
in O
experimental O
animals O
. O

-DOCSTART- O


swelling B-PHE
of O
the O
cheek O
; O
parotitis B-PHE

-DOCSTART- O


Bone B-PHE
Marrow I-PHE
Suppression I-PHE

-DOCSTART- O


Eum O
deficiency O
of O
liver O
and O
kidney O
; O
deficiency O
of O
Eum(vital O
essence O
) O
of O
the O
liver O
and O
kidney O

-DOCSTART- O


cough B-PHE
due O
to O
phlegm-damp B-PHE

-DOCSTART- O


Chronic B-PHE
Viral I-PHE
Hepatitis I-PHE
B I-PHE
Without I-PHE
Delta-agent I-PHE

-DOCSTART- O


prolapse B-PHE
of I-PHE
the I-PHE
rectum I-PHE

-DOCSTART- O


Hypertension B-PHE
. O

-DOCSTART- O


Menopausal B-PHE
syndrome I-PHE
marked O
by O
afternoon O
fever B-PHE
, O
excessive B-PHE
sweating I-PHE
, O
dizziness B-PHE
, O
tinnitus B-PHE
, O
insomnia B-PHE
and O
unsteady B-PHE
blood I-PHE
pressure I-PHE
. O

-DOCSTART- O


Uncaria O
Hook O
( O
UH O
) O
alkaloids O
are O
involved O
in O
the O
beneficial O
effects O
of O
Yokukansan O
. O

However O
, O
the O
pharmacokinetics O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
has O
not O
yet O
been O
sufficiently O
investigated O
. O

Therefore O
, O
we O
developed O
and O
validated O
a O
sensitive O
and O
specific O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
( O
LC/MS/MS O
) O
method O
for O
the O
simultaneous O
quantitation O
of O
seven O
UH O
alkaloids O
( O
corynoxeine O
, O
isocorynoxeine O
, O
rhynchophylline O
, O
isorhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
) O
in O
rat O
plasma O
and O
brain O
. O

After O
protein O
precipitation O
with O
acetonitrile O
, O
chromatographic O
separation O
was O
performed O
using O
an O
Ascentis O
Express O
RP-amide O
column O
, O
with O
gradient O
elution O
with O
0.002 O
formic O
acid O
and O
acetonitrile O
at O
0.3 O
mL/min O
. O

All O
analytes O
in O
the O
plasma O
and O
brain O
showed O
good O
linearity O
over O
a O
wide O
concentration O
range O
(r O
> O
0.995 O
) O
. O

Intra-day O
and O
inter-day O
variations O
of O
each O
constituent O
were O
8.6 O
and O
0.08 O
or O
less O
in O
the O
plasma O
, O
and O
14.9 O
and O
0.15 O
or O
less O
in O
the O
brain O
, O
respectively O
. O

The O
validated O
LC/MS/MS O
method O
was O
applied O
in O
the O
pharmacokinetic O
studies O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
to O
rats O
. O

In O
the O
plasma O
, O
rhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
were O
detected O
, O
but O
only O
geissoschizine O
methyl O
ether O
was O
detected O
in O
the O
brain O
. O

These O
results O
suggest O
that O
geissoschizine O
methyl O
ether O
is O
an O
important O
constituent O
of O
the O
pharmacological O
effects O
of O
Yokukansan O
. O

-DOCSTART- O


nausea B-PHE
without O
vomiting B-PHE
. O

-DOCSTART- O


1 O
Oral O
administration O
increases O
the O
level O
of O
cAMP B-PHE
and O
decrease O
the O
level B-PHE
of I-PHE
cGMP I-PHE
in O
plasma O
and O
in O
leukocytes O
. O
Protect O
the O
liver B-PHE
from O
damage O
. O
Hypotensive B-PHE
. O

-DOCSTART- O


Drug B-PHE
Induced I-PHE
Hepatotoxicity I-PHE

-DOCSTART- O


12-0-tetradecanoyl-phorbol-13-acetate O
isolated O
from O
its O
croton O
oil O
is O
a O
cancerigenic B-PHE
component I-PHE
. O

-DOCSTART- O


To O
desolve O
phlegm B-PHE
and O
soften O
hardness O
; O
To O
revitalize O
blood B-PHE

-DOCSTART- O


Some O
patients O
with O
major B-PHE
depressive I-PHE
disorder I-PHE
( O
MDD B-PHE
) O
do O
not O
show O
remission O
of O
their O
depressive O
symptomatology O
. O

We O
investigated O
the O
efficacy O
of O
Rokumigan O
( O
TJ-87 O
) O
and O
Hachimijiogan O
( O
TJ-7 O
) O
in O
20 O
patients O
with O
prolonged O
partial O
remitted O
MDD B-PHE
associated O
with O
fatigue B-PHE
or O
loss B-PHE
of I-PHE
energy I-PHE
. O

In O
these O
20 O
patients O
, O
TJ-7 O
or O
TJ-87 O
was O
added O
to O
the O
previous O
regimen O
for O
4 O
weeks O
. O

Six O
patients O
were O
'much O
improved' O
, O
six O
were O
'minimally O
improved' O
( O
responders O
) O
, O
and O
eight O
showed O
'no O
change' O
( O
non-responders O
) O
, O
on O
the O
Clinical O
Global O
Impression O
Global O
Improvement O
scale O
. O

All O
responders O
had O
Shofuku-fujin O
( O
tenderness B-PHE
or O
weakness B-PHE
of O
the O
lower O
abdomen O
) O
. O

In O
conclusion O
, O
we O
experienced O
12 O
outpatients O
with O
prolonged O
partial O
remitted O
MDD B-PHE
with O
fatigue B-PHE
or O
loss B-PHE
of I-PHE
energy I-PHE
, O
which O
was O
successfully O
treated O
with O
TJ-87 O
or O
TJ-7 O
. O

-DOCSTART- O


Treament O
of O
chronic B-PHE
bronchitis I-PHE
. O

-DOCSTART- O


Kidney B-PHE
Diseases I-PHE

-DOCSTART- O


Efficacy O
of O
Keishibukuryogan O
, O
a O
traditional O
Japanese O
herbal O
medicine O
, O
in O
treating O
cold B-PHE
sensation I-PHE
and O
numbness B-PHE
after O
stroke B-PHE
: O
clinical O
improvement O
and O
skin O
temperature O
normalization O
in O
22 O
stroke B-PHE
patients O
. O

-DOCSTART- O


Urinary B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
bladder B-PHE
cancer I-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Evacuation B-PHE

-DOCSTART- O


distribution O
) O
, O
energy O
supply O
and O
recovery O
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


Thoracic O
Surgery O

-DOCSTART- O


wind B-PHE
syndrome I-PHE

-DOCSTART- O


Carotid B-PHE
Artery I-PHE
Stenosis I-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
and O
disperse O
swelling B-PHE
. O

-DOCSTART- O


Infant B-PHE
, I-PHE
Diabetic I-PHE
Mother I-PHE

-DOCSTART- O


Treament O
of O
heat B-PHE
in O
the O
lung O
with O
cough B-PHE
, O
sticky B-PHE
and I-PHE
bloody I-PHE
sputum I-PHE
, O
and O
distress B-PHE
in I-PHE
the I-PHE
chest I-PHE
. O

-DOCSTART- O


HGS-TR2J O
binds O
TRAIL O
Receptor O
2 O
with O
high O
affinity O
, O
induces O
apoptosis B-PHE
and O
has O
anti-tumor B-PHE
activity I-PHE
, O
both O
as O
a O
single O
agent O
and O
in O
combination O
with O
chemotherapy O
. O

HGS-TR2J O
mimics O
the O
activity O
of O
native O
TRAIL O
( O
tumor O
necrosis O
factor-related O
apoptosis-inducing O
ligand O
) O
and O
, O
thus O
, O
is O
considered O
an O
agonistic O
antibody B-PHE
. O

Numerous O
nonclinical O
studies O
have O
shown O
that O
cell O
lines O
derived O
from O
a O
broad O
array O
of O
solid O
and O
hematological B-PHE
human I-PHE
tumors I-PHE
, O
including O
lung O
, O
colon O
, O
breast O
, O
multiple O
myeloma B-PHE
, O
prostate O
and O
pancreas O
, O
are O
sensitive O
to O
killing O
by O
apoptosis B-PHE
( O
programmed O
cell B-PHE
death I-PHE
) O
induced O
by O
native O
TRAIL O
or O
by O
agonistic O
antibodies O
to O
TRAIL O
Receptors O
1 O
and O
2.2-24 O
. O

-DOCSTART- O


Tiagabine O
blocks O
GABA O
uptake O
into O
presynaptic O
neurons O
, O
permitting O
more O
GABA O
to O
be O
available O
for O
receptor O
binding O
on O
the O
surfaces O
of O
post-synaptic O
cells O
. O

Gabapentin's O
therapeutic O
action O
on O
neuropathic B-PHE
pain I-PHE
is O
thought O
to O
involve O
voltage-gated O
N-type O
calcium O
ion O
channels O
. O

It O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent O
calcium O
channel O
in O
the O
central B-PHE
nervous I-PHE
system I-PHE
. O

-DOCSTART- O


wind B-PHE
one O
of O
the O
five O
pathogenic O
factors O
, O
also O
one O
of O
the O
six O
exogenous O
pathogenic O
factors O
which O
often O
causes O
disease B-PHE
in O
association O
with O
other O
pathogenic O
agent O
. O

It O
is O
of O
Yang O
nature O
and O
apt O
to O
change O
, O
resulting O
symptoms O
are O
usually O
migratory O
and O
variable O
. O

-DOCSTART- O


1 O
To O
clear O
heat B-PHE
and O
toxic O
material O
. O

2 O
To O
clear O
liver-heat B-PHE
to O
treat O
eye B-PHE
disease I-PHE
. O

3 O
To O
clear O
dampness-heat B-PHE
. O

-DOCSTART- O


Iohexol O
ia O
used O
in O
myelography O
, O
arthrography O
, O
nephroangiography O
, O
arteriography O
, O
and O
other O
radiographic O
procedures O
. O

-DOCSTART- O


exogenous O
exogenous B-PHE
febrile I-PHE
disease I-PHE
; O

syndrome B-PHE
of I-PHE
T'aeyang I-PHE
meridian I-PHE
affected O
by O
the O
wind B-PHE

affection O
by O
cold B-PHE
; O

common B-PHE
cold I-PHE

-DOCSTART- O


Glomerulonephritis O

-DOCSTART- O


blurred B-PHE
vision I-PHE

-DOCSTART- O


To O
strengthen O
spleen B-PHE
and O
benefit O
qi O
; O
To O
soothe O
liver B-PHE
and O
modulate O
qi O
; O
To O
revitalize O
blood B-PHE
and O
desolve O
stagnation B-PHE

-DOCSTART- O


Treament O
of O
abdomen B-PHE
pain I-PHE
due O
to O
intestinal B-PHE
worms I-PHE
, O
sores B-PHE
, O
uterine B-PHE
bleeding I-PHE
( O
drug O
carbonizing O
) O
. O

-DOCSTART- O


irregular O
chills B-PHE
and I-PHE
fever I-PHE

-DOCSTART- O


unblock O
blood B-PHE

-DOCSTART- O


Treatment O
of O
chills B-PHE
, O
fever B-PHE
and O
headache B-PHE
in O
colds B-PHE
and O
influenza B-PHE
, O
vexation B-PHE
, O
oppressed B-PHE
feeling I-PHE
in O
the O
chest O
and O
insomnia B-PHE
. O

-DOCSTART- O


Kidney B-PHE
Failure I-PHE
, I-PHE
Chronic I-PHE

-DOCSTART- O


This O
is O
an O
external B-PHE
wound I-PHE
in I-PHE
muscle I-PHE
of I-PHE
waist I-PHE
. O

-DOCSTART- O


Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
is O
one O
of O
the O
most O
frequently O
used O
prescriptions O
in O
the O
long O
history O
of O
traditional O
Chinese O
medicine O
practice O
. O

The O
prescription O
contains O
three O
Chinese O
herbs O
, O
namely O
Artemisia O
capillaries O
Thunb O
. O

( O
Compositae O
) O
, O
Rheum O
officinale O
Baillon O
( O
Polygonaceae O
) O
, O
and O
Gardenia O
jasminoids O
Ellis O
( O
Rubiaceae O
) O
, O
and O
has O
been O
widely O
used O
to O
treat O
acute B-PHE
hepatitis I-PHE
with O
jaundice B-PHE
. O

In O
this O
study O
, O
the O
in O
vitro O
anti-HSV-1 B-PHE
and I-PHE
HSV-2 I-PHE
activities I-PHE
of O
the O
water O
extract O
of O
YCHT O
were O
investigated O
. O

Results O
showed O
that O
YCHT O
water O
extract O
inhibited O
both O
HSV-1 B-PHE
and I-PHE
HSV-2 I-PHE
infections I-PHE
. O

However O
, O
the O
inhibition O
was O
more O
effective O
against O
HSV-2 B-PHE
than O
against O
HSV-1 B-PHE
. O

The O
IC(50 O
) O
and O
IC(90 O
) O
values O
of O
YCHT O
water O
extract O
against O
HSV-1 B-PHE
infection I-PHE
were O
in O
the O
range O
of O
142.5-150.1 O
and O
191.3-393.9 O
microg/ml O
, O
and O
against O
HSV-2 B-PHE
infection I-PHE
they O
were O
in O
the O
range O
of O
19.6-29.4 O
and O
42.2-97.7 O
microg/ml O
, O
respectively O
. O

The O
water O
extract O
of O
YCHT O
showed O
no O
cytotoxic O
effect O
at O
a O
concentration O
of O
500 O
microg/ml O
or O
below O
, O
and O
had O
a O
CC(50 O
) O
value O
of O
850.7+/-1.7 O
microg/ml O
. O

The O
prescription O
was O
found O
to O
diminish O
HSV-2 B-PHE
infectivity I-PHE
in O
a O
dose-dependent O
manner O
, O
and O
the O
activity O
was O
influenced O
by O
the O
incubation O
periods O
and O
the O
incubation O
temperatures O
. O

Concurrent O
addition O
of O
virus O
with O
YCHT O
or O
pre-treatment O
of O
the O
virus O
with O
the O
prescription O
extract O
both O
protected O
the O
cells O
from O
infection B-PHE
. O

In O
summary O
, O
the O
water O
extract O
of O
YCHT O
was O
concluded O
to O
inhibit O
infections B-PHE
by O
HSV-1 B-PHE
and O
HSV-2 B-PHE
and O
this O
effect O
was O
likely O
mediated O
through O
direct O
inactivation O
of O
the O
virus B-PHE
infectivity I-PHE
. O

-DOCSTART- O


red-white O
dysentery B-PHE

-DOCSTART- O


To O
control O
the O
essence O
; O

To O
astringe O
the O
intestines B-PHE
and O
stop O
diarrhea B-PHE
; O

To O
decrease O
urination B-PHE

-DOCSTART- O


Treatment O
of O
edema B-PHE
with O
oliguria B-PHE
, O
dizziness B-PHE
and O
palpitation B-PHE
caused O
by O
retained O
fluid O
, O
diminished O
function O
of O
the O
spleen B-PHE
marked O
by O
anorexia B-PHE
, O
loose O
stools B-PHE
or O
diarrhea B-PHE
, O
restlessness B-PHE
and O
insomnia B-PHE
. O

-DOCSTART- O


disperse O
stasis B-PHE

-DOCSTART- O


clear O
( O
pathogenic O
) O
fire B-PHE
and O
invigorate O
blood B-PHE

-DOCSTART- O


Intravenous O
Anesthetic O
Interaction O
Unrecognized B-PHE
Condition I-PHE

-DOCSTART- O


Coronary B-PHE
heart I-PHE
disease I-PHE
, O
angina B-PHE
pectoris I-PHE
, O
hypercholesterolemia B-PHE
, O
Parkinson B-PHE
disease I-PHE
, O
peripheral B-PHE
arterial I-PHE
diseases I-PHE
, O
chest B-PHE
impediment I-PHE
and O
heart B-PHE
pain I-PHE
, O
cough B-PHE
of O
phlegm B-PHE
asthma B-PHE
, O
diarrhea B-PHE
and O
dysentery B-PHE
, O
vaginal B-PHE
discharge I-PHE
, O
emission B-PHE
, O
retinal B-PHE
insufficiency I-PHE
syndrome I-PHE
. O

-DOCSTART- O


nine O
kinds O
of O
illness B-PHE
due O
to O
disturbance O
of O
Gi O

-DOCSTART- O


Endometriosis B-PHE

-DOCSTART- O


Treatment O
of O
scrotal B-PHE
hernia I-PHE
with O
pain B-PHE
and O
cold B-PHE
extremities I-PHE
, O
dysmenorrhea B-PHE
with O
lower O
abdominal B-PHE
pain I-PHE
and O
cold B-PHE
sensation I-PHE
, O
distending B-PHE
pain I-PHE
in I-PHE
the I-PHE
epigastrium I-PHE
with O
anorexia B-PHE
, O
vomiting B-PHE
and O
diarrhea B-PHE
, O
hydrocele B-PHE
of O
tunica O
vaginalis O
. O

Fructus O
Foeniculi O
( O
processed O
with O
salt O
) O
: O
Scrotal B-PHE
hernia I-PHE
with O
pain B-PHE
and O
cold B-PHE
extremities I-PHE
, O
dysmenorrhea B-PHE
with O
abdominal B-PHE
pain I-PHE
caused O
by O
cold B-PHE
. O

-DOCSTART- O


Woman O
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Bone B-PHE
metabolism I-PHE
/ I-PHE
density I-PHE
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


Small O
dosage O
of O
berberine O
enhances O
the O
action B-PHE
of I-PHE
acetylcholine I-PHE
on O
animals' O
hearts O
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O

-DOCSTART- O


To O
contract O
uterus O
and O
stanch O
bleeding O
, O
relieve O
pain O
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Woman O
, O
Physical O
performance O
and O
fitness O
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
absorption B-PHE
, O
Others O
, O
Body O
weight O
regulation O
, O
General O
woman O
, O
Strength O
and O
power O
, O
Digestion B-PHE
, O
Hypersensitivity B-PHE
, O
motility B-PHE

-DOCSTART- O


Treatment O
of O
cough B-PHE
, O
itching B-PHE
of O
the O
throat O
and O
profuse O
expectoration B-PHE
in I-PHE
colds I-PHE
, O
nausea B-PHE
, O
vomiting B-PHE
and O
epigastric B-PHE
distension I-PHE
caused O
by O
improper O
diet O
or O
excessive O
drinking O
. O

-DOCSTART- O


Hepatocellular B-PHE
Carcinoma I-PHE

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE
with O
chest B-PHE
congested I-PHE

-DOCSTART- O


To O
regulate O
the O
flow O
of O
qi O
in O
the O
liver B-PHE
, O
spleen B-PHE
and O
stomach B-PHE
, O
and O
to O
resolve O
phlegm B-PHE
. O

-DOCSTART- O


Treatment O
of O
fever B-PHE
due O
to O
deficiency B-PHE
of O
yin O
, O
consumptive O
fever B-PHE
, O
fever B-PHE
in O
infantile O
malnutrition B-PHE
. O

-DOCSTART- O


The O
resin O
is O
a O
strong O
anion O
exchange O
resin O
, O
which O
means O
that O
it O
can O
exchange O
its O
chloride O
anions O
with O
anionic B-PHE
bile I-PHE
acids I-PHE
in O
the O
gastrointestinal B-PHE
tract I-PHE
and O
bind O
them O
strongly O
in O
the O
resin O
matrix O
. O

-DOCSTART- O


For O
the O
treatment O
of O
Tuberculosis B-PHE
and O
Tuberculosis-related O
mycobacterial B-PHE
infections I-PHE
. O

-DOCSTART- O


Breast B-PHE
Neoplasms I-PHE

-DOCSTART- O


a O
mass O
amount O
of O
phlegm B-PHE
, O
and O
dyspnea B-PHE
and O
cough B-PHE

-DOCSTART- O


damp B-PHE
Pi I-PHE
syndrome I-PHE
; O
arthritis B-PHE
due O
to O
dampness B-PHE
; O
damp B-PHE
impediment O
[ O
blockage B-PHE
] O

-DOCSTART- O


distension B-PHE
and O
fullness B-PHE

-DOCSTART- O


To O
arrest O
discharges O
, O
promote O
healing O
of O
wounds B-PHE
and O
tissue B-PHE
regeneration I-PHE
, O
and O
alleviate O
pain B-PHE
. O

-DOCSTART- O


In O
traditional O
Chinese O
medicine O
theory O
( O
TCM O
) O
, O
the O
affected O
parts O
of O
sprains B-PHE
, O
bruises B-PHE
and O
arthritis B-PHE
are O
considered O
to O
be O
under O
certain O
conditions O
of O
TCM O
concept O
. O

We O
administered O
two O
Kampo O
medicines O
with O
synergistic O
effects O
to O
promote O
quick O
recovery I-PHE
from O
these O
conditions O
. O

Jidabokuippo O
( O
Zhidapuyifang O
in O
Chinese O
) O
, O
which O
means O
'decoction O
for O
contusions' B-PHE
is O
expected O
to O
remove O
these O
conditions O
. O

Hachimijiogan O
( O
Baweidihuangwan O
in O
Chinese O
) O
, O
which O
translates O
as O
'eight-ingredient O
pill O
with O
Rehmannia' O
is O
expected O
to O
restore O
presumed O
minute O
bone B-PHE
injury I-PHE
and O
regulates O
bone B-PHE
metabolism I-PHE
by O
changing O
such O
conditions O
based O
on O
TCM O
theory O
. O

We O
administered O
the O
two O
prescriptions O
to O
10 O
patients O
( O
age O
range O
: O
40-85 O
years O
; O
1 O
male O
, O
9 O
females O
) O
suffering O
from O
bruises B-PHE
, O
sprains B-PHE
, O
arthritis B-PHE
and O
spinal B-PHE
compression I-PHE
fracture I-PHE
without O
changing O
their O
routine O
intake O
of O
other O
drugs O
. O

Patients O
reported O
on O
changes O
in O
the O
pain O
of O
affected O
body O
parts O
by O
using O
the O
visual O
analog O
scale O
( O
VAS O
) O
before O
and O
after O
administration O
of O
Kampo O
medicine O
. O

In O
almost O
all O
cases O
, O
recovery B-PHE
began O
promptly O
after O
administration O
and O
the O
pain B-PHE
disappeared O
within O
approximately O
2 O
weeks O
. O

Large O
doses O
for O
a O
short O
time O
brought O
about O
much O
quicker O
recovery B-PHE
than O
small O
doses O
. O

Administration O
of O
a O
combination O
of O
two O
Kampo O
medicines O
, O
Jidabokuippo O
and O
Hachimijiogan O
, O
quickly O
resolved O
the O
pain B-PHE
of O
bruises B-PHE
, O
sprains B-PHE
, O
arthritis B-PHE
and O
one O
spinal B-PHE
compression I-PHE
fracture I-PHE
. O

-DOCSTART- O


Treament O
of O
spitting B-PHE
of I-PHE
blood I-PHE
, O
epistaxis B-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
, O
amenorrhea B-PHE
with O
blood O
stasis O
, O
arthralgia B-PHE
, O
traumatic O
swelling B-PHE
and O
pain B-PHE
. O

-DOCSTART- O


1 O
To O
clear O
the O
lungs B-PHE
and O
tonify O
yin O
; O
2 O
To O
strengthen O
the O
stomach B-PHE
and O
promote O
the O
production B-PHE
of I-PHE
body I-PHE
fluids I-PHE

-DOCSTART- O


Sumatriptan O
is O
a O
serotonin O
agonist O
that O
acts O
selectively O
at O
5HT1 O
receptors O
. O

Naproxen O
inhibits O
the O
activity B-PHE
of I-PHE
the I-PHE
enzymes I-PHE
cyclo-oxygenase I-PHE
I I-PHE
and I-PHE
II I-PHE
, O
resulting O
in O
a O
decreased O
formation B-PHE
of I-PHE
precursors I-PHE
of I-PHE
prostaglandins I-PHE
and I-PHE
thromboxanes I-PHE
. O

-DOCSTART- O


Melphalan O
alkylates O
DNA B-PHE
at O
the O
N7 O
position O
of O
guanine O
and O
induces O
DNA B-PHE
inter-strand I-PHE
cross-linkages I-PHE
, O
resulting O
in O
the O
inhibition O
of O
DNA B-PHE
and I-PHE
RNA I-PHE
synthesis I-PHE
and O
cytotoxicity B-PHE
against O
both O
dividing O
and O
non-dividing O
tumor B-PHE
cells I-PHE
. O

-DOCSTART- O


1 O
Its O
alcoholic O
extract O
exerts O
antipyretic O
and O
analgesic O
effect O
. O

2 O
Its O
aqueous O
extract O
is O
a O
cardiotonic O
. O

-DOCSTART- O


Neuromyelitis B-PHE
Optica I-PHE
( O
NMO B-PHE
) O
and O
NMO B-PHE
Spectrum I-PHE
Disorder I-PHE
( O
NMOSD B-PHE
) O

-DOCSTART- O


restrain O
acid B-PHE

-DOCSTART- O


warm O
the O
lumbus B-PHE
and O
knees B-PHE

-DOCSTART- O


night O
fever B-PHE
and O
chilling B-PHE
in O
the O
morning O

-DOCSTART- O


strengthen O
sinews B-PHE
and O
bones B-PHE

-DOCSTART- O


Fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

GSK2190915 O
, O
a O
potent O
5-lipoxygenase-activating O
protein O
inhibitor O
, O
prevents O
the O
synthesis B-PHE
of I-PHE
leukotrienes I-PHE
and O
5-oxo-6,8,11,14-eicosatetraenoic O
acid O
( O
5-oxo-ETE O
) O
. O

-DOCSTART- O


Others O

-DOCSTART- O


Quality O
of O
life O
, O
Others O

-DOCSTART- O


To O
diffuse O
lung O
qi O
, O
dispel O
wind-damp B-PHE
, O
disperse O
swelling B-PHE
toxin I-PHE
. O

-DOCSTART- O


Pneumonia B-PHE
, O
pyothorax B-PHE
, O
sore B-PHE
pharynx I-PHE
, O
oral B-PHE
ulcer I-PHE
, O
vesical B-PHE
calculus I-PHE
, O
swollen O
welling O
abscess B-PHE
. O

-DOCSTART- O


Doxorubicin O
forms O
complexes O
with O
DNA O
by O
intercalation O
between O
base O
pairs O
, O
and O
it O
inhibits O
topoisomerase B-PHE
II I-PHE
activity I-PHE
by O
stabilizing O
the O
DNA-topoisomerase B-PHE
II I-PHE
complex O
, O
preventing O
the O
religation O
portion O
of O
the O
ligation-religation O
reaction O
that O
topoisomerase B-PHE
II I-PHE
catalyzes I-PHE
. O

-DOCSTART- O


Gout B-PHE

-DOCSTART- O


Yokukansan O
( O
YKS O
) O
is O
a O
traditional O
Japanese O
medicine O
consisting O
of O
seven O
medicinal O
herbs O
that O
is O
used O
for O
the O
treatment O
of O
neurosis B-PHE
, O
insomnia B-PHE
, O
and O
the O
behavioral/psychological O
symptoms O
of O
dementia B-PHE
. O

This O
study O
examined O
the O
effects O
of O
YKS O
on O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
. O

Daily O
oral O
administration O
of O
YKS O
( O
0.5 O
or O
1 O
g/kg O
) O
for O
3 O
weeks O
significantly O
attenuated O
morphine O
tolerance O
and O
naloxone-precipitated O
morphine O
withdrawal O
signs O
( O
jumps O
and O
body O
weight O
loss O
) O
without O
affecting O
the O
analgesic O
effect O
of O
morphine O
. O

The O
inhibitory O
effect O
of O
YKS O
on O
withdrawal O
jumps O
in O
morphine-dependent O
mice O
was O
blocked O
by O
a O
single O
pretreatment O
with O
an O
a(2)-adrenoceptor O
antagonist O
, O
yohimbine O
, O
but O
not O
by O
an O
a(1)-adrenoceptor O
antagonist O
, O
prazosin O
. O

A O
similar O
inhibitory O
effect O
on O
withdrawal O
jumps O
was O
observed O
by O
repeated O
administration O
of O
yohimbine O
. O

The O
membrane O
expression O
of O
a(2A)-adrenoceptors O
in O
the O
pons/medulla O
was O
decreased O
in O
morphine O
withdrawn O
animals O
; O
this O
reduction O
was O
prevented O
by O
repeated O
administration O
of O
YKS O
or O
yohimbine O
. O

Competitive O
radioligand O
and O
[(35)S]guanosine-5'-O-(3-thiotriphosphate O
) O
binding O
assays O
revealed O
that O
YKS O
and O
its O
constituent O
herbs O
, O
Glycyrrhiza O
( O
GR O
) O
and O
Uncaria O
hook O
( O
UH O
) O
, O
had O
specific O
binding O
affinity O
for O
and O
antagonist O
activity O
against O
the O
a(2A)-adrenoceptor O
. O

Certain O
chemical O
constituents O
, O
including O
GR O
- O
derived O
glycyrrhizin O
and O
its O
metabolite O
, O
18b-glycyrrhetinic O
acid O
, O
and O
UH-derived O
geissoschizine O
methyl O
ether O
( O
GME O
) O
, O
shared O
such O
activities O
. O

Repeated O
administration O
of O
GR O
, O
UH O
, O
glycyrrhizin O
or O
GME O
significantly O
inhibited O
morphine O
withdrawal O
signs O
. O

These O
results O
suggest O
that O
YKS O
and O
its O
active O
constituents O
inhibit O
morphine O
tolerance O
and O
physical O
dependence O
, O
and O
that O
the O
latter O
is O
due O
at O
least O
in O
part O
to O
the O
prevention O
of O
the O
decreased O
membrane O
expression O
of O
the O
a(2A)-adrenoceptor O
in O
the O
brainstem O
by O
its O
prolonged O
blockade O
. O

-DOCSTART- O


Effects O
of O
Yokukansan O
, O
a O
traditional O
Japanese O
medicine O
, O
on O
thiamine B-PHE
deficiency I-PHE
( O
TD B-PHE
) O
- O
induced O
decrease O
of O
glutamate O
uptake O
were O
examined O
in O
cultured O
rat O
cortical O
astrocytes O
. O

Yokukansan O
( O
100 O
- O
500 O
microg O
/ O
ml O
) O
ameliorated O
the O
TD B-PHE
- O
induced O
decrease O
in O
glutamate O
uptake O
by O
astrocytes B-PHE
, O
implying O
that O
yokukansan O
may O
contain O
active O
herbs O
and O
compounds O
possessing O
this O
effect O
. O

Among O
the O
seven O
constituent O
herbs O
of O
yokukansan O
, O
significant O
effects O
were O
found O
for O
glycyrrhiza O
. O

Furthermore O
, O
glycyrrhizin O
and O
its O
metabolite O
18 O
beta O
- O
glycyrrhetinic O
acid O
( O
10(-7)-10(-4)M O
) O
, O
among O
the O
eight O
components O
of O
glycyrrhiza O
, O
ameliorated O
the O
TD B-PHE
- O
induced O
decrease O
of O
glutamate O
uptake O
in O
astrocytes O
in O
a O
concentration O
- O
dependent O
manner O
. O

These O
substances O
inhibited O
protein B-PHE
kinase I-PHE
C I-PHE
( O
PKC B-PHE
) O
activity O
under O
the O
in O
vitro O
conditions O
. O

These O
lines O
of O
evidence O
suggest O
that O
glycyrrhizin O
, O
a O
main O
component O
of O
glycyrrhiza O
, O
and O
its O
metabolite O
18 O
beta O
- O
glycyrrhetinic O
acid O
are O
likely O
responsible O
for O
amelioration O
of O
dysfunction O
of O
glutamate O
transport O
in O
astrocytes O
. O

The O
inhibition O
of O
the O
PKC B-PHE
activity I-PHE
might O
be O
related O
to O
the O
pharmacological O
efficacy O
of O
these O
substances O
. O

-DOCSTART- O


Effects O
of O
tokishakuyakusan O
, O
Keishibukuryogan O
and O
Unkeito O
on O
DNA B-PHE
polymerase I-PHE
alpha I-PHE
activity I-PHE
in O
uteri O
of O
pregnant O
mare's O
serum O
gonadotropin-treated O
immature O
rats O
. O

-DOCSTART- O


warm O
the O
lung B-PHE

-DOCSTART- O


This O
is O
a O
transmission O
of O
pathogenic O
factor O
of O
pyogenic B-PHE
febrile I-PHE
disease I-PHE
from O
Taeyanggyeong O
to O
Yangmyeonggyeong O
. O

-DOCSTART- O


support O
five O
viscera B-PHE

-DOCSTART- O


disperse O
accumulation B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


Atrophy B-PHE

-DOCSTART- O


Taxation B-PHE
damage I-PHE
and O
sinew B-PHE
bone I-PHE
pain I-PHE
, O
impotence B-PHE
, O
stomachache B-PHE
, O
innominate B-PHE
toxin I-PHE
swelling I-PHE
, O
knife B-PHE
wound I-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Kids O
, O
Others O
, O
Fetus O

-DOCSTART- O


Corylifolinin O
( O
isobavachalcone O
) O
dilates O
coronary B-PHE
artery I-PHE
significantly O
. O

-DOCSTART- O


A O
symptom O
that O
the O
chest O
is O
heavy O
and O
full O
. O

-DOCSTART- O


abdominal B-PHE
fullness I-PHE
; O
abdominal B-PHE
distension I-PHE

-DOCSTART- O


nourish O
Eum O
( O
Yin O
) O
and O
nourish O
blood B-PHE

-DOCSTART- O


Its O
alcoholic O
extract O
inhibits O
the O
heart B-PHE
and O
lowers O
blood B-PHE
pressure I-PHE
in O
anesthetized O
cats O
. O

-DOCSTART- O


fever B-PHE
with O
dysphoria B-PHE
; O
dysphoria B-PHE
with O
smothery O
sensation O
; O
smothery O
fever B-PHE

-DOCSTART- O


ceruminal B-PHE
impaction I-PHE

-DOCSTART- O


swelling B-PHE
of I-PHE
carbuncle I-PHE
is O
lumped O
at O
the O
neck O

-DOCSTART- O


dizziness B-PHE

-DOCSTART- O


Organophosphate B-PHE
Poisoning I-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
after O
phlegm B-PHE
due O
to O
Wind B-PHE
sidesae O
blocked O
Gi O
. O

-DOCSTART- O


Both O
acted O
at O
the O
same O
active O
site O
of O
penicillinbinding O
protein O
2A O
but O
at O
relatively O
high O
MICs O
of O
32 O
g/ml O
. O

The O
relatively O
high O
MICs O
make O
it O
less O
likely O
for O
both O
drugs O
to O
saturate O
target O
sites O
, O
thereby O
maintaining O
additive O
antibacterial B-PHE
effect I-PHE
. O

-DOCSTART- O


blood B-PHE
wind I-PHE
of O
female O

-DOCSTART- O


cool O
blood B-PHE
and O
stop O
bleeding B-PHE

-DOCSTART- O


Dim B-PHE
vision I-PHE
, O
flooding B-PHE
and O
spotting I-PHE
, O
bleeding I-PHE
due O
to O
external B-PHE
injury I-PHE
, O
sore B-PHE
toxin I-PHE
and O
intractable O
lichen B-PHE
. O

-DOCSTART- O


skin B-PHE
disease I-PHE
on O
palms O
. O

-DOCSTART- O


Ankylosing B-PHE
Spondylitis I-PHE

-DOCSTART- O


hoarseness B-PHE
due O
to O
singing O

-DOCSTART- O


dyspnea B-PHE
with O
coughing B-PHE

-DOCSTART- O


dry O
phlegm B-PHE
; O
dry-phlegm B-PHE
( O
syndrome O
) O

-DOCSTART- O


Delayed O
recovering O
of O
drug O
transport O
barrier O
by O
inhibiting O
the O
synthesis O
of O
barrier O
components O
. O

-DOCSTART- O


Water O
extract O
of O
Samultang O
reduces O
apoptotic B-PHE
cell I-PHE
death I-PHE
by O
h(2)o(2)-induced O
oxidative B-PHE
injury I-PHE
in O
sk-N-mc O
cells O
. O

-DOCSTART- O


carbuncle B-PHE
and O
cellulitis B-PHE
of O
the O
back O
; O

carbuncle B-PHE
on O
the O
back O

-DOCSTART- O


To O
eliminate O
fluid B-PHE
and O
relieve O
edema B-PHE
( O
sthenia-syndrome B-PHE
with O
edema B-PHE
and O
ascites B-PHE
) O
. O

-DOCSTART- O


abdominal B-PHE
mass I-PHE
; O
mass B-PHE
in I-PHE
the I-PHE
abdomen I-PHE

-DOCSTART- O


Wind-evil O
attacked O
meridian O
, O
facial B-PHE
paralysis I-PHE
, O
muscle B-PHE
numbness I-PHE
, O
pain B-PHE
of I-PHE
tendons I-PHE
and I-PHE
bone I-PHE
. O

-DOCSTART- O


For O
ascariasis B-PHE
and O
taeniasis B-PHE
. O

For O
constipation B-PHE
due O
to O
dryness B-PHE
of O
intestine O
. O

-DOCSTART- O


( O
1 O
) O
hematochezia B-PHE
( O
2 O
) O
viginal B-PHE
bleeding I-PHE

-DOCSTART- O


wind B-PHE
rash I-PHE
; O
German B-PHE
measles I-PHE
; O
rubella B-PHE
; O
urticaria B-PHE

-DOCSTART- O


traumatic B-PHE
cataract I-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Overall O
CVD B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
General O
skin B-PHE
health I-PHE
, O
Others O

-DOCSTART- O


eliminate O
vacuity O
and O
clod O
of O
the O
spleen O
and O
the O
stomach O

-DOCSTART- O


To O
dispel O
wind-damp B-PHE
, O
quicken O
blood B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Urinary B-PHE
system I-PHE
health I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
absorption B-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Pregnancy B-PHE

-DOCSTART- O


To O
expel O
wind B-PHE
and O
heat B-PHE
, O
purge O
pathogenic O
fire O
and O
relax O
the O
bowels O
. O

-DOCSTART- O


cool O
blood B-PHE

-DOCSTART- O


Neurological B-PHE
systems I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE

-DOCSTART- O


Strength B-PHE
and O
power B-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE

-DOCSTART- O


Intelligence B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Memory B-PHE

-DOCSTART- O


Hepatoma B-PHE

-DOCSTART- O


bloody B-PHE
stool I-PHE
; O
hematochezia B-PHE

-DOCSTART- O


To O
invigorate O
blood B-PHE
and O
stop O
pain B-PHE
. O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Erythroid I-PHE
Leukemia I-PHE

-DOCSTART- O


Perennial B-PHE
Allergic I-PHE
Rhinitis I-PHE

-DOCSTART- O


Apical B-PHE
Ballooning I-PHE
Syndrome I-PHE

-DOCSTART- O


absorption B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
motility O
, O
Evacuation B-PHE

-DOCSTART- O


Overactive B-PHE
Bladder I-PHE
( O
OAB B-PHE
) O

-DOCSTART- O


For O
activating O
blood B-PHE
and O
modulating O
period O

-DOCSTART- O


To O
invigorate O
the O
function B-PHE
of I-PHE
the I-PHE
kidney I-PHE
, O
to O
alleviate O
asthma B-PHE
, O
and O
to O
relieve O
diarrhea B-PHE
. O

-DOCSTART- O


It O
may O
also O
bind O
to O
bacterial B-PHE
potassium I-PHE
transporters I-PHE
, O
thereby O
inhibiting O
their O
function O
. O

-DOCSTART- O


Deficiency O
of O
yin O
of O
the O
liver B-PHE
and O
the O
kidney B-PHE
marked O
by O
tinnitus B-PHE
, O
impairment B-PHE
of I-PHE
hearing I-PHE
, O
dizziness B-PHE
and O
blurred B-PHE
vision I-PHE
. O

-DOCSTART- O


sore B-PHE
of I-PHE
scrotum I-PHE

-DOCSTART- O


Pemetrexed O
binds O
to O
and O
inhibits O
the O
enzyme O
thymidylate B-PHE
synthase I-PHE
which O
catalyses O
the O
substrate O
to O
an O
essential O
precursor O
in O
DNA B-PHE
synthesis I-PHE
. O

Carboplatin O
is O
activated O
intracellularly O
to O
form O
reactive O
platinum O
complexes O
that O
bind O
to O
nucleophilic O
groups O
such O
as O
GC-rich O
sites O
in O
DNA B-PHE
, O
thereby O
inducing O
intrastrand O
and O
interstrand O
DNA B-PHE
cross-links O
, O
as O
well O
as O
DNA-protein B-PHE
cross-links O
. O

By O
binding O
to O
the O
ATP-binding O
site O
, O
enzastaurin O
selectively O
inhibits O
protein B-PHE
kinase I-PHE
C I-PHE
beta I-PHE
, O
which O
appears O
to O
be O
cytotoxic O
in O
cells O
with O
DNA B-PHE
alterations O
or O
DNA O
damage O
which O
may O
decrease O
tumor B-PHE
blood I-PHE
supply I-PHE
, O
preventing O
growth B-PHE
. O

-DOCSTART- O


RK-0202 O
, O
an O
oral O
rinse O
for O
the O
prevention O
and O
treatment O
of O
mucositis B-PHE
, O
is O
based O
on O
the O
company's O
ProGelz O
technology O
and O
is O
comprised O
of O
the O
potent O
antioxidant O
N-acetylcysteine O
in O
a O
polymer O
matrix O
. O

-DOCSTART- O


deficiency O
of O
both O
Gi O
( O
vital O
energy O
) O
and O
blood B-PHE

-DOCSTART- O


Schizophrenia B-PHE
Prodrome I-PHE

-DOCSTART- O


For O
use O
in O
the O
treatment O
of O
symptomatic O
anaemia B-PHE
associated O
with O
chronic B-PHE
renal I-PHE
failure I-PHE
( O
CRF B-PHE
) O
in O
adult O
and O
paediatric O
patients O
. O

Also O
for O
use O
in O
the O
treatment O
of O
anaemia B-PHE
and O
reduction B-PHE
of I-PHE
transfusion I-PHE
requirements O
in O
adult O
patients O
receiving O
chemotherapy O
for O
solid B-PHE
tumours I-PHE
, O
malignant B-PHE
lymphoma I-PHE
or O
multiple B-PHE
myeloma I-PHE
, O
and O
at O
risk O
of O
transfusion O
as O
assessed O
by O
the O
patient's O
general O
status O
( O
e.g O
. O
cardiovascular O
status O
, O
pre-existing O
anaemia B-PHE
at O
the O
start O
of O
chemotherapy O
) O
. O

Also O
for O
used O
to O
increase O
the O
yield O
of O
autologous B-PHE
blood I-PHE
from O
patients O
in O
a O
predonation O
program O
. O

When O
administered O
subcutaneously O
, O
Epoetin O
Zeta O
is O
equivalent O
to O
Epoetin O
Alfa O
in O
terms O
of O
clinical O
effectiveness O
. O

-DOCSTART- O


Neoplasms B-PHE
, I-PHE
Breast I-PHE

-DOCSTART- O


dissipate O
depression B-PHE

-DOCSTART- O


vomiting B-PHE
and O
diarrhea B-PHE
due O
to O
visceral O
cold B-PHE

-DOCSTART- O


Motivation O
, O
Mood O
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Others O
, O
effort O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


Its O
active O
component O
, O
triterpenic O
acid O
, O
increases O
cornary O
flow O
and O
improve O
systemic B-PHE
circulation. I-PHE
. O

-DOCSTART- O


disperse O
cold B-PHE

-DOCSTART- O


epiphora B-PHE
; O
lacrimation B-PHE

-DOCSTART- O


Cardiovascular B-PHE
Disorder I-PHE

-DOCSTART- O


terminate O
delivery O

-DOCSTART- O


To O
supplement O
qi O
and O
nourish O
yin O
, O
clear O
fire O
and O
engender O
liquid O
. O

-DOCSTART- O


To O
dispel O
wind-heat B-PHE
, O
to O
promote O
eruption B-PHE
, O
and O
to O
cause O
diuresis B-PHE
. O

-DOCSTART- O


To O
resolve O
phlegm B-PHE
and O
benefit O
throat B-PHE

-DOCSTART- O


1 O
Aloperine O
inhibits O
exudative B-PHE
inflammation I-PHE
and O
hemolysis B-PHE
of O
red O
blood B-PHE
cells O
2 O
. O

Its O
decoction O
or O
sophocarpine O
relieves O
asthma B-PHE
in O
guinea-pigs O
induced O
by O
acetylcholine O
and O
histamine O
. O

3 O
. O
Sophocarpine O
or O
matrine O
inhibits O
sarcoma180 B-PHE
in O
vitro O
. O

-DOCSTART- O


Shosaikoto O
, O
which O
is O
one O
of O
the O
Japanese O
and O
Chinese O
traditional O
herbal O
medicine O
mixtures O
, O
has O
several O
immunomodulating B-PHE
activities I-PHE
. O

Especially O
, O
Shosaikoto O
is O
a O
potent O
polyclonal O
B O
cell O
mitogen O
in O
vivo O
and O
in O
vitro O
. O

In O
order O
to O
characterize O
the O
active O
substances O
for O
mitogenic B-PHE
activity I-PHE
, O
Shosaikoto O
was O
fractionated O
by O
means O
of O
ethanol O
precipitation O
to O
give O
two O
fractions O
, O
called O
ethanol-precipitate O
( O
EP O
) O
fraction O
and O
ethanol-soluble O
( O
ES O
) O
fraction O
. O

The O
EP O
fraction O
consisted O
mainly O
of O
polysaccharides O
and O
showed O
significant O
mitogenic B-PHE
activity I-PHE
. O

The O
ES O
fraction O
consisted O
of O
low O
molecular O
compounds O
and O
did O
not O
show O
the O
activity O
in O
vitro O
. O

The O
EP O
fraction O
of O
hot O
water O
extracts O
of O
Glycyrrhizae O
Radix O
and O
Bupureuri O
Radix O
showed O
the O
activities O
, O
and O
the O
ES O
fraction O
of O
a O
hot O
water O
extract O
of O
Glycyrrhizae O
Radix O
and O
all O
fractions O
of O
hot O
water O
extract O
of O
Scutellariae O
Radix O
showed O
the O
cytotoxicity O
. O

These O
results O
suggested O
that O
the O
crude O
polysaccharide O
fractions O
could O
play O
an O
important O
role O
in O
the O
mitogenic B-PHE
activity I-PHE
by O
Shosaikoto O
. O

-DOCSTART- O


Decompensated B-PHE
Cirrhosis I-PHE

-DOCSTART- O


Cough B-PHE
and O
asthma B-PHE
, O
fright O
epilepsy B-PHE
, O
wind-cold-damp B-PHE
impediment I-PHE
, O
dysentery B-PHE
, O
prolapse B-PHE
of I-PHE
rectum I-PHE
, O
knocks B-PHE
and O
falls B-PHE
. O

-DOCSTART- O


Cardiovascular B-PHE
Diseases I-PHE

-DOCSTART- O


1 O
Its O
decoction O
enhances O
th O
intestinal B-PHE
contraction I-PHE
and O
tensity O
of O
rabbits O
in O
vitro O
, O
which O
can O
be O
counteracted O
by O
atropine O
. O

2 O
. O
Inhibiting O
the O
growth O
of O
sarcoma B-PHE
180 I-PHE
in O
mice O
. O

-DOCSTART- O


1 O
To O
clear O
heat B-PHE
and O
toxic B-PHE
material I-PHE
, O
deprive O
dampness B-PHE
and O
kill O
parasites B-PHE
. O

For O
sorethroat B-PHE
, O
dysentery B-PHE
, O
trichomonas B-PHE
enteritis I-PHE
, O
toothache B-PHE
, O
stomachache B-PHE
and O
leucorrhagia B-PHE
, O
external O
use O
for O
tinea B-PHE
and O
eczema B-PHE
. O

2 O
To O
relieve O
dyspnea B-PHE
and O
cough B-PHE
. O

3 O
Anticarcinogenic B-PHE
. O
For O
malignant B-PHE
hydatidiform I-PHE
mole I-PHE
, O
chorionic B-PHE
epithelioma I-PHE
and O
leukemia B-PHE
. O

-DOCSTART- O


Knee B-PHE
Osteoarthritis I-PHE

-DOCSTART- O


Malignancy B-PHE

-DOCSTART- O


Lysophospholipids O
have O
been O
found O
to O
mediate O
the O
activity O
of O
this O
drug O
. O

-DOCSTART- O


Crohn's B-PHE
Disease I-PHE

-DOCSTART- O


Swelling B-PHE
and O
pain B-PHE
due O
to O
blood B-PHE
stagnation I-PHE
caused O
by O
external B-PHE
injuries I-PHE
. O

-DOCSTART- O


Insulin O
binds O
to O
the O
insulin O
receptor O
( O
IR O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

The O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-PHE
kinase I-PHE
activity O
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

The O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin O
receptor O
substrates O
( O
IRS O
) O
proteins O
, O
Cbl B-PHE
, O
APS B-PHE
, O
Shc B-PHE
and O
Gab B-PHE

These O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-PHE
of I-PHE
downstream I-PHE
signaling I-PHE
molecules I-PHE
including O
PI3 B-PHE
kinase I-PHE
and O
Akt B-PHE
. O

Akt O
regulates O
the O
activity B-PHE
of I-PHE
glucose I-PHE
transporter I-PHE
4 I-PHE
( O
GLUT4 B-PHE
) O
and O
protein B-PHE
kinase I-PHE
C I-PHE
( O
PKC B-PHE
) O
which O
play O
a O
critical O
role O
in O
metabolism O
. O

-DOCSTART- O


Treatment O
of O
rheumatic B-PHE
arthritis I-PHE
with O
muscular B-PHE
contracture I-PHE
, O
aching B-PHE
of O
the O
loins O
and O
knees O
, O
inflammation B-PHE
of O
the O
throat O
, O
carbuncle B-PHE
and O
boils O
, O
traumatic B-PHE
injuries I-PHE
. O

-DOCSTART- O


Imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine B-PHE
kinases I-PHE
( O
TK B-PHE
) O
, O
thereby O
inhibiting O
ATP B-PHE
binding I-PHE
and O
preventing O
phosphorylation B-PHE
and O
the O
subsequent O
activation O
of O
growth O
receptors O
and O
their O
downstream O
signal B-PHE
transduction I-PHE
pathways I-PHE
. O

Temozolomide O
is O
converted O
at O
physiologic O
pH O
to O
the O
short-lived O
active O
compound O
, O
monomethyl O
triazeno O
imidazole O
carboxamide O
( O
MTIC O
) O
. O

The O
cytotoxicity B-PHE
of I-PHE
MTIC I-PHE
is O
due O
primarily O
to O
methylation B-PHE
of I-PHE
DNA I-PHE
at O
the O
O6 O
and O
N7 O
positions O
of O
guanine O
, O
resulting O
in O
inhibition B-PHE
of I-PHE
DNA I-PHE
replication I-PHE
. O

-DOCSTART- O


Growth B-PHE

-DOCSTART- O


Treatment O
of O
: O
1 O
Hemorrhages B-PHE
due O
to O
external B-PHE
injuries I-PHE
. O
Dragon's O
blood O
( O
Xuejie O
) O
can O
be O
taken O
alone O
for O
external O
use O
, O
or O
it O
can O
be O
combined O
with O
Cattail O
pollen O
( O
Puhuang O
) O
. O

-DOCSTART- O


A O
74-year-old O
man O
was O
admitted O
to O
our O
hospital O
complaining O
of O
severe O
neck B-PHE
pain I-PHE
and O
general O
fatigue B-PHE
. O

He O
had O
been O
undergoing O
treatment O
for O
post-operative O
neck B-PHE
pain I-PHE
at O
the O
out-patient O
clinic O
of O
our O
hospital O
, O
but O
was O
now O
complaining O
of O
pain B-PHE
more O
intense O
than O
usual O
. O

Chest O
X-rays O
revealed O
diffuse O
ground O
glass O
shadows O
in O
bilateral O
lung O
fields O
, O
and O
computed O
tomography O
revealed O
diffuse O
intestinal O
shadows O
. O

A O
drug O
lymphocyte O
stimulation O
test O
( O
DLST O
) O
was O
also O
performed O
at O
that O
time O
. O

Steroid O
pulse O
therapy O
improved O
the O
clinical O
symptoms O
, O
hypoxemia B-PHE
and O
chest O
X-ray O
findings O
. O

DLST O
performed O
again O
with O
Yokukansan O
and O
Hachimijiogan O
133 O
days O
after O
the O
initial O
diagnosis O
of O
pneumonitis O
showed O
Yokukansan O
was O
positive O
. O

This O
result O
showed O
Yukukansan O
may O
be O
a O
causative O
drug O
for O
allergic O
drug-induced B-PHE
pneumonitis I-PHE
. O

Any O
drugs O
including O
kanpo O
may O
be O
possible O
to O
induce O
allergic B-PHE
pneumonitis I-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE

-DOCSTART- O


Alzheimer B-PHE
Disease I-PHE

-DOCSTART- O


To O
dispel O
wind-heat B-PHE
, O
to O
subdue O
hyperactivity B-PHE
of I-PHE
the I-PHE
liver I-PHE
, O
and O
improve O
eyesight B-PHE
. O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
depression B-PHE
. O

-DOCSTART- O


To O
stop O
bleeding B-PHE
and O
promote O
the O
healing B-PHE
of I-PHE
wounds I-PHE
. O

-DOCSTART- O


seven O
injuries B-PHE
; O
seven O
kinds O
of O
impairments B-PHE

-DOCSTART- O


Regulation O
of O
qi O

-DOCSTART- O


Eye B-PHE
pain I-PHE
, O
eye B-PHE
swelling I-PHE
, O
red B-PHE
eyes I-PHE
and O
tearing B-PHE
. O

-DOCSTART- O


Its O
leaf O
infusion O
from O
NaCl O
solution O
inhibits O
the O
growth O
of O
Bacillus B-PHE
coli I-PHE
. O

-DOCSTART- O


phthisical B-PHE
cough I-PHE
due O
to O
Eum O
deficiency O

-DOCSTART- O


swollen O
check O
, O
mumps B-PHE
; O
epidemic B-PHE
parotitis I-PHE

-DOCSTART- O


Infection B-PHE

-DOCSTART- O


Behavioral B-PHE
and I-PHE
psychological I-PHE
symptoms I-PHE
of I-PHE
dementia I-PHE
( O
BPSD B-PHE
) O
are O
commonly O
seen O
in O
patients O
with O
Alzheimer's B-PHE
disease I-PHE
( O
AD B-PHE
) O
and O
other O
forms O
of O
senile B-PHE
dementia I-PHE
. O

BPSD B-PHE
have O
a O
serious O
impact O
on O
the O
quality O
of O
life O
of O
dementia B-PHE
patients O
, O
as O
well O
as O
their O
caregivers O
. O

However O
, O
an O
effective O
drug O
therapy O
for O
BPSD B-PHE
has O
not O
been O
established O
. O

Recently O
, O
the O
traditional O
Japanese O
medicine O
Yokukansan O
( O
YKS O
, O
Yi-gan O
san O
in O
Chinese O
) O
has O
been O
reported O
to O
improve O
BPSD B-PHE
in O
a O
randomized O
, O
single-blind O
, O
placebo-controlled O
study O
. O

Moreover O
, O
abnormalities B-PHE
of I-PHE
the I-PHE
serotonin I-PHE
( O
5-HT B-PHE
) O
system O
such O
as O
5-HT2A O
receptors O
have O
been O
reported O
to O
be O
associated O
with O
BPSD B-PHE
of O
AD B-PHE
patients O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
YKS O
on O
head-twitch O
response O
induced O
by O
2,5-dimethoxy-4-iodoamphetamine O
( O
DOI O
, O
5 O
mg/kg O
, O
i.p O
. O
) O
in O
mice O
, O
a O
behavioral O
response O
that O
is O
mediated O
, O
in O
part O
, O
by O
5-HT2A O
receptors O
. O

Acute O
treatment O
with O
YKS O
( O
100 O
and O
300 O
mg/kg O
, O
p.o O
. O
) O
had O
no O
effect O
on O
the O
DOI-induced B-PHE
head-twitch I-PHE
response I-PHE
, O
whilst O
14 O
days O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
significantly O
inhibited O
this O
response O
. O

Moreover O
, O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
decreased O
expression O
of O
5-HT2A O
receptors O
in O
the O
prefrontal O
cortex O
, O
which O
is O
part O
of O
the O
circuitry O
mediating O
the O
head-twitch B-PHE
response I-PHE
. O

These O
findings O
suggest O
that O
the O
inhibition O
of O
DOI-induced B-PHE
head-twitch I-PHE
response O
by O
YKS O
may O
be O
mediated O
, O
in O
part O
, O
by O
altered O
expression O
of O
5-HT2A O
receptors O
in O
the O
prefrontal O
cortex O
, O
which O
suggests O
the O
involvement O
of O
the O
5-HT B-PHE
system I-PHE
in O
psychopharmacological O
effects O
of O
YKS O
. O

-DOCSTART- O


Obesity B-PHE

-DOCSTART- O


relieve O
pain B-PHE

-DOCSTART- O


To O
eliminate O
phlegm B-PHE
and O
relieve O
cough B-PHE
. O

For O
acute O
and O
chronic B-PHE
bronchitis I-PHE
. O

-DOCSTART- O


Non-Small B-PHE
Cell I-PHE
Lung I-PHE
Cancer I-PHE

-DOCSTART- O


To O
regulate O
the O
qi O
of O
the O
liver B-PHE
and O
stomach B-PHE
, O
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Bacterial B-PHE
infections I-PHE
of O
the O
ear O

-DOCSTART- O


Urinary B-PHE
Bladder I-PHE
, I-PHE
Neurogenic I-PHE

-DOCSTART- O


Retention B-PHE
of I-PHE
milk I-PHE
in O
babies O
, O
profuse O
sputum B-PHE
and O
infantile B-PHE
convulsions I-PHE
. O

-DOCSTART- O


To O
stablize O
liver B-PHE
and O
suppress O
dizziness B-PHE
; O
To O
soothe O
neck B-PHE
and O
wake-up O
brain B-PHE

-DOCSTART- O


burn B-PHE

-DOCSTART- O


Melanoma B-PHE

-DOCSTART- O


reddish B-PHE
turbid I-PHE
urine I-PHE

-DOCSTART- O


night B-PHE
sweat I-PHE
and O
nocturnal B-PHE
emission I-PHE

-DOCSTART- O


urinary B-PHE
incontinence I-PHE
; O
galacturia B-PHE
; O
stranguria B-PHE
with O
chyluria B-PHE
; O
stranguria B-PHE
marked O
by O
chyluria B-PHE

-DOCSTART- O


To O
dissipate O
stasis B-PHE
and O
quicken O
blood B-PHE
, O
relieve O
pain B-PHE
. O

-DOCSTART- O


replenish O
essence-marrow O

-DOCSTART- O


( O
1 O
) O
diarrhea B-PHE
( O
2 O
) O
diarrhea B-PHE
and O
urination B-PHE
( O
3 O
) O
diarrhea B-PHE
and O
dysentery B-PHE

-DOCSTART- O


A O
UPLC/Q-TOF-MS/MS O
method O
for O
analyzing O
the O
constituents O
in O
rat O
plasma O
after O
oral O
administration O
of O
Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
, O
a O
traditional O
Chinese O
medical O
formula O
, O
has O
been O
established O
. O

The O
UPLC/MS O
fingerprints O
of O
the O
samples O
were O
established O
first O
in O
vitro O
and O
in O
vivo O
, O
with O
45 O
compounds O
in O
YCHT O
and O
21 O
compounds O
in O
rat O
plasma O
after O
oral O
administration O
of O
YCHT O
were O
detected O
. O

Of O
the O
45 O
detected O
compounds O
in O
vitro O
, O
30 O
were O
identified O
, O
and O
all O
of O
the O
21 O
compounds O
detected O
in O
rat O
plasma O
were O
identified O
either O
by O
comparing O
the O
retention O
time O
and O
mass O
spectrometry O
data O
with O
that O
of O
reference O
compounds O
or O
by O
mass O
spectrometry O
analysis O
and O
retrieving O
the O
reference O
literatures O
. O

Of O
the O
identified O
21 O
compounds O
in O
rat O
plasma O
, O
19 O
were O
the O
original O
form O
of O
compounds O
absorbed O
from O
the O
45 O
detected O
compounds O
in O
vitro O
, O
2 O
were O
the O
metabolites O
of O
the O
compounds O
existed O
in O
YCHT O
. O

It O
is O
concluded O
that O
a O
rapid O
and O
validated O
method O
has O
been O
developed O
based O
on O
UPLC-MS/MS O
, O
which O
shows O
high O
sensitivity O
and O
resolution O
that O
is O
more O
suitable O
for O
identifying O
the O
bioactive O
constituents O
in O
plasma O
after O
oral O
administration O
of O
Chinese O
herbal O
medicines O
, O
and O
provides O
helpful O
chemical O
information O
for O
further O
pharmacology O
and O
active O
mechanism O
research O
on O
the O
Chinese O
medical O
formula O
. O

-DOCSTART- O


Ureteral B-PHE
Stent I-PHE
Occlusion I-PHE

-DOCSTART- O


De O
Novo O
Kidney O
Transplant O
Patients O

-DOCSTART- O


Glaucoma B-PHE

-DOCSTART- O


excessive O
drinking O
of O
water O
due O
to O
thirst B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
soothe O
sinews B-PHE
and O
free O
network O
vessels B-PHE
. O

-DOCSTART- O


Ovarian B-PHE
Hyperstimulation I-PHE
Syndrome I-PHE

-DOCSTART- O


Rosuvastatin O
is O
a O
competitive O
inhibitor O
of O
HMG-CoA O
reductase O
, O
which O
reductase O
catalyzes O
the O
conversion O
of O
HMG-CoA O
to O
mevalonate O
, O
an O
early O
rate-limiting O
step O
in O
cholesterol O
biosynthesis O
. O

Lapaquistat O
acetate O
is O
a O
squalene O
synthase O
inhibitor O
investigated O
for O
the O
treatment O
of O
hypercholesterolemia B-PHE
. O

-DOCSTART- O


moisten O
the O
liver B-PHE

-DOCSTART- O


vomiting B-PHE
of O
milk O

-DOCSTART- O


Oxcarbazepine O
produces O
blockade B-PHE
of I-PHE
voltage-sensitive I-PHE
sodium I-PHE
channels I-PHE
, O
resulting O
in O
stabilization O
of O
hyperexcited O
neural B-PHE
membranes I-PHE
, O
inhibition O
of O
repetitive B-PHE
neuronal I-PHE
firing I-PHE
, O
and O
diminution O
of O
propagation B-PHE
of I-PHE
synaptic I-PHE
impulses I-PHE
. O

These O
actions O
are O
thought O
to O
be O
important O
in O
the O
prevention O
of O
seizure B-PHE
spread I-PHE
in O
the O
intact O
brain O
. O

Gabapentin's O
therapeutic O
action O
on O
neuropathic B-PHE
pain I-PHE
is O
thought O
to O
involve O
voltage-gated B-PHE
N-type I-PHE
calcium I-PHE
ion I-PHE
channels I-PHE
. O

It O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent B-PHE
calcium I-PHE
channel I-PHE
in O
the O
central O
nervous O
system O
. O

-DOCSTART- O


Toxoplasmosis B-PHE

-DOCSTART- O


white B-PHE
turbid I-PHE
urine I-PHE

-DOCSTART- O


nourish O
essence-marrow B-PHE

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myelomonocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


warm O
the O
menses B-PHE
and O
stop O
bleeding B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
resolve O
phlegm B-PHE
and O
promote O
blood B-PHE
circulation I-PHE
to O
remove O
obstruction B-PHE
in I-PHE
the I-PHE
channels I-PHE
. O

-DOCSTART- O


Atrophic B-PHE
Vaginitis I-PHE

-DOCSTART- O


Treatment O
of O
stagnation B-PHE
of I-PHE
undigested I-PHE
meat I-PHE
with O
epigastric B-PHE
distension I-PHE
, O
diarrhea B-PHE
and O
abdominal B-PHE
pain I-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
epigastric B-PHE
pain I-PHE
or O
abdominal B-PHE
colic I-PHE
, O
after O
childbirth O
, O
heraial O
pain B-PHE
, O
hyperlipemia B-PHE
. O

-DOCSTART- O


cough B-PHE
due O
to O
dryness B-PHE
of I-PHE
the I-PHE
lung I-PHE

-DOCSTART- O


profuse B-PHE
bleeding I-PHE
after O
delivery B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
Inv(16)(p13.1q22 O
) O
; O
CBFB-MYH11 O

-DOCSTART- O


secure O
the O
essence O

-DOCSTART- O


Septic B-PHE
Shock I-PHE

-DOCSTART- O


Sore B-PHE
Throat I-PHE
Due O
to O
a O
Common O
Cold B-PHE

-DOCSTART- O


Neuropathic B-PHE
pain I-PHE

-DOCSTART- O


cool O
blood B-PHE
and O
alleviate O
edema B-PHE

-DOCSTART- O


close O
sores B-PHE

-DOCSTART- O


Kids O
, O
Protective B-PHE
immunity I-PHE
, O
Metabolism B-PHE

-DOCSTART- O


